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A B S T R A C T
Background
Although antidepressants are oMen a first-line treatment for adults with moderate to severe depression, many people do not respond
adequately to medication, and are said to have treatment-resistant depression (TRD). Little evidence exists to inform the most appropriate
'next step' treatment for these people.
Objectives
To assess the eNectiveness of standard pharmacological treatments for adults with TRD.
Search methods
We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) (March 2016), CENTRAL, MEDLINE, Embase,
PsycINFO and Web of Science (31 December 2018), the World Health Organization trials portal and ClinicalTrials.gov for unpublished and
ongoing studies, and screened bibliographies of included studies and relevant systematic reviews without date or language restrictions.
Selection criteria
Randomised controlled trials (RCTs) with participants aged 18 to 74 years with unipolar depression (based on criteria from DSM-IV-TR or
earlier versions, International Classification of Diseases (ICD)-10, Feighner criteria or Research Diagnostic Criteria) who had not responded
to a minimum of four weeks of antidepressant treatment at a recommended dose. Interventions were:
(1) increasing the dose of antidepressant monotherapy;
(2) switching to a diNerent antidepressant monotherapy;
(3) augmenting treatment with another antidepressant;
(4) augmenting treatment with a non-antidepressant.
All were compared with continuing antidepressant monotherapy. We excluded studies of non-standard pharmacological treatments (e.g.
sex hormones, vitamins, herbal medicines and food supplements).
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Data collection and analysis
Two reviewers used standard Cochrane methods to extract data, assess risk of bias, and resolve disagreements. We analysed continuous
outcomes with mean diNerence (MD) or standardised mean diNerence (SMD) and 95% confidence interval (CI). For dichotomous outcomes,
we calculated a relative risk (RR) and 95% CI. Where suNicient data existed, we conducted meta-analyses using random-eNects models.
Main results
We included 10 RCTs (2731 participants). Nine were conducted in outpatient settings and one in both in- and outpatients. Mean age of
participants ranged from 42 - 50.2 years, and most were female.
One study investigated switching to, or augmenting current antidepressant treatment with, another antidepressant (mianserin). Another
augmented current antidepressant treatment with the antidepressant mirtazapine. Eight studies augmented current antidepressant
treatment with a non-antidepressant (either an anxiolytic (buspirone) or an antipsychotic (cariprazine; olanzapine; quetiapine (3 studies);
or ziprasidone (2 studies)). We judged most studies to be at a low or unclear risk of bias. Only one of the included studies was not industry-
sponsored.
There was no evidence of a diNerence in depression severity when current treatment was switched to mianserin (MD on Hamilton
Rating Scale for Depression (HAM-D) = -1.8, 95% CI -5.22 to 1.62, low-quality evidence)) compared with continuing on antidepressant
monotherapy. Nor was there evidence of a diNerence in numbers dropping out of treatment (RR 2.08, 95% CI 0.94 to 4.59, low-quality
evidence; dropouts 38% in the mianserin switch group; 18% in the control).
Augmenting current antidepressant treatment with mianserin was associated with an improvement in depression symptoms severity
scores from baseline (MD on HAM-D -4.8, 95% CI -8.18 to -1.42; moderate-quality evidence). There was no evidence of a diNerence in
numbers dropping out (RR 1.02, 95% CI 0.38 to 2.72; low-quality evidence; 19% dropouts in the mianserin-augmented group; 38% in the
control). When current antidepressant treatment was augmented with mirtazapine, there was little diNerence in depressive symptoms (MD
on Beck Depression Inventory (BDI-II) -1.7, 95% CI -4.03 to 0.63; high-quality evidence) and no evidence of a diNerence in dropout numbers
(RR 0.50, 95% CI 0.15 to 1.62; dropouts 2% in mirtazapine-augmented group; 3% in the control).
Augmentation with buspirone provided no evidence of a benefit in terms of a reduction in depressive symptoms (MD on Montgomery and
Asberg Depression Rating Scale (MADRS) -0.30, 95% CI -9.48 to 8.88; low-quality evidence) or numbers of drop-outs (RR 0.60, 95% CI 0.23
to 1.53; low-quality evidence; dropouts 11% in buspirone-augmented group; 19% in the control).
Severity of depressive symptoms reduced when current treatment was augmented with cariprazine (MD on MADRS -1.50, 95% CI -2.74 to
-0.25; high-quality evidence), olanzapine (MD on HAM-D -7.9, 95% CI -16.76 to 0.96; low-quality evidence; MD on MADRS -12.4, 95% CI -22.44
to -2.36; low-quality evidence), quetiapine (SMD -0.32, 95% CI -0.46 to -0.18; I2 = 6%, high-quality evidence), or ziprasidone (MD on HAM-D
-2.73, 95% CI -4.53 to -0.93; I2 = 0, moderate-quality evidence) compared with continuing on antidepressant monotherapy.
However, a greater number of participants dropped out when antidepressant monotherapy was augmented with an antipsychotic
(cariprazine RR 1.68, 95% CI 1.16 to 2.41; quetiapine RR 1.57, 95% CI: 1.14 to 2.17; ziprasidone RR 1.60, 95% CI 1.01 to 2.55) compared with
antidepressant monotherapy, although estimates for olanzapine augmentation were imprecise (RR 0.33, 95% CI 0.04 to 2.69). Dropout
rates ranged from 10% to 39% in the groups augmented with an antipsychotic, and from 12% to 23% in the comparison groups. The most
common reasons for dropping out were side eNects or adverse events.
We also summarised data about response and remission rates (based on changes in depressive symptoms) for included studies, along with
data on social adjustment and social functioning, quality of life, economic outcomes and adverse events.
Authors' conclusions
A small body of evidence shows that augmenting current antidepressant therapy with mianserin or with an antipsychotic (cariprazine,
olanzapine, quetiapine or ziprasidone) improves depressive symptoms over the short-term (8 to 12 weeks). However, this evidence is
mostly of low or moderate quality due to imprecision of the estimates of eNects. Improvements with antipsychotics need to be balanced
against the increased likelihood of dropping out of treatment or experiencing an adverse event. Augmentation of current antidepressant
therapy with a second antidepressant, mirtazapine, does not produce a clinically important benefit in reduction of depressive symptoms
(high-quality evidence). The evidence regarding the eNects of augmenting current antidepressant therapy with buspirone or switching
current antidepressant treatment to mianserin is currently insuNicient.
Further trials are needed to increase the certainty of these findings and to examine long-term eNects of treatment, as well as the
eNectiveness of other pharmacological treatment strategies.
P L A I N   L A N G U A G E   S U M M A R Y
Are there e4ective medications for treating depression that does not improve with the first medication used?
Background
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Depression is a common problem oMen treated with antidepressant medication. However, many people do not get better with
antidepressant treatment and have 'treatment-resistant depression' (TRD). Several diNerent treatment approaches can be tried - such as
increasing the dose of the current medication, adding another medication, or switching to a diNerent antidepressant.
Cochrane reviewers looked at the available evidence to see which of these options may be the best treatment for people with TRD.
Search date
In December 2018, we searched eight medical databases for suitable clinical trials.
Study characteristics
We included 10 randomised controlled trials (RCTs) with 2731 participants (RCTs produce the most robust evidence). These trials
investigated three diNerent treatment strategies:
1. changing to a diNerent antidepressant,
2. adding a second antidepressant to the current antidepressant treatment, or
3. adding a diNerent type of medication to current antidepressant treatment - an anti-anxiety medication or an antipsychotic
We found no trials of increasing the dose of current antidepressant medication. Nine of the 10 studies included in this review were
sponsored by pharmaceutical companies.
Key results
One small study investigated changing current antidepressant treatment to a diNerent antidepressant (mianserin) or adding mianserin to
current treatment. We are uncertain about the eNect changing treatment to mianserin has on depressive symptoms or the likelihood of
dropping out of treatment. People who added mianserin to their current antidepressant treatment showed fewer depressive symptoms,
but the likelihood of dropping out was not clear.
Adding the antidepressant mirtazapine to current antidepressant treatment had little or no eNect on depressive symptoms or on the
likelihood of dropping out of treatment.
The eNect of adding an anti-anxiety medication (buspirone) to ongoing antidepressant treatment on depressive symptoms or dropping
out is currently uncertain. These findings were based on one small study.
Most studies looked at the eNects of adding an antipsychotic medication (cariprazine, quetiapine, ziprasidone or olanzapine) to current
antidepressant treatment. These suggested that adding cariprazine results in a small reduction in depressive symptoms; adding quetiapine
reduces depressive symptoms; and adding ziprasidone probably results in a small reduction in depressive symptoms. However, our results
also suggest that adding these medicines to current treatment probably increases the likelihood of dropping out of treatment. The most
common reasons for dropping out were side eNects or adverse events. Adding olanzapine to ongoing treatment may reduce depressive
symptoms, but the eNects on dropping out are uncertain (findings based on one small study).
Nearly all (9/10) of the studies assessed the eNects of treatment in the short-term – six or eight weeks aMer beginning the new treatment
– so the longer term eNects of most treatments are unknown.
Quality of the evidence
We judged the quality of the evidence as high, moderate, or low for diNerent outcomes. The main limitation we identified was that the
evidence for many of the treatment options investigated came from only one study, and some of these studies also had few participants.
We rated the evidence to be low quality for:
1. switching from the current antidepressant treatment to another antidepressant (mianserin);
2. supplementing current antidepressant treatment with a second antidepressant (mianserin), or with an anti-anxiety medication
(buspirone), or with the antipsychotic olanzapine.
This means we are uncertain about the eNects of these treatments on depression symptoms or the likelihood of dropping out of treatment.
We rated the quality of the evidence for adding mirtazapine (an antidepressant), cariprazine (an antipsychotic) or quetiapine (an
antipsychotic) to ongoing antidepressant treatment on depressive symptoms as high, meaning we are very confident in the eNect of these
treatment strategies.
Pharmacological interventions for treatment-resistant depression in adults (Review)
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We rated the quality of the evidence for adding the antipsychotic ziprasidone to ongoing antidepressant treatment on the eNect on
depressive symptoms as moderate, which means the true eNect may be diNerent from what we found, although findings are likely to be
close.
We rated the quality of the evidence for adding mirtazapine (an antidepressant) to ongoing antidepressant treatment on the likelihood
of dropping out of treatment as high. We rated the quality of the evidence for adding cariprazine, olanzapine or ziprasidone (all
antipsychotics) on the likelihood of dropping out as moderate.
Pharmacological interventions for treatment-resistant depression in adults (Review)


















































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Switching to mianserin (60 mg/d) compared to continuing on current antidepressant (fluoxetine 20
mg/d) for treatment-resistant depression in adults
Switching to mianserin (60 mg/d) compared to continuing on current antidepressant (fluoxetine 20 mg/d) for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: inpatient and outpatient
Intervention: switching to mianserin (60 mg/d)
Comparison: continuing on current antidepressant (fluoxetine 20 mg/d)









Risk with continuing on cur-
rent antidepressant (fluoxe-
tine 20 mg/d)
Risk difference with switching to
mianserin (60 mg/d)
Depressive symptoms (HAM-D)






MD - 1.8 (-5.23 to
1.63)
The mean depressive symptom
score (HAM-D) was 15.6
MD 1.8 lower









184 per 1,000 199 more per 1,000
(11 fewer to 661 more)









368 per 1,000 118 more per 1,000
(88 fewer to 468 more)








184 per 1,000 179 more per 1,000
(22 fewer to 630 more)
Quality of life - not measured - - - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).












































































































































GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for imprecision (broad confidence interval that crossed the null)
2 Downgraded two levels for imprecision (very broad confidence interval that crossed the null)
3 Downgraded two levels for imprecision (very broad confidence interval)
 
 
Summary of findings 2.   Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) compared to augmentation of
current antidepressant (fluoxetine 20 mg/d) with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) compared to augmentation of current antidepressant (fluoxetine 20 mg/d)
with placebo for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: inpatient and outpatient
Intervention: augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d)
Comparison: augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo









(95% CI) Risk with augmentation of cur-
rent antidepressant (fluoxetine
20 mg/d) with placebo
Risk difference with augmentation
of current antidepressant (fluox-
etine 20 mg/d) with mianserin (60
mg/d)
Depressive symptoms (HAM-D)






- The mean depressive symptom
score (HAM-D) was 15.6
MD 4.8 lower









184 per 1,000 4 more per 1,000
(114 fewer to 317 more)









368 per 1,000 258 more per 1,000




















































































































































184 per 1,000 254 more per 1,000
(17 more to 766 more)
Quality of life - not measured - - - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for imprecision (broad confidence interval)
2 Downgraded two levels for imprecision (broad confidence interval that crossed the null)
3 Downgraded two levels for imprecision (very broad confidence interval)
 
 
Summary of findings 3.   Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) compared to augmentation of current
antidepressant (SSRI/SNRI) therapy with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) compared to augmentation of current antidepressant (SSRI/SNRI) therapy with
placebo for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: outpatients
Intervention: augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d)
Comparison: augmentation of current antidepressant (SSRI/SNRI) therapy with placebo









(95% CI) Risk with augmentation of current
antidepressant (SSRI/SNRI) therapy
with placebo
Risk difference with augmentation
of current antidepressant (SSRI/
SNRI) with mirtazapine (30 mg/d)
Depressive symptoms (BDI-II)





- The mean depressive symptom score
(BDI-II) was 19.7
MD 1.7 lower





















































































































































33 per 1,000 17 fewer per 1,000
(28 fewer to 21 more)









359 per 1,000 79 more per 1,000
(11 fewer to 194 more)








244 per 1,000 51 more per 1,000
(29 fewer to 159 more)




- The mean quality of life (EQ-5D-5L) at
12 weeks was 0.73
MD 0.01 lower
(0.06 lower to 0.04 higher)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
 
 
Summary of findings 4.   Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) compared to augmentation of current
antidepressant (SSRI) with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) compared to augmentation of current antidepressant (SSRI) with placebo for
treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: outpatient
Intervention: augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d)





















































































































































(95% CI) Risk with augmentation of current
antidepressant (SSRI) with placebo
Risk difference with augmenta-
tion of current antidepressant
(SSRI) with busiprone (20 mg/d
to 60 mg/d)
Depressive symptoms (MADRS)






- The mean depressive symptom score
(MADRS) was 30.5 % reduction from
baseline
MD 0.3 % reduction from baseline
lower









185 per 1,000 74 fewer per 1,000
(143 fewer to 98 more)
Response to treatment - not measured - - - - -
Remission - not measured - - - - -
Quality of life - not measured - - - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for imprecision (very broad confidence interval that crossed the null)
 
 
Summary of findings 5.   Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) compared to augmentation of
current antidepressant (various) with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) compared to augmentation of current antidepressant (various) with













































































































































Patient or population: treatment-resistant depression in adults
Setting: outpatient
Intervention: augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d)
Comparison: augmentation of current antidepressant (various) with placebo









(95% CI) Risk with augmentation of
current antidepressant (vari-
ous) with placebo
Risk difference with augmentation
of current antidepressant (vari-
ous) with cariprazine (1 mg/d to
4.5 mg/d)
Depressive symptoms (MADRS) - Any dose






- The mean depressive symptom
score (MADRS) - any dose - was
16.4 points
MD 1.5 points lower
(2.74 lower to 0.25 lower)








119 per 1,000 81 more per 1,000
(19 more to 168 more)
Study populationResponse (≥ 50% improvement in MADRS








383 per 1,000 103 more per 1,000
(27 more to 199 more)









299 per 1,000 21 more per 1,000
(42 fewer to 99 more)
Quality of life - not measured - - - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect













































































































































1 Downgraded one level for imprecision (broad confidence interval)
2 Downgraded one level for imprecision (broad confidence interval that crossed the null)
 
 
Summary of findings 6.   Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) compared to
augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) compared to augmentation of current antidepres-
sant (fluoxetine 20 mg/d to 60 mg/d) with placebo for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: outpatient
Intervention: augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d)
Comparison: augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo









(95% CI) Risk with augmentation of current
antidepressant (fluoxetine 20 mg/
d to 60 mg/d) with placebo
Risk difference with augmen-
tation of current antidepres-
sant (fluoxetine 20 mg/d to 60
mg/d) with olanzapine (5 mg/
d to 20 mg/d)
Depressive symptoms (HAM-D)






- The mean depressive symptom score
(HAM-D) was -3.8
MD 7.9 lower
(16.76 lower to 0.96 higher)
Depressive symptoms (MADRS)






- The mean depressive symptom score
(MADRS) was -1.2
MD 12.4 lower









300 per 1,000 201 fewer per 1,000
(288 fewer to 507 more)








100 per 1,000 500 more per 1,000
(13 fewer to 4,021 more)
Remission - not reported - - - - -













































































































































*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded two levels for imprecision (very broad confidence interval that crossed the null)
2 Downgraded two levels for imprecision (very broad confidence interval)
 
 
Summary of findings 7.   Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) compared to augmentation of
current antidepressant (various) with placebo for treatment-resistant depression in adults
Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) compared to augmentation of current antidepressant (various) with
placebo for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: outpatient
Intervention: augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d)
Comparison: augmentation of current antidepressant (various) with placebo









(95% CI) Risk with augmentation of current an-
tidepressant (various) with placebo
Risk difference with augmenta-
tion of current antidepressant
(various) with quetiapine (150
mg/d to 300 mg/d)
Depressive symptoms (MADRS or HAM-





- The mean depressive symptom score
(MADRS or HAM-D) - any dose was not
calculable
SMD 0.32 lower
(0.46 lower to 0.18 lower)






159 per 1,000 52 more per 1,000













































































































































Study populationResponse (≥ 50% reduction in MADRS







442 per 1,000 110 more per 1,000
(40 more to 194 more)
Study populationRemission (MADRS score ≤ 8/HAM-D







233 per 1,000 123 more per 1,000
(54 more to 210 more)
Quality of life (% max score of Q-LES-
Q-SF) - Any dose






- The mean quality of life (% max score of
Q-LES-Q-SF) - any dose was 55%
MD 0.57 higher
(1.52 lower to 2.65 higher)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for imprecision (broad confidence interval which crossed the null)
2 Downgraded one level for imprecision (broad confidence interval)
 
 
Summary of findings 8.   Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) compared to augmentation of
current antidepressant (SSRI) with placebo or continue on SSRI monotherapy for treatment-resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) compared to augmentation of current antidepressant (SSRI) with placebo
or continue on SSRI monotherapy for treatment-resistant depression in adults
Patient or population: treatment-resistant depression in adults
Setting: outpatient
Intervention: augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d)
Comparison: augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy






















































































































































Risk with augmentation of cur-
rent antidepressant (SSRI) with
placebo or continue on SSRI
monotherapy
Risk difference with Augmenta-
tion of current antidepressant
(SSRI) with ziprasidone (40 mg/d
to 160 mg/d)
Depressive symptoms (HAM-D) - Any dose
Scale from: 0 to 54 (worse)





- The mean depressive symptom
score (HAM-D) - any dose was 14.87
points
MD 2.73 points lower
(4.53 lower to 0.93 lower)








227 per 1,000 136 more per 1,000
(2 more to 352 more)
Study populationResponse (≥ 50% reduction in MADRS/








182 per 1,000 145 more per 1,000
(13 more to 371 more)








250 per 1,000 77 more per 1,000
(50 fewer to 238 more)
Quality of life - not measured - - - - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded one level for imprecision (broad confidence interval)
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B A C K G R O U N D
Description of the condition
Depression is a common mental disorder, characterized by sadness,
loss of interest or pleasure, feelings of guilt or low self-worth,
disturbed sleep or appetite, feelings of tiredness, and poor
concentration. By 2030, depression is predicted to be the leading
cause of disability in high-income countries (Mathers 2005).
Severity of depression can be classified using the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition (DSM-IV)
criteria as mild (five or more symptoms with minor functional
impairment), moderate (symptoms or functional impairment are
between 'mild' and 'severe') and severe (most symptoms present
and interfere with functioning) (NICE 2009).
Antidepressants are oMen prescribed as the first-line treatment for
adults with moderate to severe depression (NICE 2009). In England
in 2014, 57.1 million prescriptions for antidepressants were issued
at a cost of GBP 265 million (NHS Digital 2015). However, two-thirds
of people do not respond fully to such pharmacotherapy (Trivedi
2006). Such nonresponse may be because of intolerance to the
prescribed medication or non-adherence to the treatment regimen,
but may also be the result of treatment 'resistance', where an
adequate dose and duration of treatment has been prescribed. The
earliest definition of treatment-'resistant' depression was given
by the World Psychiatric Association; it defined 'resistance' as
"an absence of clinical response to treatment with a tricyclic
antidepressant at a minimum dose of 150 mg per day of imipramine
(or equivalent drug) for 4 to 6 weeks" (WPA 1974). Subsequently,
others have suggested more complex classification systems based
on nonresponse to multiple courses of treatment (Fava 2005;
Fekadu 2009; Thase 1997), and used other terms such as 'treatment
refractory' depression and 'antidepressant resistant' depression to
describe this condition. For the purpose of this review, we will use
the term 'treatment-resistant depression' as this is the descriptor
that has, generally, represented the broadest definition of the
condition.
Globally, the prevalence of major depressive disorder (MDD) has
been estimated to be 4.7 % (Ferrari 2013), with a lifetime prevalence
as high as 17% (Kessler 2013). Depression imposes an economic
burden on society in terms of both the direct costs of treatment
and indirectly through its eNects on productivity (Wang 2003).
Healthcare utilisation and related costs of TRD are higher than for
MDD (Gibson 2010; Mahlich 2018). If up to one-third of patients
have 'treatment-resistant' depression (TRD), it is thus clear that
this condition represents a considerable burden to patients, health
systems and society.
Description of the intervention
Antidepressants are commonly used as the first-line treatment
for adults with moderate to severe depression (NICE 2009).
There are five main types of antidepressants: tricyclic (TCAs) and
related antidepressants; monoamine-oxidase inhibitors (MAOIs);
selective serotonin re-uptake inhibitors (SSRIs); serotonin and
noradrenaline reuptake inhibitors (SNRIs); and noradrenergic and
specific serotonin antidepressants (NaSSAs). SSRIs are generally
better tolerated than other classes of antidepressants and are safer
with regards to overdose than TCAs. It is, therefore, not surprising
that SSRIs are the most commonly prescribed antidepressants for
treating depression (NHS Information Centre 2011).
There is no standard approach to the treatment of those whose
depression does not respond to antidepressant medication.
Guidance published by the American Psychiatric Association
(APA 2010) and the National Institute for Health and Clinical
Excellence (NICE 2009) suggests that the potential 'next step' may
include increasing the dose of the antidepressant medication
or switching to another antidepressant (within the same
or a diNerent pharmacological class) or augmentation with
another pharmacological or psychological treatment. In terms of
combination treatment with an additional pharmacological agent,
this may comprise either: (1) another antidepressant or (2) a non-
antidepressant medication, which may include (i) lithium, (ii) an
antipsychotic (e.g. olanzapine), (iii) pindolol, (iv) triiodothyronine
(T3) or (v) buspirone.
How the intervention might work
Most antidepressants work by inhibiting the uptake of monoamine
neurotransmitters into neurons. The SSRI group inhibit the uptake
of serotonin, and many of the older tricyclics have actions on both
serotonin and noradrenaline (along with other pharmacological
actions not thought to be important in depression).
For those people whose depression has not responded to
initial treatment with an antidepressant, increasing the dose
or switching medication may improve their outcome through
the associated pharmacological actions, for example, increasing
levels of neurotransmitters such as serotonin and noradrenaline.
Increased serotonin neurotransmission may also be expected
when two serotonergic drugs with diNerent modes of action are
combined (NICE 2009). For example, mirtazapine is a noradrenergic
and specific serotonergic antidepressant (NaSSA) that acts by
antagonising the adrenergic alpha2-autoreceptors and alpha2-
heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors
(Anttila 2001). In general, the rationale for combination therapy
with two diNerent antidepressants or augmentation with a non-
antidepressant medication (such as lithium), is that such treatment
broadens the pharmacological actions involved (Anderson 2008).
Why it is important to do this review
Antidepressants continue to be the first-line treatment for many
people with depression. However, two-thirds of people prescribed
antidepressants for depression do not respond fully to such
medication (Trivedi 2006). It is, therefore, important to summarise
the evidence on the eNectiveness of pharmacological interventions
for people with TRD in order to establish the best 'next step'
treatment for this patient group.
There have been several narrative reviews of the evidence on
the treatment of people whose depression has not responded to
antidepressant medication alone (e.g. Carvalho 2008; Nierenberg
2007; Papakostas 2009). Systematic reviews of the eNectiveness
of combination treatment for people with depression have not
examined the evidence for the treatment-resistant population
(Friedman 2004; Pampallona 2004). Others have summarised the
evidence for the eNectiveness of particular treatment strategies
for those who have not responded to antidepressants: (1)
augmentation (Carvalho 2007) with lithium (Bauer 1999) or
atypical antipsychotics (Shelton 2008); and (2) within- or between-
class switches (Papakostas 2008), and one review focused on
interventions for older people (≥ 55 years) (Cooper 2011). However,
a number of these reviews included uncontrolled studies or non-
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randomised studies or both, as well as randomised controlled trials
(RCTs) (Carvalho 2007; Cooper 2011; Shelton 2008).
A previous systematic review of RCTs investigating
pharmacological and psychological treatments for people with TRD
failed to find strong evidence to guide the management of such
people (Stimpson 2002). However this review, along with others
(e.g. Bauer 1999, which summarised the evidence for lithium up
to June 1997) is out-of-date and a number of relevant RCTs have
been published subsequently. These include a review by Edwards
2013 that has a narrow focus both in terms of the interventions
to be examined (lithium or an atypical antipsychotic) and the
definition of treatment resistance. The latter is defined as "failure
to respond to at least two previous antidepressants in the current
episode of depression". While this definition of treatment resistance
has been frequently used, we know that many people do not
respond to an initial course of antidepressants and there is little
evidence to inform the most appropriate 'next step' treatment for
this group (NICE 2009). Therefore, given the continued reliance
upon antidepressants as a first-line treatment for depression,
we propose using an inclusive definition of treatment resistance
(based on nonresponse to at least four weeks of antidepressant
medication) in order to help establish the best 'next step' treatment
for the large number of people whose depression does not respond
to antidepressants. The rise in the number of prescriptions for
antidepressants in recent years means that a review of the evidence
for the eNectiveness of pharmacological interventions for people
with TRD is timely (Pincus 1998; McManus 2000; Middleton 2001).
Studies examining psychological interventions for TRD will be
excluded as these are the focus of another review (Ijaz 2018).
Together, the evidence from these two linked reviews will provide
a comprehensive review of the main interventions for the
management of  TRD, which will  inform clinical decision-making
with regards to the best 'next step' for adults whose depression has
not responded to first-line treatment with medication.
O B J E C T I V E S
To assess the eNectiveness of pharmacological interventions for
TRD in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The methods used in our review were previously described in a
published protocol (Williams 2013).
Randomised controlled trials (RCTs) were eligible for inclusion in
the review. Trials employing a cross-over design could be included
in the review, using data from the first active treatment stage only.
Cluster RCTs were also eligible for inclusion.
Any other study design, including quasi-randomised studies and
non-randomised studies, were excluded from this review.
Types of participants
Age range
Participants were adults aged 18 to 74 years.
If the study included some participants that were aged under 75
years and some over the age of 74 years, we excluded the study
if the mean age of participants was over 74 years. Similarly, if the
study included some participants that were aged under 18 years
and some aged 18 years or older, we excluded the study if the mean
age of participants was less than 18 years.
Definition of treatment-resistant depression
For a study to be eligible for inclusion in this review, all of
the participants had to meet our criteria for treatment-resistant
depression at the point at which they were randomly allocated
to treatment. We included studies that began with an open-label
lead-in phase to confirm treatment resistance provided that only
participants meeting our definition of TRD continued into the
randomised treatment phase.
We defined treatment-resistant depression as a primary diagnosis
of unipolar depression that had not responded (or had
only partially responded) to a minimum of four weeks of
antidepressant treatment at a recommended dose (at least 150
mg/day imipramine or equivalent antidepressant (e.g. 20 mg/day
citalopram)).
We excluded studies that included participants who had not
responded because of intolerance to antidepressant medication.
While there have been initiatives to improve access to
psychological therapies in England and elsewhere, access to
psychological treatment is still limited and antidepressants are
oMen the first-line treatment for adults with depression. Therefore,
this review did not include studies of interventions intended for
those who had not responded to psychological treatment.
Diagnosis
Acceptable diagnoses of unipolar depression included those
based on criteria from DSM-IV-TR or earlier versions (APA 2000),
International Classification of Diseases (ICD)-10 (WHO 1992),
Feighner criteria (Feighner 1972) or Research Diagnostic Criteria
(Spitzer 1978). Studies that had not used standardised diagnostic
criteria were excluded.
Comorbidity
Studies of participants with comorbid schizophrenia or bipolar
disorder were excluded.
Studies including both unipolar and bipolar participants were
excluded unless data were available for the subgroup of unipolar
participants.
This review included studies involving participants with comorbid
physical conditions or other psychological disorders (e.g. anxiety)
for whom the pharmacological therapy was not being primarily
used to manage the physical illness, in other words, the focus of
treatment was TRD - not the comorbidity.
Types of interventions
Experimental interventions
The experimental interventions were based on the 'next step'
approach to the management of depression that had not
responded to treatment with antidepressants:
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• increasing the dose of antidepressant monotherapy;
• switching to a diNerent antidepressant monotherapy;
• augmenting treatment with another antidepressant;
• augmenting treatment with a non-antidepressant.
Antidepressants can be grouped as TCAs, MAOIs, SSRIs, SNRIs and
NaSSAs.
Non-antidepressant medications used as augmentors included
antipsychotics (e.g. olanzapine), anxiolytics (e.g. buspirone),
antimania drugs (e.g. lithium) and beta-blockers (e.g. pindolol).
Studies examining non-standard pharmacological approaches for
treating TRD (e.g. sex hormones, vitamins, herbal medicines
and food supplements) were excluded. Studies examining
psychological interventions given in addition to antidepressant
medication for individuals with TRD are included in another review
(Ijaz 2018).
Comparator interventions
• The control comparison was continuing on the initial
antidepressant monotherapy.
Full details of comparisons made can be found in the Data
extraction and management section.
Types of outcome measures
Primary outcomes
1. Change in depressive symptoms as measured on rating scales
for depression, either clinician-rated (e.g. Hamilton Rating Scale
for Depression (HAM-D; Hamilton 1960) or Montgomery-Asberg
Depression Rating Scale (MADRS; Montgomery 1979)), or self-report
(e.g. Beck Depression Inventory (BDI; Beck 1961; Beck 1996) (or
other validated measures)). Data on observer-rated and self-report
outcomes were analysed separately.
2. Number of dropouts from study or treatment (all-cause dropout)
within the trials. Where available, we extracted data on reasons for
dropout and summarised these in narrative form.
Secondary outcomes
3. Response or remission rates, or both, based on changes in
depression measures - either clinician-rated (e.g. HAM-D; Hamilton
1960) or self-report (e.g. BDI; Beck 1961; Beck 1996) or other
validated measures. Response is frequently quantified as at least
a 50% reduction in symptoms on the HAM-D or BDI but we
accepted the study's original definition. Remission is based on the
absolute score on the depression measure. Examples of definitions
of remission include 7 or less on the HAM-D and 10 or less on BDI.
Again, we accepted the study authors' original definition.
4. Improvement in social adjustment and social functioning
including the Global Assessment of Function (Luborsky 1962)
scores, where reported, were summarised in narrative form.
5. Improvement in quality of life as measured on the Short Form
(SF)-36 (Ware 1993), Health of the Nation Outcome Scales (HoNOS)
(Wing 1994), or World Health Organization Quality of Life (WHOQOL)
(WHOQOL 1998) or similar scale, where reported, were summarised
in narrative form.
6. Economic outcomes (e.g. days of work absence/ability to return
to work, number of appointments with primary care physician,
number of referrals to secondary services, use of additional
treatments), where reported were summarised in narrative form.
7. Adverse eNects (e.g. completed/attempted suicides), where
reported, were summarised in narrative form.
Timing of outcome assessment
Outcomes at each reported follow-up point were summarised.
Where appropriate and if the data allowed, outcomes were
categorised as short-term (up to 12 weeks) and longer-term (longer
than 12 weeks). 
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled Trials Register
(CCMDCTR)
The Cochrane Common Mental Disorders (CCMD) Group maintains
an archived register of RCTs, the CCMDCTR. This register contains
over 40,000 reference records (reports of RCTs) for anxiety and
depressive disorders, bipolar disorder, eating disorders, self-harm
and other mental disorders within the scope of this Group. The
CCMDCTR is a partially studies-based register, with 50% of the
reference records tagged to over 12,000 individually PICO-coded
study records. Reports of trials for inclusion in the register were
routinely collated from generic searches of MEDLINE (1950-),
Embase (1974-) and PsycINFO (1967-), quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL)
and review-specific searches of additional databases (to June
2016). Reports of trials were also sourced from international trial
registries, drug companies, the handsearching of key journals,
conference proceedings and other (non-Cochrane) systematic
reviews and meta-analyses. Details of the CCMD Group's core
search strategies (used to identify RCTs) can be found on the
Group's website, with an example of the core MEDLINE search
displayed in Appendix 1.
The Group’s Specialised Register had fallen out of date with the
Editorial Group’s move from Bristol to York in the summer of 2016.
Electronic searches
We searched the CCMDCTR-Studies Register using the following
terms:
Condition = ((depressi* or "aNective disorder" or "mood disorder*")
and ("treatment-resistant" or recurrent))
Additionally we searched the CCMDCTR-References Register using
a more sensitive set of terms (keywords and subject headings) to
identify additional untagged/uncoded references:
1. depressi* [Ti, Ab, KW]
2. (*refractory* or *resistan* or *recurren*) [Ti, Ab]
3. (augment* or potentiat*) [Ti, Ab]
4. (chronicity or "chronic depress*" or "chronically depress*" or
"depressed chronic*" or "chronic major depressi*" or "chronic
aNective disorder*" or "chronic mood disorder*" or (chronic* and
(relaps* or recurr*))) [Ti, Ab, KW]
5. ("persistent depress*" or "persistently depress*" or "depression
persist*" or "persistent major depress*" or "persistence of
depress*" or "persistence of major depress*") [Ti, Ab]
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6. (nonrespon* or non-respon* or "non respon*" or "not respon*"
or "no respon*" or "partial respon*" or "partially respon*" or
"incomplete respon*" or "incompletely respon*" or unrespon*) [Ti,
Ab]
7. ("failed to respond" or "failed to improve" or "failure to respon*"
or "failure to improve" or "failed medication*" or "antidepressant
fail*" or "treatment fail*") [Ti, Ab]
8. (inadequate* and respon*) [Ti, Ab]
9. "treatment-resistant depression" [KW]
10. (recurrence or "recurrent depression" or "recurrent disease")
[KW]
11. "drug resistance" [KW]
12. "treatment failure" [KW]
13. "drug potentiation" [KW]
14. augmentation [KW]
15. or/2-14
16. (1 and 15)
We applied no date or language restrictions to our search. Our
search of the CCMDCTR was up-to-date as of 18 March 2016.
We ran additional searches via the following biomedical databases
(1 January 2016 to 31 December 2018) (Appendix 2):
1. MEDLINE/Premedline (Ovid);
2. Embase (Ovid);
3. Cochrane Central Register of Controlled Trials (CENTRAL);
4. PsycINFO (Ovid);
5. Web of Science Core Collection (Clarivate Analytics).
We used the term 'treatment-resistant' or 'treatment refractory'
depression to search international trials registries, including the
WHO trials portal (ICTRP) and ClinicalTrials.gov (to 31 December
2018) (Appendix 2), to identify any additional ongoing and
unpublished studies. We contacted principal Investigators, when
necessary, to request further details of ongoing/unpublished
studies or trials reported as conference abstracts only. These
searches are up-to-date as of 31 December 2018.
Searching other resources
Reference lists of all included studies and other relevant systematic
reviews were searched for papers that might meet the inclusion
criteria. Subject experts were also contacted to ensure that all
relevant published and unpublished studies were considered for
inclusion.
Data collection and analysis
Selection of studies
One review author (NW, PD or SI) examined titles and abstracts
to remove obviously irrelevant reports and then screened study
abstracts against inclusion criteria using a standardised abstract
screening form. In any case of uncertainty, an over-inclusive
approach was taken and the full paper was obtained along with
those for the studies assessed as meeting the inclusion criteria.
Two review authors (of CW, MT, NW, GL, DK, PD and SI) screened
each paper for inclusion or exclusion from the review. If any
disagreements arose, these were discussed with a third review
author. If it was not possible to determine eligibility for a study, it
was added to the list of those awaiting assessment and the authors
were contacted for further information or clarification.
The study selection process was documented using a PRISMA study
selection flow diagram.
Data extraction and management
Data regarding participants, interventions and their comparators,
methodological details, and treatment eNects, including dropouts
and possible biases, were independently extracted by two review
authors (PD and SI) using a standardised data extraction form. If
any disagreements arose, these were discussed with a third review
author. The data extraction form was piloted during the first phase
of data extraction.
Information relating to study population, definition of TRD, sample
size, interventions, comparators, potential biases in the conduct of
the trial, outcomes, follow-up and methods of statistical analysis
was abstracted.
Main planned comparisons
1. Increasing the dose of antidepressant monotherapy compared
with continuing on an antidepressant.
2. Switching to a diNerent antidepressant monotherapy compared
with continuing on an antidepressant.
3. Augmenting treatment with another antidepressant compared
with continuing on an antidepressant.
4. Augmenting treatment with a non-antidepressant compared
with continuing on an antidepressant.
Within each of these strategies, where there was suNicient data,
this review summarised the evidence for each drug individually.
For example, taking the fourth approach of augmenting with
a non-antidepressant medication, the augmentor could have
been lithium, olanzapine, buspirone or pindolol. In this case,
the evidence for each of these four drugs would be presented
separately, rather than combined, to summarise the evidence for
a particular 'treatment approach'. This was done to maximise the
clinical relevance of the findings.
Given the large number of possible combinations of medications
that could be evaluated, it was not possible to provide an
exhaustive list of all the potential comparisons. However, one
example for each of the diNerent approaches have been given
below.
1. Citalopram 40 mg/day compared with remaining on citalopram
20 mg/day.
2. Switching to mianserin compared with remaining on fluoxetine.
3. Addition of mianserin to fluoxetine compared with remaining on
fluoxetine alone.
4. Nortriptyline plus lithium compared with remaining on
nortriptyline alone.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
included study using Cochrane's 'Risk of bias' tool (Higgins 2011a).
If any disagreements arose, these were discussed with a third
review author. The following criteria were assessed:
• sequence generation: was the allocation sequence adequately
generated?
• allocation concealment: was allocation adequately concealed?
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• blinding of participants, study personnel and outcome assessors
for each outcome: was knowledge of the allocated treatment
adequately prevented during the study?
• incomplete outcome data for each main outcome or class
of outcomes: were incomplete outcome data adequately
addressed?
• selective outcome reporting: are reports of the study free of
suggestion of selective outcome reporting?
• other sources of bias: was the study apparently free of other
problems that could put it at a high risk of bias?
A description of what was reported to have happened in each study
was generated and a judgement on the risk of bias was made for
each domain within and across studies, based on the following
three categories: low risk of bias; unclear risk of bias; high risk of
bias.
Where studies provided little or no detail about randomisation, the
authors were contacted to seek clarification.
All risk of bias data were presented graphically and described in the
text.
Measures of treatment e4ect
Continuous outcomes were analysed by calculating the mean
diNerence (MD) between groups, where studies used the same
outcome measure for comparison. Where diNerent outcome
measures were used to assess the same outcome, the standardised
mean diNerence (SMD) and 95% confidence intervals (CI) were
calculated. The SMD was interpreted as follows: 0.2 represents a
small eNect, 0.5 a moderate eNect, and 0.8 a large eNect (Cohen
1988).
We calculated risk ratios (RRs) for dichotomous outcomes. When
overall risks were significant, the number needed to treat for an
additional beneficial outcome (NNTB) or for an additional harmful
outcome (NNTH) to produce one outcome was calculated by
combining the overall RR with an estimate of prevalence of the
event in the control group of the trials.
Unit of analysis issues
Cluster-randomised trials
We planned to incorporate results from cluster RCTs into the review
using generic inverse variance methods (Higgins 2011). With cluster
RCTs, it is important to ensure that the data were analysed taking
into account the clustered nature of the data. The intracluster
correlation coeNicient (ICC) would be extracted for each trial. Where
no such data were reported, this information was requested from
study authors. If this was not available, in line with the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011), we
planned to use estimates from similar studies in order to 'correct'
data for clustering, where this had not been done. We did not,
however, identify any cluster RCTs that met the inclusion criteria for
our review.
Cross-over trials
For cross-over trials, only results from the first randomised
treatment period were to be included in the analysis. We did
not, however, identify any cross-over trials that met the inclusion
criteria for our review.
Studies with multiple treatment groups
Trials that have more than two arms (e.g. pharmacological
intervention (A); pharmacological intervention (B); and control)
can cause problems in pairwise meta-analysis. Where we identified
studies with two or more active treatment arms, the following
approach was undertaken (dependent on whether the outcome
was continuous or dichotomous).
For a continuous outcome: means, standard deviations (SDs) and
the number of participants for each active treatment group were
pooled across treatment arms as a function of the number of
participants in each arm to be compared against the control group
(Higgins 2011).
For a dichotomous outcome: active treatment groups were
combined into a single arm for comparison against the control
group (in terms of the number of people with events and sample
sizes), or the control group was split equally (Higgins 2011).
Dealing with missing data
Where there were missing data, study authors were contacted
to obtain data. If an outcome was missing for more than 50%
of participants, this study was excluded from the analysis. When
available, we used intention-to-treat (ITT) analyses from study
reports and wrote to study authors to request relevant unreported
analyses.
Assessment of heterogeneity
Heterogeneity was assessed using the Chi2 test, which provides
evidence of variation in eNect estimates beyond that of chance.
The Chi2 test has low power to assess heterogeneity when there
are few included studies or small numbers of participants, so
the P value was conservatively set at 0.1. Heterogeneity was also
quantified using the I2 statistic, which calculates the percentage of
variability due to heterogeneity rather than chance. We expected,
a priori, that there would be considerable clinical heterogeneity
between studies, therefore I2 values between 50% and 90% were
considered to represent substantial statistical heterogeneity and
were explored further. However, the importance of the observed
I2 value depended on the magnitude and direction of treatment
eNects and the strength of evidence for heterogeneity (Higgins
2011).
Assessment of reporting biases
Reporting bias was managed by undertaking comprehensive
searches for papers that were not restricted to the English
language. Outcome reporting bias was determined for all included
studies and trial protocols were sought wherever possible. If
outcome data were missing, these were requested from authors.
We had planned to use funnel plots to help detect reporting biases
if at least 10 studies were included for a comparison (Higgins 2011)
and undertake formal assessment of asymmetry in the funnel plot
using the Egger test (Egger 1997).
Data synthesis
Given the potential for heterogeneity in the included interventions,
we used a random-eNects model for all analyses. This approach
incorporated the assumption that the diNerent studies were
estimating diNerent, yet related, intervention eNects and it took
into account diNerences between studies even if there was no
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statistically significant heterogeneity. Heterogeneity was tested
formally using both the Chi2 test and I2 statistic (as outlined
above). We sought clinical advice in terms of combining treatment
groups in order to ensure that findings were clinically meaningful.
Where studies reported both short-term and long-term outcomes,
separate meta-analyses were conducted for each of these time
points.
Where meta-analysis was not possible (e.g. due to insuNicient
data or substantial heterogeneity), a narrative assessment of the
evidence was given. This assessment summarised the evidence
according to intervention type.
Subgroup analysis and investigation of heterogeneity
A priori, we considered the degree of treatment resistance recorded
at the point of entry to the trial as a potential eNect modifier.
Therefore, the following subgroup analyses were planned:
• severity of depression: classifying participants as non-
responders or partial responders at baseline;
• Length of acute treatment phase (before trial entry): four weeks
or longer; 12 weeks or longer and six months or longer.
Such subgroup analyses were only to be conducted when there
were data from at least 10 studies to be included (Higgins 2011).
Sensitivity analysis
Sensitivity analyses were planned to explore how much
of the variation between studies comparing pharmacological
interventions for TRD was accounted for by between-study
diNerences in:
• study quality: allocation concealment was used as a marker of
trial quality. Studies that had not used allocation concealment
were to be excluded;
• blinding: studies that were unblinded (participants, study
personnel or outcome assessors) were excluded;
• attrition: studies with more than 20% dropout were excluded;
• missing data: studies that had imputed missing data were
excluded;
• funding source: studies funded by pharmaceutical companies
were excluded;
• publication type:  studies not published in full (conference
abstract/proceedings, doctoral dissertation) were excluded.
Sensitivity analysis was planned by excluding the studies above
and comparing each of the results with the full analysis which
included all trials.
Summary of findings tables
'Summary of findings' tables were prepared for all of the
comparisons in this review for the following outcomes: depressive
symptoms, dropouts, response to treatment, remission from
depression and quality of life. Where studies reported outcome
data based on more than one method of measurement (e.g.
multiple depression severity scales) we reported the study's own
choice of primary outcome in the 'Summary of findings' table.
Similarly, where studies reported data for more than one time
point, we chose the time point corresponding to the primary
outcome to include in the summary of findings.
R E S U L T S
Description of studies
Results of the search
We identified 7969 references through our searches of bibliographic
databases and trial registries and 19 references from additional
sources. AMer removing duplicates, we screened 7342 titles and
abstracts, of which we excluded 6728 as not relevant. Full-text
reports of 614 references were obtained and screened against our
eligibility criteria. We excluded 573 articles and provided reasons
for exclusion in Figure 1. We used a hierarchy of reasons for
exclusion, shown in Table 1, which also reports the number and
frequency of articles excluded for each reason. The most common
reasons for exclusions were: that the intervention evaluated was
not a standard pharmacological treatment (n = 131, 22.9%), study
participants did not meet the definition of treatment-resistant
depression (n = 112, 19.5%), the comparison made in the study was
not one of interest to the review (for example, there was no control
group that continued on the original antidepressant therapy) (n =
100, 17.5%) or the study was not randomised (n = 106, 18.5%).
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Figure 1.   Flow diagram
 
Eligibility could not be determined for six references and no
response was received from requests to study authors for further
clarification (see Characteristics of studies awaiting classification).
In total, 35 references reporting ten studies were included in this
review. All studies contributed data to meta-analyses. We contacted
the authors of 57 articles to clarify details of their study and received
a response from 11. Full details of the study flow are given in a
PRISMA flow diagram in Figure 1.
Included studies
Included studies
We identified ten studies (35 references) that were eligible for
inclusion in the review (Appelberg 2001; Bauer 2009 (ONYX); Dunner
2007; Durgam 2016; El-Khalili 2010 (PEARL); Ferreri 2001; Kessler
2018; McIntyre 2007; Papakostas 2015; Shelton 2001). Further
information on each study can be found in the Characteristics of
included studies table.
Design
All of the included studies were parallel-group randomised
controlled trials and the unit of allocation was the individual
participant. Eight studies were multisite (number of sites ranged
from two to 84). One study had a single site (McIntyre 2007). The
number of study sites was not reported in Dunner 2007.
Five studies were three-arm trials (Bauer 2009 (ONYX); Dunner 2007;
Durgam 2016; El-Khalili 2010 (PEARL); Ferreri 2001).
Length of follow-up was short-term (12 weeks or less) in nine
studies. Only one study (Kessler 2018) reported data for longer-term
outcomes (24 and 52 weeks).
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Sample sizes
Sample size ranged from 20 (Shelton 2001) to 819 (Durgam 2016)
with a median of 122 participants (IQR: 71, 472).
Setting and date
All studies were carried out in high-income countries. Four studies
were conducted in the US (Dunner 2007; El-Khalili 2010 (PEARL);
Papakostas 2015; Shelton 2001); one each in Canada (McIntyre
2007), England (Kessler 2018) Finland (Appelberg 2001) and France
(Ferreri 2001); and two in multiple countries across Europe, North
America and Australia (Bauer 2009 (ONYX); Durgam 2016).
Nine studies were conducted solely in outpatient medical settings
and one (Ferreri 2001) included both in- and outpatients. One study
(Kessler 2018) was conducted in primary care. Six studies were
conducted in the decade 2000 to 2009 (Appelberg 2001; Bauer
2009 (ONYX); Dunner 2007; Shelton 2001; Ferreri 2001; McIntyre
2007) and four since 2010 (Durgam 2016; El-Khalili 2010 (PEARL);
Papakostas 2015; Kessler 2018).
Participants
The mean age of participants was very similar across the included
studies, ranging from 42 years (Shelton 2001) to 50.2 years (Kessler
2018). The majority of participants in the included studies were
women (51.7% in Dunner 2007 to 75% in Shelton 2001).
Definition of treatment-resistant depression
Participants had a diagnosis of major depressive disorder (MDD)
according to DSM III-R (Ferreri 2001), DSM-IV (Appelberg 2001;
Bauer 2009 (ONYX); Dunner 2007; El-Khalili 2010 (PEARL); McIntyre
2007; Papakostas 2015; Shelton 2001) DSM-IV-TR (Durgam 2016),
or ICD-10 (Kessler 2018) criteria. Participants were additionally
required to have a HAM-D score of at least 18 (McIntyre 2007), 20
(Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); Shelton 2001) or 25
(Ferreri 2001); a MADRS score of 22 or more (Durgam 2016); a BDI-II
score of 14 or more (Kessler 2018); or a score of greater than four on
the clinical global impressions (CGI) scale (Dunner 2007). MDD was
recurrent for all participants in Shelton 2001.
In nine studies, participants had TRD at the time of enrolment
(Appelberg 2001; Bauer 2009 (ONYX); Dunner 2007; Durgam 2016;
El-Khalili 2010 (PEARL); Ferreri 2001; McIntyre 2007; Shelton
2001; Kessler 2018). In one study (Papakostas 2015), participants
were recruited with Major Depressive Disorder. Following an 8-
week open-label treatment with fluoxetine (10 mg/d or greater),
participants who continued to meet DSM criteria were considered
to be treatment-resistant and randomised to adjunctive treatment
with an antipsychotic.
In eight of the nine studies where participants had TRD at the
time of enrolment, participants had had an inadequate response
to at least one antidepressant at the manufacturers recommended
minimum dose (or above) for a minimum of four (Bauer 2009
(ONYX); Dunner 2007) or six (Appelberg 2001; Durgam 2016; El-
Khalili 2010 (PEARL); Ferreri 2001; Kessler 2018; McIntyre 2007)
weeks. Two of these studies (Bauer 2009 (ONYX) and El-Khalili 2010
(PEARL)) had a further requirement of at least one dose increase as
permitted by the label. In the ninth trial (Shelton 2001), participants
had failed to respond to antidepressants of two diNerent classes
(each given for a minimum of four weeks).
Two of the studies in which participants had TRD at enrolment had
an open-label lead-in phase in which participants had a trial of a
further antidepressant at or above the recommended minimum
dose for six weeks (Dunner 2007; Shelton 2001). Only participants
with an inadequate response to this were then randomised into the
main trial.
Two studies had exclusion criteria based on resistance to prior
antidepressant treatments. Durgam 2016 and Papakostas 2015
both excluded individuals with an inadequate response to three
or more antidepressants at suNicient doses during the current
depressive episode.
Further details of previous antidepressant treatments can be found
in the Characteristics of included studies table.
Interventions
There were no studies of increasing the dose of antidepressant
monotherapy that met the inclusion criteria for the review.
One study looked at the eNectiveness of switching from current
antidepressant therapy (fluoxetine) to another antidepressant
(mianserin, Ferreri 2001) compared with continuing on the original
antidepressant therapy.
Two studies examined the eNects of augmenting current
antidepressant treatment with another antidepressant compared
with continuing on antidepressant monotherapy. The adjunctive
treatment was mianserin in one study (Ferreri 2001, a three-arm
trial) and mirtazapine in the other (Kessler 2018).
Eight studies examined the eNectiveness of augmenting treatment
with a non-antidepressant medication compared with continuing
on an antidepressant. The adjunctive treatment was an anxiolytic
(buspirone) in one study (Appelberg 2001) and an antipsychotic
in seven studies (Bauer 2009 (ONYX); Dunner 2007; Durgam 2016;
El-Khalili 2010 (PEARL); McIntyre 2007; Papakostas 2015; Shelton
2001). Three studies examined the eNectiveness of antipsychotic
quetiapine (Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); McIntyre
2007), two studied ziprasidone (Papakostas 2015; Dunner 2007),
and there was a single study for cariprazine (Durgam 2016) and
olanzapine (Shelton 2001). Four studies were three-arm trials
which investigated higher and lower doses of the augmented
antipsychotic (quetiapine - Bauer 2009 (ONYX); El-Khalili 2010
(PEARL); cariprazine - Durgam 2016; ziprasidone - Dunner 2007).
Length of treatment was six weeks in four studies (Appelberg 2001;
Bauer 2009 (ONYX); El-Khalili 2010 (PEARL);Ferreri 2001), eight
weeks in four studies (Dunner 2007; Durgam 2016; McIntyre 2007;
Papakostas 2015; Shelton 2001) and up to 52 weeks in one study
(Kessler 2018).
Comparisons
Participants in the comparator arm continued to receive the same
dose of antidepressant monotherapy in all of the trials. In all but
one trial (Dunner 2007), a placebo was given in addition to the
continued antidepressant treatment.
Primary outcomes
1). Change in depressive symptoms
All studies reported one or more measures of depressive symptoms
measured on a severity rating scale. Six studies used the
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Montgomery-Asberg Depression Scale (Appelberg 2001; Bauer
2009 (ONYX); Dunner 2007; Durgam 2016; El-Khalili 2010 (PEARL);
Shelton 2001), six the Hamilton Depression Rating Scale (Bauer
2009 (ONYX); El-Khalili 2010 (PEARL); Ferreri 2001; McIntyre
2007; Papakostas 2015; Shelton 2001), one the Beck Depression
Inventory-II (BDI-II) and Patient Health Questionnaire-9 (PHQ-9)
(Kessler 2018), and one the Quick Inventory of Depressive
Symptomatology - self-report version (QIDS-SR, Papakostas 2015).
Five studies reported mean change from baseline in each study
arm (Ferreri 2001; Kessler 2018; McIntyre 2007; Papakostas 2015;
Shelton 2001), one reported mean percentage change from
baseline (Appelberg 2001) and four studies reported a least squares
mean change estimated from an analysis of covariance (ANCOVA)
incorporating baseline depression severity as a covariate in the
model (Bauer 2009 (ONYX); Dunner 2007; Durgam 2016; El-Khalili
2010 (PEARL).
2). Number of dropouts
All studies reported the number of participants in each arm who
dropped out during the treatment period for any reason.
Secondary outcomes
3). Response or remission rates
Nine studies reported a dichotomous outcome of response to
treatment, defined as a reduction of 50% or more from baseline to
end of treatment in score on either the MADRS (Bauer 2009 (ONYX);
Dunner 2007; Durgam 2016; El-Khalili 2010 (PEARL); Shelton
2001), HAM-D (Papakostas 2015), BDI-II (Kessler 2018) or QIDS-SR
(Papakostas 2015).
Eight studies reported remission from depression using a cut-oN
score of less than or equal to eight (Bauer 2009 (ONYX); El-Khalili
2010 (PEARL)); or ten (Dunner 2007; Durgam 2016) on the MADRS,
seven (McIntyre 2007; Papakostas 2015) or eight (Ferreri 2001) on
the HAM-D, nine on the BDI-II (Kessler 2018) or five on the QIDS-SR
(Papakostas 2015).
4). Social Adjustment and Social functioning scales
No studies reported data on either social adjustment or social
functioning.
5). Improvement in Quality of Life Measure
Three studies reported data on quality of life. Bauer 2009 (ONYX);
El-Khalili 2010 (PEARL) reported mean change from baseline in
quality of life using the Quality of Life Enjoyment and Satisfaction
Questionnaire short-form (Q-LES-Q-SF). Kessler 2018 reported
mean scores on the five-level EQ-5D (EQ-5D-5L) scale, and the
aggregate mental functioning and aggregate physical functioning
scales of the SF-12 at follow-up.
6). Economic outcomes
One study (Kessler 2018) reported direct costs to health and social
services, costs to patients and carers, and time oN work for patients
and carers.
7). Adverse Events
Eight studies reported arm-level adverse event data (Bauer 2009
(ONYX); Dunner 2007; Durgam 2016; El-Khalili 2010 (PEARL); Ferreri
2001; Kessler 2018; McIntyre 2007; Papakostas 2015). Information
on adverse events was incompletely reported in two studies
(Appelberg 2001; Shelton 2001).
Excluded studies
In total, we excluded 573 references at full-text screening. In
accordance with the guidance in the Cochrane Handbook, we have
provided a list of those studies that almost met our eligibility
criteria and further details of their reason for exclusion (see table
of Excluded studies). Of these 105 studies, the primary reasons for
exclusion were as follows: 45 did not have a comparator arm where
participants continued with current antidepressant medication
only (with or without placebo); 33 did not meet our criteria
for treatment-resistant depression at the point of randomisation
and in 26 studies no formal diagnostic criteria for diagnosis of
depression were applied at the point of randomisation.
The STAR*D trial (STAR*D 2004) was one of our excluded studies.
This study evaluated a sequence of diNerent treatment options for
depression. Participants who failed to respond to treatment were
randomised into the next level of the study. Participants enrolled in
level one had MDD, not TRD (therefore, this level was not eligible
for our review). Each successive level involved a switching to a
diNerent treatment strategy or augmenting current treatment with
additional medication. As none of these later levels included a
group that continued on current antidepressant medication alone
they were also not eligible for inclusion.
Ongoing studies
We did not identify any ongoing studies.
Studies awaiting classification
There was insuNicient information in the study reports for six
studies (Cao 2005; Clunie 2001; Euctr-002130-11-Es 2007; Gulrez
2012; Moica 2018; Zhu 2003) to determine eligibility for inclusion
in our review. Two of these reports were trial protocols (Clunie
2001; Euctr-002130-11-Es 2007) and no publications relating to the
studies could be identified.
We were unable to contact the authors for further information
for two of these (Euctr-002130-11-Es 2007; Zhu 2003) and did not
receive a response for the remainder (Cao 2005; Clunie 2001; Gulrez
2012; Moica 2018). Further information on these studies can be
found in the Characteristics of studies awaiting classification table.
Risk of bias in included studies
Full details of the risk of bias  for the included studies are
given in the  Characteristics of included studies table. Graphical
representations of the overall risk of bias in included studies are
presented for each risk of bias item (Figure 2) and for each study
(Figure 3). Given the small number of studies included in the various
comparisons, no formal assessment of reporting bias using a funnel
plot was undertaken.
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
Allocation
Random Sequence Generation (Selection Bias)
All included studies described themselves as randomised. Five
studies did not provide any information on how the randomisation
sequence was generated (Appelberg 2001; Bauer 2009 (ONYX);
Dunner 2007; McIntyre 2007; Shelton 2001) and were rated as
being at an unclear risk of bias. Four studies described the use
of a computer or web-based soMware (Durgam 2016; El-Khalili
2010 (PEARL); Kessler 2018; Papakostas 2015) or a randomisation
schedule (Ferreri 2001) and were judged to be at low risk.
Allocation Concealment (Selection Bias)
Allocation concealment was not described and was therefore rated
as unclear in six studies (Appelberg 2001; Bauer 2009 (ONYX);
Dunner 2007; Ferreri 2001; McIntyre 2007; Shelton 2001). Three
studies describing a centralised allocation system (Durgam 2016;
Kessler 2018; Papakostas 2015) were assessed as low risk. The final
study was judged to be at low risk of bias for allocation concealment
due to the use of a computer-generated randomisation sequence in
combination with study treatments reported to be administered in
identical packaging (El-Khalili 2010 (PEARL).
Blinding
Performance Bias (blinding of participants and those delivering
the intervention)
Nine studies reported the use of a placebo intervention in the
comparator arm identical in form and appearance to the active
intervention and were therefore judged to be at a low risk of
bias (Appelberg 2001; Bauer 2009 (ONYX); Durgam 2016; El-Khalili
2010 (PEARL); Ferreri 2001; Kessler 2018; McIntyre 2007; Papakostas
2015; Shelton 2001).One study was described as an open-label trial
and therefore assigned a high risk of bias rating for this domain
(Dunner 2007).
Detection Bias (blinding of outcome assessors).
All of the included studies were judged to be at a low risk of
bias for this domain. Eight studies were described as double-
blind and reported the use of a placebo identical in appearance
to the active intervention (Appelberg 2001; Bauer 2009 (ONYX);
Durgam 2016; El-Khalili 2010 (PEARL); Papakostas 2015; Shelton
2001) and we regarded this as suNicient information to conclude
that outcome assessors were blinded to treatment allocation. Two
studies (Dunner 2007; Kessler 2018) explicitly stated that outcome
assessors were blind to treatment allocation. None of the included
studies evaluated the success of blinding.
Incomplete outcome data
Overall, attrition was less than 20% in four studies (Appelberg 2001,
14.8%; Bauer 2009 (ONYX), 14%; Durgam 2016, 17.3%; Kessler 2018,
4%), between 20 and 30% in four studies (El-Khalili 2010 (PEARL),
22.9%; Ferreri 2001, 24.3%; Papakostas 2015, 26.6%; Shelton 2001,
20%) and over 40% in two studies (Dunner 2007, 40.6%; McIntyre
2007, 41.4%).
Eight studies (Appelberg 2001; Bauer 2009 (ONYX); Dunner 2007;
Durgam 2016; El-Khalili 2010 (PEARL); Ferreri 2001; McIntyre
2007; Shelton 2001) described modified intention-to-treat analyses
including all participants with at least one post-baseline eNicacy
assessment. Last observation carried forward (LOCF) was used
to account for missing data and no significant imbalances in
missing data between trial arms were noted. Each of these studies,
therefore, was judged to be at low risk of bias for this domain. One
study (Papakostas 2015) reported an intention-to-treat analysis
based on all originally randomised patients but provided no
information about how missing data were handled (37 of 139
randomised participants dropped out of the study), so was judged
to be at an unclear risk of bias. The primary analyses of Kessler 2018
compared the treatment groups as randomised without imputing
missing values. Sensitivity analyses were conducted to investigate
the influence of missing data.
Selective reporting
One study (El-Khalili 2010 (PEARL)) was judged to be at a low risk
of selective outcome reporting bias as all outcomes of interest to
the review that were described in the study protocol were reported.
Risk of bias for this domain was rated as unclear for seven studies
(Bauer 2009 (ONYX); Dunner 2007; Durgam 2016; Ferreri 2001;
Kessler 2018; McIntyre 2007; Papakostas 2015). No protocol was
available for two studies (Dunner 2007; Ferreri 2001) and the study
protocol did not provide any details of the outcomes to be assessed
in another study (McIntyre 2007). Three studies reported additional
outcome data not detailed in the study protocol (Bauer 2009
(ONYX), Durgam 2016, Papakostas 2015). Kessler 2018 administered
the PHQ-9 questionnaire at 12, 24 and 52 weeks but only reported
data for the 12-week time point. Two studies were judged to be at
a high risk of bias for selective outcome reporting. Shelton 2001
listed depression severity as measured by the HAM-D as the primary
outcome measure. However, dichotomous outcomes of response
and remission were determined using MADRS scores. Appelberg
2001 did not report results in full for the primary outcome of
depression severity for all time points measured.
Other potential sources of bias
No other potential sources of bias were identified.
E4ects of interventions
See: Summary of findings for the main comparison Switching
to mianserin (60 mg/d) compared to continuing on current
antidepressant (fluoxetine 20 mg/d) for treatment-resistant
depression in adults; Summary of findings 2 Augmentation of
current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/
d) compared to augmentation of current antidepressant (fluoxetine
20 mg/d) with placebo for treatment-resistant depression in adults;
Summary of findings 3 Augmentation of current antidepressant
(SSRI/SNRI) with mirtazapine (30 mg/d) compared to augmentation
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of current antidepressant (SSRI/SNRI) therapy with placebo
for treatment-resistant depression in adults; Summary of
findings 4 Augmentation of current antidepressant (SSRI) with
busiprone (20 mg/d to 60 mg/d) compared to augmentation of
current antidepressant (SSRI) with placebo for treatment-resistant
depression in adults; Summary of findings 5 Augmentation
of current antidepressant (various) with cariprazine (1 mg/d to
4.5 mg/d) compared to augmentation of current antidepressant
(various) with placebo for treatment-resistant depression in adults;
Summary of findings 6 Augmentation of current antidepressant
(fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/
d) compared to augmentation of current antidepressant (fluoxetine
20 mg/d to 60 mg/d) with placebo for treatment-resistant
depression in adults; Summary of findings 7 Augmentation of
current antidepressant (various) with quetiapine (150 mg/d to
300 mg/d) compared to augmentation of current antidepressant
(various) with placebo for treatment-resistant depression in adults;
Summary of findings 8 Augmentation of current antidepressant
(SSRI) with ziprasidone (40 mg/d to 160 mg/d) compared to
augmentation of current antidepressant (SSRI) with placebo or
continue on SSRI monotherapy for treatment-resistant depression
in adults
Comparison 1 - Increasing the dose of antidepressant
monotherapy compared with continuing on an antidepressant
None of the included studies compared increasing the
dose of antidepressant monotherapy with continuing on an
antidepressant.
Comparison 2 - Switching to a di4erent antidepressant
monotherapy compared with continuing on an antidepressant
One study examined the eNects of switching to a diNerent
antidepressant monotherapy compared with continuing on an
antidepressant (Ferreri 2001). Participants who had failed to
respond to at least six weeks of treatment with fluoxetine were
randomised to continue this treatment or switch to mianserin at a
dose of 60 mg per day. The study was a three arm trial - in the third
arm participants had their fluoxetine treatment augmented with
mianserin. Participants in the two monotherapy arms (fluoxetine
only or mianserin only) also received a placebo in addition to their
antidepressant.
Primary Outcomes
Change in depressive symptoms
Clinician-rated measures
One study (Ferreri 2001, n = 71) found no evidence of a diNerence
in mean change from baseline in HAM-D 17 scores when current
antidepressant medication (fluoxetine) was switched to mianserin
compared with continuing on current treatment (MD -1.8, 95% CI
-5.23 to 1.63; low-quality evidence; Analysis 1.1).
Self-report measures
No self-report measures of depressive symptoms were made in the
study.
Dropouts
There was no evidence of a diNerence in the numbers of
participants dropping out when antidepressant medication was
switched to mianserin than when current medication was
continued (one study, Ferreri 2001, n = 72; RR 2.08, 95% CI 0.94 to
4.59; low-quality evidence; Analysis 1.2)
Reasons for dropping out
Participants' reasons for discontinuation are reported in Table 2.
The main reasons for dropping out were intolerance to medication
or adverse events in the mianserin arm and ineNectiveness of





One study (Ferreri 2001, n = 71) found no evidence of a diNerence in
response to treatment between participants whose antidepressant
was switched to mianserin and those who continued on their
current medication (RR 1.32, 95% CI 0.76 to 2.27; low-quality
evidence; Analysis 1.3).
Self-report measures




There was no evidence of a diNerence in the numbers
of participants experiencing remission from depression when
antidepressant medication was switched to mianserin than when
current medication was continued (one study, Ferreri 2001, n = 71;
RR 1.97, 95% CI 0.88 to 4.42; low-quality evidence; Analysis 1.4).
Self-report measures
No self-report measures of remission from depression were made
in the study.
Social adjustment and social functioning
No data on social adjustment or functioning were reported.
Quality of life
No data on quality of life were reported.
Economic outcomes
No data on any economic outcomes were reported.
Adverse e,ects
One study (Ferreri 2001, n = 72) reported arm-level adverse
event data, including the number of participants in each arm
that experienced at least one adverse event and the numbers
of each type of adverse event occurring in each arm. More
participants reported adverse events aMer switching to mianserin
than continuing fluoxetine (70.5% versus 28.1%). The most
commonly reported adverse events were dizziness and drowsiness
in the mianserin arm and headache and asthenia in the fluoxetine
arm.
Further details can be found in Table 3. The number of participants
who discontinued medication due to adverse events is reported in
Table 2 and described under the primary outcome of dropouts.
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Comparison 3 - Augmenting treatment with another
antidepressant compared with continuing on an
antidepressant
Two studies examined the eNects of augmenting antidepressant
treatment with a second antidepressant. Augmentation was with
mianserin in one study (Ferreri 2001) and mirtazapine in the other
study (Kessler 2018).
Primary Outcomes
Change in depressive symptoms
Clinician-rated measures
Augmentation with mianserin
One study (Ferreri 2001, n = 70) found evidence of a diNerence
in HAM-D scores when current antidepressant mediation was
augmented with mianserin compared with placebo (MD -4.8, 95%
CI -8.18 to -1.42; moderate-quality evidence; Analysis 2.1)
Augmentation with mirtazapine




No studies reported change in depressive symptoms based on a
self-report scale.
Augmentation with mirtazapine
One study (Kessler 2018, n = 480) found insuNicient evidence of
diNerence in BDI-II scores between participants whose current
antidepressant medication was augmented with mirtazapine and
those who medication was augmented with placebo at 12 weeks
(MD -1.7, 95% CI -4.03 to 0.63; high-quality evidence; Analysis 3.1),
24 weeks (MD -0.9, 95% CI -3.39 to 1.59; high-quality evidence;
Analysis 3.1) or 52 weeks (MD 0.1, 95% CI -2.38 to 2.58; high-quality
evidence; Analysis 3.1). There was also insuNicient evidence of a
diNerence between groups on PHQ-9 scores obtained at 12 weeks
(MD -0.89, 95% CI -2.08 to 0.30; high-quality evidence; Analysis 3.2).
Dropouts
Augmentation with mianserin
The was no evidence of a diNerence in numbers dropping out of
treatment when current antidepressant treatment was augmented
with mianserin compared with placebo (one study, Ferreri 2001, n =
70; RR 1.02, 95% CI 0.38 to 2.72; low-quality evidence; Analysis 2.2).
Augmentation with mirtazapine
One study (Kessler 2018, n = 480) found no evidence of a
diNerence in the number of participants dropping out of treatment
augmented with mirtazapine compared with those who received
placebo at 12, 24 or 52 weeks (12 weeks: RR 0.50, 95% CI 0.15 to 1.62;
24 weeks: RR 0.50, 95% CI 0.19 to 1.30; 52 weeks: (RR 0.46, 95% CI
0.18 to 1.18; all high-quality evidence; Analysis 3.3)
Reasons for dropping out





One study (Ferreri 2001, n = 70) found evidence of an increased
response to treatment when current antidepressant medication
was augmented with mianserin compared with placebo (RR = 1.70,
95% CI 1.03 to 2.78; moderate-quality evidence; Analysis 2.3).
Augmentation with mirtazapine




No self-report measures of response to treatment were made in the
study.
Augmentation with mirtazapine
The was weak evidence that participants whose current
antidepressant medication was augmented with mirtazapine had
an increased response to treatment compared with placebo at
12 weeks (Kessler 2018, n = 480; RR 1.22, 95% CI 0.97 to 1.54;
high-quality evidence; Analysis 3.4). There was no evidence for a
diNerence at 24 or 52 weeks (24 weeks: RR 1.01, 95% CI 0.83 to





One study (Ferreri 2001, n = 70) found evidence of an
increased likelihood of meeting criteria for remission when
current antidepressant medication was augmented with mianserin
compared with placebo (RR 2.38, 95% CI 1.09 to 5.16; low-quality
evidence; Analysis 2.4).
Augmentation with mirtazapine




No studies reported the outcome of remission determined using a
self-report measure.
Augmentation with mirtazapine
There was no evidence (Kessler 2018, n = 480) of a diNerence
in the numbers of participants meeting the criteria for remission
when current antidepressant medication was augmented with
mirtazapine compared with placebo at any time point measured
(12 weeks; RR 1.21, 95% CI 0.88 to 1.65; 24 weeks; RR 1.16, 95% CI
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0.86 to 1.55; 52 weeks; RR 0.98, 95% CI 0.74 to 1.30; high-quality
evidence; Analysis 3.4).
Social adjustment and social functioning
No data on social adjustment or functioning were reported.
Quality of life
Augmentation with mianserin
No quality of life data were reported.
Augmentation with mirtazapine
One study (Kessler 2018, n = 480) measured quality of life using
the EQ-5D-5L and SF-12. There was no evidence of a diNerence
in EQ-5D-5L scores between participants whose medication was
augmented with mirtazapine compared with placebo at any of the
time points measured (12 weeks; MD -0.01, 95% CI -0.06 to 0.04; 24
weeks: MD -0.02, 95% CI -0.07 to 0.03; 52 weeks: MD -0.03, 95% CI
-0.08 to 0.02; all high-quality evidence; Analysis 3.6).
On the SF-12 checklist, there was evidence of an improvement
on the aggregate mental functioning subscale in the mirtazapine
augmentation group at 12 weeks (MD 3.61, 95% CI 1.23 to 5.99; high-
quality evidence; Analysis 3.7) compared with placebo but not at
24 or 52 weeks (24 weeks: MD 1.98, 95% CI -0.64 to 4.60; 52 weeks:
MD 1.29, 95% CI -1.44 to 4.02; high-quality evidence; Analysis 3.7).
There was no evidence of a diNerence in scores on the aggregate
physical functioning subscale at any of the time points measured
(12 weeks: MD -1.76, 95% CI -4.20 to 0.68; 24 weeks: MD -2.49, 95%
CI -5.04 to 0.06; 52 weeks: MD -0.98, 95% CI -3.61 to 1.65; all high-
quality evidence; Analysis 3.8).
Economic outcomes
Augmentation with mianserin
No economic outcomes were reported.
Augmentation with mirtazapine
One study (Kessler 2018, n = 480) reported direct costs to health
and social services, costs to patients and carers, and time oN work
for patients and carers. There was no evidence of a diNerence
in resource use cost when current antidepressant treatment was
augmented with mirtazapine compared with placebo for any of
the resources considered. Cost-eNectiveness analyses were also
reported. No clinically important diNerences in quality adjusted
life years (QALYs) or costs were observed between the two groups
at 12 weeks follow-up (diNerence of 0.002, (95% CI –0.002 to
0.005) QALYs); (diNerence in costs £2 (95% CI –£27 to £31)) or at
52 weeks follow-up (diNerence of 0.009 (95% CI –0.016 to 0.035)
QALYs); (diNerence in costs £69 (95% CI –£74 to £206)). There was,
therefore, no evidence that mirtazpine was a cost-eNective use of
NHS resources.
Adverse e,ects
All of the included studies reported some information about
adverse events. Further details can be found in Table 3.
Two studies of augmentation of current antidepressant therapy
with an additional antidepressant reported the number of
participants in each arm that experienced an adverse event. The
incidence of adverse events was higher when augmenting with
mianserin (44.7%, Ferreri 2001) or mirtazapine (69.3%, Kessler
2018) than placebo (28.1% and 38.1% in the respective control
groups). Both studies also reported the frequency of each type of
adverse event experienced. The most commonly reported adverse
events were dizziness, somnolence, dry mouth, asthenia, and
weight increase.
One study (Kessler 2018) reported the number of participants
experiencing serious adverse events (SAEs). The overall incidence
of SAEs was low and the majority were judged by the study
investigators to be unrelated (or unlikely to be related) to
study medication. The incidence of adverse events was 3.32% in
participants whose current antidepressant therapy was augmented
with mirtazapine compared with 1.25% when augmented with
placebo.
The number of participants who discontinued in studies due to
adverse events are reported in Table 2 and described under the
primary outcome of dropouts.
Comparison 4 - Augmenting treatment with a non-
antidepressant compared with continuing on an
antidepressant
Eight studies examined the eNects of augmenting antidepressant
treatment with a non-antidepressant. Augmentation was with
an anxiolytic (buspirone) in one study (Appelberg 2001) and an
antipsychotic (cariprazine, olanzapine, quetiapine or ziprasidone)
in seven studies (Bauer 2009 (ONYX); Dunner 2007; Durgam 2016;
El-Khalili 2010 (PEARL); McIntyre 2007; Papakostas 2015; Shelton
2001).
Primary Outcomes
Change in depressive symptoms
Clinician-rated measures
Augmentation with buspirone
One study (Appelberg 2001, n = 102) found no evidence of a
diNerence in mean change from baseline in MADRS scores when
augmenting current antidepressant medication with the anxiolytic
buspirone compared with placebo (MD -0.30, 95% CI -9.48 to 8.88;
low-quality evidence; Analysis 4.1).
Augmentation with cariprazine
One three-arm, study (Durgam 2016, n = 808) found a reduction
in MADRS scores from baseline (the primary outcome for the
study) when antidepressant treatment was augmented with the
antipsychotic cariprazine at a dose of 2 mg/d to 4.5 mg/d (MD -2.1,
95% CI -3.63 to -0.57; Analysis 5.1) compared with placebo, but
there was only weak evidence of an eNect at the lower dose of 1 mg/
d to 2 mg/d (MD -0.90 , 95% CI -2.29 to 0.49; Analysis 5.1). Pooling the
two active treatment arms showed an overall eNect for cariprazine
(MD -1.50, 95% CI -2.74 to -0.25; high-quality evidence; Analysis 5.1).
Augmentation with olanzapine
One study (Shelton 2001, n = 20) found evidence of a reduction in
MADRS scores when augmenting current antidepressant treatment
with the antipsychotic olanzapine compared with placebo (MD
-12.4, 95% CI -22.44 to -2.36; low-quality evidence; Analysis 6.1).
However, evidence of a diNerence between groups was weaker
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based on the HAM-D rating scale, which was the primary outcome
for the study (MD -7.9, 95% CI -16.76 to 0.96; low-quality evidence;
Analysis 6.2).
Augmentation with quetiapine
Three studies (Bauer 2009 (ONYX); El-Khalili 2010 (PEARL);
McIntyre 2007 n = 977) found evidence of a reduction in
depressive symptomology (measured using MADRS - Bauer 2009
(ONYX); El-Khalili 2010 (PEARL) - or HAM-D - McIntyre 2007)
when augmenting current antidepressant treatment with the
antipsychotic quetiapine at a dose of 150 or 200 mg/d (SMD -0.34,
95% CI -0.53 to -0.14; I2 = 28%; Analysis 7.1). Two of these studies
(Bauer 2009 (ONYX); El-Khalili 2010 (PEARL) also examined the
eNects of adjunctive quetiapine at a higher dose of 300 mg/d and
found evidence of a reduction in MADRS scores compared with
placebo (MD -2.85, 95% CI -4.23 to -1.47, I2 = 0%; Analysis 7.1).
Pooling across doses, there was evidence overall (three studies
(Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); McIntyre 2007 n = 977)
of a beneficial eNect for quetiapine on symptoms of depression
(SMD -0.32, 95% CI -0.46 to -0.18; I2 = 6%, high-quality evidence;
Analysis 7.1).
Augmentation with ziprasidone
Two studies examined the eNectiveness of augmenting current
antidepressant therapy with the antipsychotic ziprasidone (Dunner
2007; Papakostas 2015, n = 199). Dunner 2007 was a three-arm
study comparing two doses of ziprasidone (80 mg/d or 160 mg/d)
with continuing on antidepressant monotherapy alone. Papakostas
2015 compared augmenting current antidepressant therapy with
40 mg/d to 160 mg/d of ziprasidone (mean dose 98 mg) with
placebo.
Dunner 2007 found no evidence of a diNerence in mean change in
HAM-D scores (the primary outcome of the study) for a dose of 80
mg (n = 41, mean diNerence -0.91, 95% CI -4.84 to 3.02; Analysis 8.1)
or 160 mg per day (n = 39; MD -2.56, 95% CI -6.72 to 1.60; Analysis
8.1) but confidence intervals were wide. Papakostas 2015 found
evidence of a reduction in depressive symptoms on the HAM-D (MD
-3.10, 95% CI -5.19 to -1.01; Analysis 8.1) for a mean dose of 98 mg/d
(range 40 mg to 160 mg) of ziprasidone daily. Pooling across doses,
there was evidence overall for a greater reduction from baseline
in HAM-D scores for ziprasidone compared with antidepressant
monotherapy (MD -2.73, 95% CI -4.53 to -0.93; I2 = 0, moderate-
quality evidence; Analysis 8.1).
Dunner 2007 also assessed depression severity using the MADRS
scale. There was no evidence of a diNerence in mean change in
MADRS scores at any dose (80 mg/d: MD -1.53, 95% CI -6.94 to 3.88;
160 mg/d: 3.82, 95% CI -9.64 to 2.00; pooled dose: MD -2.62, 95% CI
-7.47 to 2.23; low-quality evidence; Analysis 8.2).
Self-report measures
Augmentation with ziprasidone
Papakostas 2015, (n = 139) found evidence of a reduction in
scores on the self-report QIDS-SR (MD -2.50, 95% CI -3.83 to -1.17;
moderate-quality evidence; Analysis 8.3) for a dose of 40 mg to 160
mg of ziprasidone daily.
Dropouts
All of the included studies reported the numbers of participants
who discontinued in each trial arm. Participants' reasons for
discontinuation are reported in Table 2.
Augmentation with buspirone
There was no evidence of a diNerence in the number of
participants dropping out of treatment augmented with the
anxiolytic buspirone compared with those who received placebo
(one study, Appelberg 2001, n = 108; RR 0.60, 95% CI 0.23 to 1.53;
low-quality evidence; Analysis 4.2).
Augmentation with cariprazine
In a three-arm trial of augmentation with cariprazine (Durgam 2016,
n = 821), more participants in the intervention arms dropped out
than in the placebo arm (RR 1.68, 95% CI 1.16 to 2.41; moderate-
quality evidence; Analysis 5.2). The evidence was weaker for the
lower dose of 1 mg to 2 mg of cariprazine per day (RR 1.43, 95% CI
0.94 to 2.17; Analysis 5.2) than for the higher dose of 2 mg to 4.5 mg
per day (RR 1.92, 95% CI 1.30 to 2.84; Analysis 5.2).
Augmentation with olanzapine
One study of augmentation with olanzapine (Shelton 2001, n =
20) found no evidence of a diNerence in numbers dropping out
although the confidence interval was wide (RR 0.33, 95% CI 0.04 to
2.69; low-quality evidence; Analysis 6.3).
Augmentation with quetiapine
Three trials of augmentation with quetiapine (Bauer 2009 (ONYX);
El-Khalili 2010 (PEARL); McIntyre 2007; n = 977) provided weak
evidence of greater dropout in the intervention arms compared
with the placebo group (RR 1.33, 95% CI 0.9 to 1.95; I2=
1%, moderate-quality evidence; Analysis 7.2). When doses of
quetiapine were considered separately, those who received the
higher dose of 300 mg/d were more likely to drop out compared
with the placebo group (two studies, Bauer 2009 (ONYX); El-Khalili
2010 (PEARL); RR 1.82, 95% CI 1.29 to 2.57; I2 = 0%; Analysis 7.2)
but there was no evidence of a diNerence in dropouts for the lower
dose of 150 mg/d or 200 mg/d of quetiapine compared with placebo
(three studies, Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); McIntyre
2007; RR 1.18, 95% CI 0.86 to 1.63; I2 = 42%; moderate-quality
evidence; Analysis 7.2).
Augmentation with ziprasidone
There was evidence from two studies (Dunner 2007, Papakostas
2015, n = 199) that dropout was greater for those who
received treatment augmented with ziprasidone compared with
antidepressant monotherapy (RR 1.60, 95% CI 1.01 to 2.55, I2 = 0%;
moderate-quality evidence; Analysis 8.4).
Reasons for dropping out
All of the eight studies that examined the eNects of augmenting
antidepressant treatment with a non-antidepressant reported
participants' reasons for discontinuation and these are detailed in
full in Table 2. Across all of the studies, the most common reason for
dropping out was due to an adverse event or an inability to tolerate
the side eNects of treatment (8.05% of all randomised participants).
Greater numbers of participants dropped out for this reason from
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active intervention arms than from placebo arms and at higher
compared with lower doses (in the case of trials with more than one
active intervention arm). The proportion of participants dropping
out due to adverse events or intolerability was considerably higher
for Dunner 2007 than any of the other included studies (n = 16,
26.67%).
Withdrawal of consent or unwillingness to continue was the second
most frequently reported reason for dropping out (3.69% of all
randomised participants). The proportion of participants dropping
out for this reason was higher for Dunner 2007 than any of the other
studies (n = 6, 10%).
In four trials, participants dropped out due to protocol violations
(Appelberg 2001; Bauer 2009 (ONYX); Durgam 2016; Shelton 2001).
Two trials (Bauer 2009 (ONYX); El-Khalili 2010 (PEARL)) reported
dropouts post-randomisation due to failure to fulfil eligibility
criteria.
‘Lost to follow-up’ was cited as the reason for the dropout of
2.35% of all randomised participants. 1.15% dropped out due to
the ineNicacy of their treatment and 0.43% because they stopped
taking their study medication or due to extreme non-compliance.
Secondary Outcomes
Response to treatment
Seven studies reported data on the dichotomous outcome of
response to treatment (Bauer 2009 (ONYX); Dunner 2007; Durgam
2016; El-Khalili 2010 (PEARL); McIntyre 2007; Papakostas 2015;
Shelton 2001). All measured response using an observer-rated tool
(MADRS or HAM-D). One study additionally assessed response using
a self-report rating scale (QIDS-SR; Papakostas 2015).
Clinician-rated measures
Augmentation with buspirone
No data were reported for the outcome of response to treatment for
augmentation of current antidepressant treatment with buspirone.
Augmentation with cariprazine
One three-arm, study (Durgam 2016, n = 808) found that
those whose antidepressant treatment was augmented with the
antipsychotic cariprazine at a dose of 2 mg/d to 4.5 mg/d or 1 mg/d
to 2 mg/d were more likely to meet criteria for response compared
with the placebo group (2 mg/d to 4.5 mg/d: RR 1.29, 95% CI 1.06
to 1.57; 1 mg/d to 2 mg/d: RR 1.25, 95% CI 1.03 to 1.53; Analysis
5.3). When pooling the two active treatment arms, there was a
27% increased likelihood of response to treatment for those who
received augmented treatment with cariprazine compared with
placebo (RR 1.27, 95% CI 1.07 to 1.52; moderate-quality evidence;
Analysis 5.3).
Augmentation with olanzapine
The single small study of augmentation with olanzapine (Shelton
2001, n = 20) found that those who received augmented treatment
were more likely to meet criteria for response compared with the
placebo group but the confidence interval was very wide (RR 6.00,
95% CI 0.87 to 41.21; low-quality evidence; Analysis 6.4).
Augmentation with quetiapine
There was evidence from three studies (Bauer 2009 (ONYX); El-
Khalili 2010 (PEARL); McIntyre 2007; n = 977) that those whose
antidepressant treatment was augmented with quetiapine (any
dose) were more likely to meet criteria for response compared
with those receiving placebo (RR = 1.20, 95% CI 1.02 to 1.40; I2 =
0%; moderate-quality evidence; Analysis 7.3). A benefit in terms of
response to treatment was found at both higher (300 mg/d; two
studies; Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); RR 1.29, 95%
CI 1.10 to 1.50, I2 = 0%; Analysis 7.3) and lower doses (150 mg/d or
200 mg/d; three studies Bauer 2009 (ONYX); El-Khalili 2010 (PEARL);
McIntyre 2007; RR 1.25, 95% CI 1.09 to 1.43; I2= 0%; Analysis 7.3)
compared with placebo.
Augmentation with ziprasidone
In a three-arm trial, Dunner 2007 found no evidence of a diNerence
in response (based on scores on the MADRS) for augmenting with
ziprasidone at a daily dose of either 80 mg (RR 1.90, 95% CI 0.39 to
9.28; Analysis 8.5) or 160 mg (RR 3.16, 95% CI 0.72 to 13.76; Analysis
8.5) compared with continuing with antidepressant therapy alone.
Papakostas 2015 found weak evidence (RR 1.71, 95% CI 0.97 to
3.00; Analysis 8.5) that those whose antidepressant treatment was
augmented with ziprasidone (mean dose: 98 mg/d, range 40 mg
to 160 mg) were more likely to meet criteria for response (based
on scores of the HAM-D; with response being the primary outcome
for this study) than those who received placebo. Pooling across
studies and doses, there was evidence that those whose current
antidepressant therapy was augmented with ziprasidone were
more likely to meet criteria for response (RR 1.80, 95% CI 1.07 to
3.04; moderate-quality evidence; Analysis 8.5).
Self-report measures
Augmentation with ziprasidone
Papakostas 2015 also measured response to treatment on the self-
report SIDS-SR scale and found evidence that those who received
augmentation with ziprasidone were more likely to meet criteria
for response to treatment in the ziprasidone augmentation arm
compared with the placebo group (n = 139, RR = 2.34, 95% CI 1.16
to 4.72; moderate-quality evidence; Analysis 8.6).
Remission
Six studies reported the outcome of remission from depression at
the end of the treatment period (Bauer 2009 (ONYX); Dunner 2007;
Durgam 2016; El-Khalili 2010 (PEARL); McIntyre 2007; Papakostas
2015). All six studies defined remission based on a cut-oN on an
observer-rated depression scale (MADRS or HAM-D). One study
additionally assessed remission using a self-report rating scale
(QIDS-SR; Papakostas 2015).
Clinician-rated measures
No data were reported for the outcome of remission for
augmentation of current antidepressant treatment with either the
anxiolytic buspirone or with the antipsychotic olanzapine.
Augmentation with cariprazine
One three-arm, study (Durgam 2016, n = 808) found no evidence of
a diNerence in the number meeting criteria for remission amongst
participants whose current antidepressant was augmented with
either 1 mg/d to 2 mg/d (RR 1.06, 95% CI 0.83 to 1.37; Analysis 5.4)
or 4 mg/d to 5 mg/d (RR 1.07, 95% CI 0.83 to 1.38; Analysis 5.4) of
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cariprazine compared with placebo. Pooling across the cariprazine
arms showed no evidence of a diNerence between groups (RR 1.07,
95% CI 0.86 to 1.33; moderate-quality evidence; Analysis 5.4).
Augmentation with quetiapine
There was evidence of an increased likelihood of meeting criteria
for remission in those who received augmentation of current
antidepressant therapy with quetiapine at a higher dose (300 mg/
d, two studies, Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); RR 1.53,
95% CI 1.13 to 2.07; I2 = 32%; Analysis 7.5) or lower dose (150
mg/d or 200 mg/d, three studies, Bauer 2009 (ONYX); El-Khalili
2010 (PEARL); McIntyre 2007; RR 1.51, 95% CI 1.19 to 1.93; I2 = 0%;
Analysis 7.5) than those receiving a placebo.
Pooling across the quetiapine doses showed that those who
received quetiapine (any dose) in addition to their antidepressant
medication had a 50% increased likelihood of meeting criteria
for remission compared with those who received placebo (three
studies, Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); McIntyre 2007;
RR 1.53, 95% CI 1.22 to 1.90; I2 = 0%; moderate-quality evidence;
Analysis 7.5).
Augmentation with ziprasidone
There was little evidence of a diNerence in remission outcomes
based on clinician-rated scales for those who received ziprasidone
in addition to antidepressant medication compared with those
who continued on antidepressant monotherapy (Dunner 2007,
Papakostas 2015, n = 199; RR 1.27, 95% CI 0.81 to 2.00, I2 = 0%;
moderate-quality evidence; Analysis 8.7).
Self-report measures
Augmentation with ziprasidone
Papakostas 2015 (n = 139) found evidence that those whose
antidepressant treatment was augmented with ziprasidone were
more likely to meet criteria for remission when this was determined
using a self-report instrument (RR 2.33, 95% CI 1.03 to 5.25;
moderate-quality evidence; Analysis 8.8).
Social adjustment and social functioning
No studies reported data on social adjustment or functioning.
Quality of life
No quality of life data were reported in studies that
examined augmentation with buspirone, cariprazine, olanzapine or
ziprasidone.
Augmentation with quetiapine
Two three-arm trials (Bauer 2009 (ONYX); El-Khalili 2010 (PEARL), n
= 884) found no evidence of a diNerence in terms of quality of life
for those whose antidepressant treatment was augmented with the
antipsychotic quetiapine compared with placebo (dose 150 mg/d:
MD 0.70, 95% CI -2.31 to 3.71, I2= 36%; 300 mg/d: MD 0.35, 95% CI
-2.06 to 2.77, I2= 0; pooled across arms: mean diNerence 0.57, 95%
CI -1.52 to 2.65, I2= 0%; Analysis 7.4).
Economic outcomes
No studies reported data on any economic outcomes.
Adverse e,ects
All of the included studies reported some information about
adverse events. Further details can be found in Table 3.
In the study of augmentation of current antidepressant therapy
with the anxiolytic busiprone, Appelberg 2001 reported no
serious adverse events and that there were "no statistically
significant diNerences" (p.450) in scores on the Udvalg for Kliniske
Undersøgelser (UKU) side eNect rating scale (Lingjaerde 1987)
between treatment groups during the study.
Six studies of augmentation of current antidepressant therapy with
an antipsychotic reported arm-level adverse event data (Bauer
2009 (ONYX); Dunner 2007; Durgam 2016; El-Khalili 2010 (PEARL);
McIntyre 2007; Papakostas 2015). Four of these studies reported
the number of participants in each arm that experienced at least
one adverse event (Bauer 2009 (ONYX); Dunner 2007; Durgam
2016; El-Khalili 2010 (PEARL)). The incidence of adverse events
ranged from 40% to 66.9% in the control arms and from 65% to
100% in the intervention arms. All six of the studies reported the
frequency of each type of adverse event. A seventh study (Shelton
2001) described the most commonly occurring events across all
treatment groups but did not report the numbers experiencing
each type of event. Across all six studies, the most commonly
reported adverse events were somnolence, dry mouth, akathisia,
asthenia, dizziness, headache, nausea, constipation, diarrhoea and
changes in appetite or weight.
Six studies of augmentation with an antipsychotic reported the
numbers of participants experiencing serious adverse events
(SAEs) (Bauer 2009 (ONYX); Dunner 2007; Durgam 2016; El-Khalili
2010 (PEARL); McIntyre 2007; Papakostas 2015). Overall, the
number of serious adverse events reported was low. Further details
of the events reported are provided in Table 3.
The number of participants who discontinued in studies due to
adverse events are reported in Table 2 and described under the
primary outcome of dropouts.
Subgroup analyses
No subgroup analyses were undertaken to explore potential
sources of heterogeneity because there were fewer than ten studies
available in any comparison.
Sensitivity analysis
There were too few studies to enable pre-planned sensitivity
analyses to be conducted.
D I S C U S S I O N
This review focused on pharmacological approaches for adults
with treatment-resistant depression (TRD). We identified one
randomised controlled trial that examined switching current
antidepressant treatment to another antidepressant and two trials
that augmented current antidepressant therapy with a second
antidepressant. We identified eight randomised controlled trials
that examined augmentation of current antidepressant therapy
with a non-antidepressant. Augmentation was with an anxiolytic
(busiprone) in one study and with an antipsychotic (cariprazine,
olanzapine, quetiapine or ziprasidone) in seven studies. We did not
identify any studies meeting our eligibility criteria that examined
increasing the dose of current antidepressant monotherapy.
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Summary of main results
The main findings of the review are summarised in eight key
tables (Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4; Summary
of findings 5; Summary of findings 6; Summary of findings 7;
Summary of findings 8).
The single study that examined switching from current
antidepressant treatment to another antidepressant found no
evidence of a diNerence in depressive symptoms, response to
treatment, remission rates or numbers dropping out (all moderate-
quality estimates). The sample size was small (n = 72 for this
comparison) and there was imprecision in the estimates, therefore
our confidence in these findings is limited.
Evidence for the eNectiveness of augmenting current
antidepressant treatment with another antidepressant was mixed.
There was moderate-quality evidence from one study that
augmenting with mianserin was associated with a greater
reduction in depression severity scores from baseline, an
increased response to treatment and increased remission of
depressive symptoms. There was no evidence of a diNerence
in numbers dropping out of treatment (moderate-quality) but
there was considerable imprecision in this estimate. A second
study, of augmentation of current antidepressant treatment with
mirtazapine, found no evidence of a diNerence in depressive
symptoms or other outcomes (remission, quality of life, numbers
dropping out of treatment; all estimates high-quality) at any time
point, although there was weak evidence of an increased response
to treatment at 12 weeks (but not at later follow-up). There were
also no diNerences in resource use costs between treatment groups
or evidence that augmenting current treatment with mirtazapine
was cost-eNective compared with continuing on antidepressant
monotherapy.
The single study (n = 102) that focused on augmentation of
current antidepressant therapy with the anxiolytic busiprone
found no evidence of a diNerence in depressive symptoms (low-
quality) or numbers dropping out (moderate-quality). No data were
reported for response to treatment or remission rates. There was
considerable imprecision (very wide confidence intervals) in the
estimates of eNect for the depression outcomes and therefore our
confidence in these findings is limited.
Seven studies examined the eNectiveness of augmenting current
antidepressant therapy with an antipsychotic (cariprazine,
olanzapine, quetiapine or ziprasidone). All found evidence of a
greater reduction in depression severity scores from baseline
in the augmentation group compared with the control group.
For cariprazine (moderate-quality), quetiapine (high-quality) and
ziprasidone (moderate-quality), this diNerence was modest,
corresponding to an average diNerence of between 1.5 and 2.7
points on the depression severity scale used that equate to an
eNect size of approximately 0.18 to 0.42 SD. The NICE guidelines
group (NICE 2004) previously suggested that a diNerence of around
0.33 SD equated to a minimum clinically important diNerence
(MCID) and, therefore, the eNects seen here may be clinically
relevant. However, there is some evidence that patients with TRD
require larger improvements in their symptoms to report feeling
better (Button 2015). A larger eNect was observed in the study of
augmentation with olanzapine (n = 20) but certainty in this estimate
was judged to be low due to imprecision.
We also found evidence to support a beneficial eNect of adjunctive
treatment with an antipsychotic for the dichotomous outcome of
response to treatment. The eNect was largest for olanzapine, but
this estimate was judged to be of low quality due to considerable
imprecision.The evidence for all other antipsychotics was judged to
be of moderate quality.
Findings for the more stringent outcome of remission of
depressive symptoms (where measured) were mixed. There was
moderate-quality evidence that augmentation with quetiapine was
associated with an increased likelihood of remission of depressive
symptoms compared with continuing on an existing antidepressant
treatment alone. There was no evidence of a diNerence for
cariprazine (moderate-quality). For ziprasidone, there was no
evidence of a diNerence when remission was determined using
an observer-rated measure (HAM-D), but increased likelihood of
remission when depressive symptoms were self-reported (QIDS-
SR) (both estimates, moderate-quality). Remission rates were not
reported for olanzapine.
There was moderate-quality evidence of a diNerential dropout
rate when current antidepressant therapy was augmented with
cariprazine, quetiapine or ziprasidone, with those who received
an antipsychotic drug being more likely to drop out. There
was no evidence of a diNerence in dropout rates when current
therapy was augmented with olanzapine but the quality of this
estimate was low. The most common reason for dropping out was
an adverse event. Definitions of adverse events varied between
included studies but reports of adverse events were higher in the
groups who received augmented treatment with an antipsychotic
compared with those who continued antidepressant therapy alone
or augmented with a placebo.
Data for all other outcomes were limited. Two trials found no
evidence of a diNerence in quality of life for participants whose
current treatment was augmented with quetiapine compared with
placebo (moderate-quality). One trial found no evidence of a
diNerence in resource use costs (to health and social services,
patients and carers) when current antidepressant treatment was
augmented with mirtazapine compared with placebo.
None of the studies we identified reported data on social
adjustment or functioning.
Due to the small number of studies identified, we were unable
to conduct any subgroup analyses or explore the robustness of
the findings through sensitivity analyses. Our confidence in the
majority of the eNect estimates obtained in this review was lowered
by the imprecision of these estimates.
In summary, there is a small body of evidence on the eNectiveness
of augmenting current antidepressant therapy with a second
pharmacological treatment. There is currently insuNicient evidence
to support the addition of busiprone to current antidepressant
treatment but further trials may change this conclusion. There
is evidence of a benefit for augmenting antidepressant therapy
with the antidepressant mianserin (based on a single study) or
with an antipsychotic, but this needs to be balanced against the
increased likelihood of dropping out of treatment or experiencing
an adverse event as a side eNect of treatment. There is currently
insuNicient evidence to support switching existing antidepressant
treatment to another antidepressant but further trials may change
this conclusion.
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Overall completeness and applicability of evidence
Our search was comprehensive; we utilised the CMDCTR's
trial reference and studies registers, which were collated from
searches (from inception) of multiple databases, and also included
assessment of unpublished literature accessed by contacting study
authors. In addition, we screened reference lists of included studies
and contacted study authors for any unpublished or ongoing
studies.
Despite this, we identified only a small body of evidence. Individual
comparisons were supported by only one, two or three studies.
Importantly, we identified a number of gaps in the literature. There
were no trials of increasing the dose of existing antidepressant
medication and only one of switching to another antidepressant
treatment that were eligible for inclusion in our review. Only two
trials assessed eNicacy outcomes (depressive symptoms, response
to treatment and remission) using a self-report tool. Only three
studies reported quality of life data, none reported on social
adjustment/functioning and only one study reported economic
outcomes. Only one study (Kessler 2018) assessed outcomes
beyond the short term (duration of studies ranged between six
and eight weeks) so long-term outcomes of treatment of most
treatment strategies are unknown.
Findings from this review are applicable to adults with TRD
defined as "depression (meeting diagnostic criteria) that has not
responded to at least 4 weeks treatment with a therapeutic
dose of antidepressant medication". Definitions of TRD varied
between studies ranging from between one and three previous
failed treatments. Duration of treatment in most trials was six
to eight weeks which is comparable with other pharmacological
intervention trials in depressed patients. The age and gender
distribution of participants recruited in the included studies
reflect the average age/gender profile of depressed patients -
women in their 40s. In terms of the severity of depression, mean
depression scores on the HAM-D/MADRS equated to moderate/
severe depression. Nine trials recruited outpatients from hospital
(secondary care) outpatient clinics. Only one trial recruited
participants from primary care. Whilst we know that many patients
with TRD will be seen in primary care settings (Thomas 2013),
similarities in terms of age, gender and severity of depression
increase the generalisability of review findings. Four studies were
conducted in the US, one each in Canada, England, Finland and
France, and two in multiple countries across Europe, North America
and Australia. As such, findings may have limited generalisability
to other countries where the system for delivering mental health
care is substantially diNerent from those described in the included
studies.
Quality of the evidence
We assessed the quality of the evidence using the GRADE approach
for each of the outcomes presented in the summary of findings
tables (Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3; Summary of findings 4; Summary
of findings 5; Summary of findings 6; Summary of findings 7;
Summary of findings 8).
Study limitations
All studies were judged to be at a low or unclear (due to insuNicient
reporting) risk of selection bias. Outcome assessors were blinded in
all included studies and a placebo intervention was administered
in the comparator arm of all but one study to protect against
performance and detection bias. We had no concerns in relation to
completeness of outcome data. Although we had some concerns
with regards to the possibility of selective outcome reporting in
some of the studies, we did not consider that these would reduce
the confidence in the estimates of eNect as none of the issues
identified directly related to the outcomes of interest. Overall, we
did not consider any of the included studies to be at a suNicient risk
of bias to warrant downgrading the evidence for any outcome.
Consistency of e4ect
For each of the majority of comparisons made in this review,
only one study provided data. For two of the treatment strategies
considered (augmenting with quetiapine and augmenting with
ziprasidone), data were provided from two or more studies.
No significant heterogeneity was observed for any outcome for
augmentation of current treatment with ziprasidone. An I2 value
of 42% was observed for the numbers of participants dropping
out when current antidepressant treatment was augmented with
quetiapine compared to placebo. The confidence intervals for three
studies contributing to this estimate overlapped and a statistical
test for heterogeneity was not significant (P = 0.18). No significant
heterogeneity was observed for any other outcomes for these
comparisons. We did not therefore downgrade any of the evidence
included in the review for inconsistency.
Imprecision
Imprecision is the key issue aNecting our confidence in the body
of evidence identified in this review. For each of many of the
comparisons examined, only one study contributed data. Some
of the included studies had very small sample sizes (e.g. Dunner
2007; Shelton 2001) and were arguably underpowered to detect a
diNerence between treatment groups. Many of the eNect estimates
obtained had wide confidence intervals. For augmentation with
the anxiolytic buspirone, the estimates of treatment eNects (mean
change in depression severity, response to treatment and numbers
dropping out) were judged to have very serious imprecision and
are therefore of low quality. Estimates of treatment eNectiveness
and numbers dropping out for augmentation with olanzapine also
exhibited very serious imprecision, as did those for switching to or
augmenting current treatment with mianserin. For each of these
treatment strategies, the true eNect may be substantially diNerent
from the estimate of the eNect obtained in this review.
Indirectness
The studies included in this review were free from indirectness in
terms of the comparisons of interest (all direct comparisons) as well
as the target population, types of intervention, comparator and
methods of outcome determination.
Publication bias
We minimised the likelihood of publication bias by searching for
and including unpublished and ongoing studies. However, due
to the small numbers of studies available for each comparison
of interest, we were unable to perform a formal test of small-
study bias (Eggers test) and are therefore unable to reach any
formal conclusion regarding the absence of publication bias for this
review.
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Potential biases in the review process
We attempted to contact authors of included studies in order to
resolve any queries related to their study and/or to obtain missing
information relevant to this review. This, combined with a very
comprehensive search strategy, including searching trial registers
for unpublished literature along with the inclusion of non-English
language papers, minimised the likelihood of publication bias,
although the small number of included studies precluded the use of
a funnel plot to formally test for such bias. Moreover, our attempts
to obtain missing information addressed the potential for selective
outcome reporting.
We judged two studies to be at high risk of bias for selective
outcome reporting although these issues did not relate directly
to the outcomes of interest and therefore we judged these as
unlikely to bias the findings of this review. All but one study
included a placebo group, minimising the potential for detection
and performance bias. All but one (Kessler 2018) of the included
studies were industry sponsored and, as shown by previous reviews
(e.g. Lundh 2017), may be more likely to give a favourable view of
the drug trialled.
The small number of included studies precluded us from
undertaking prespecified subgroup analyses and we were therefore
unable to determine whether severity of depression and length of
the acute treatment phase were potential eNect modifiers.
Agreements and disagreements with other studies or
reviews
We identified seven previous systematic reviews of
pharmacological interventions for treatment-resistant depression.
The majority restricted their inclusion to randomised controlled
trials. Most looked at the eNectiveness of augmentation strategies
(with an antipsychotic or other pharmacological agent, Edwards
2013; Liu 2015; Zhou 2015; Zhou 2015a). Two reviews examined
the eNectiveness of switching to another antidepressant (Bschor
2010; Ruhe 2006) and one looked at increasing the dose of
existing antidepressant treatment (Ruhe 2006a). The definition of
treatment-resistant depression was not always clear within the
reviews’ eligibility criteria and some also considered non-standard
pharmacological treatments. Consequently, other reviews have
included a somewhat diNerent set of trials.
Zhou 2015 conducted a systematic review and network meta-
analysis of augmenting antidepressant treatment with an atypical
antipsychotic. Whilst their definition of TRD was similar to ours
(current episode of major depressive disorder diagnosed according
to standard diagnostic interview and an inadequate response to at
least one course of conventional antidepressant treatment), they
did not specify the length of the initial treatment trial. RCTs of
augmentation with an atypical antipsychotic compared with either
augmentation with another atypical antipsychotic or with placebo
were suitable for inclusion. Several of their included studies were
excluded from our review as formal diagnostic criteria were not
applied at the point of randomisation or because the length of prior
antidepressant treatment was less than four weeks. The review
included studies examining the atypical antipsychotics risperidone
and aripiprazole, whereas these studies did not meet our inclusion
criteria. Conversely, Zhou 2015 did not include any evidence for
ziprasidone or cariprazine (the one study of cariprazine included in
our review was published beyond the search dates of Zhou 2015).
Nonetheless, Zhou's findings are broadly consistent with ours -
atypical antipsychotics were more eNicacious than placebo (SMDs
ranged from -0.27 to -0.43). All, apart from risperidone, had more
side eNect discontinuations than placebo (ORs ranged from 2.72 to
6.40), but only quetiapine (mean 250 mg to 350 mg daily) had more
all-cause dropouts than placebo (OR = 1.89).
Zhou 2015a also published a systematic review and network meta-
analysis of all pharmacological augmentation agents (evidence
was identified for aripiprazole, bupropion, buspirone, lamotrigine,
lithium, methylephenidate, olanzpine, pindolol, quetiapine,
risperidone, thyroid hormone). TRD was defined as in Zhou 2015.
The authors identified one small trial of the anxiolytic buspirone
(Appelberg 2001, also included in our review). None of the nine
trials of augmentation with lithium compared with placebo met
the inclusion criteria for this review (as formal diagnostic criteria
were not applied at the point of randomisation or because the
length of prior antidepressant treatment was less than four weeks).
Four included RCTs of augmentation with pindolol compared with
placebo also failed to meet our inclusion criteria.
Edwards 2013 examined the eNectiveness of augmenting an SSRI
with either lithium or an antipsychotic. TRD was defined as
failure to respond to at least two previous antidepressants in
the current episode of depression. No continuous outcome of
depression severity was reported. Edwards identified evidence for
aripiprazole, olanzapine, quetiapine and lithium. We excluded all
three aripiprazole studies included in the Edwards review as none
applied formal diagnostic criteria at the point of randomisation.
Five of six olanzapine studies were excluded from our review for
the same reason (Shelton 2005a being the exception). The review
found evidence that augmenting current antidepressant therapy
with olanzapine increased response rates (OR = 1.60, 95% CI 1.01
to 2.53). This estimate, based on five studies, was more precise
than ours. None of the quetiapine studies included in our review
(Bauer 2009 (ONYX); El-Khalili 2010 (PEARL); McIntyre 2007) met the
inclusion criteria for Edwards 2013 as only one treatment failure
was required for entry in these trials and that treatment did not
have to be an SSRI. No studies of ziprasidone were included. Dunner
2007 was excluded by Edwards 2013 as the dosages were high and
not used in the UK. Papakostas 2015 was published beyond the
dates of their search as was the cariprazine study included in our
review (Durgam 2016).
Liu 2015 carried out a systematic review of the eNectiveness of
augmenting current antidepressant therapy with the beta-blocker
pindolol in participants with a primary diagnosis of unipolar
TRD who failed to respond to at least one SSRI compared with
continuing on antidepressant therapy (with or without placebo).
None of the five trials identified met the inclusion criteria for our
review (three did not meet our criteria for TRD, one included bipolar
patients, and the mean age of participants was greater than 74
years in the fiMh study).
Two systematic reviews examined the eNectiveness of switching to
another antidepressant. Bschor 2010 defined TRD as depression
determined using formal diagnostic criteria and a failure to
respond to four weeks or more of antidepressant treatment at
standard or higher dose. In addition to the one study included
in our review (Ferreri 2001), the authors included two further
studies that did not meet our inclusion criteria (both examined
a switch to fluoxetine and neither employed formal diagnostic
criteria to diagnose depression at the point of randomisation to
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treatment). Bschor 2010 found no evidence a diNerence in response
to treatment or remission from depression when switching to
another antidepressant compared with continuing on current
antidepressant treatment (no continuous measure of depression
symptoms was considered in the review). Ruhe 2006 examined
switching antidepressants aMer an insuNicient response to an SSRI
and included six RCTs in their review. One of these was the STAR*D
study, from which three levels met the criteria for inclusion in
the review. Thus, there were eight randomised comparisons in
total. Only one (Ferreri 2001) met our inclusion criteria (seven
did not include a comparator arm that continued on current
antidepressant therapy alone or with placebo). The review authors'
definition of TRD was not described in the paper.
Finally, Ruhe 2006a examined the eNectiveness of dose escalating
in participants who had failed to respond to a minimum of three
weeks of treatment with an SSRI. They identified seven randomised
studies, none which met the inclusion criteria for our review (four
did not meet our definition of TRD as participants had only had
three weeks of prior SSRI treatment, two had no comparator group
that continued on the same dose of the SSRI, and one did not apply
diagnostic criteria at point of randomisation).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review found moderate- to high-quality evidence that
augmenting antidepressant treatment with an antipsychotic
– cariprazine (moderate), quetiapine (high) or ziprasidone
(moderate) - for individuals with treatment-resistant depression
reduced depressive symptoms over the short term (8 to 12 weeks).
Findings from a small study of the antipsychotic olanzapine also
suggested augmenting current antidepressant treatment with this
drug may reduce symptoms of depression but this study was of
low quality. However, those who received adjunctive antipsychotic
treatment were more likely to experience adverse events or not
tolerate treatment compared with those who received placebo.
As such, adjunctive treatment with an antipsychotic may be less
acceptable.
There was no evidence that augmenting antidepressant treatment
with an anxiolytic, buspirone, reduced symptoms of depression
compared with placebo. However, this evidence was judged to be
low-quality.
There was some evidence that augmenting existing antidepressant
treatment with a second antidepressant may be beneficial but this
was not consistent across diNerent drugs. There was moderate-
quality evidence that adjunctive treatment with mianserin reduced
depressive symptoms over the short term (six weeks). However,
there was no evidence of improvements in depressive symptoms
when existing antidepressant treatment was augmented with
mirtazapine compared with placebo.
There was no evidence that switching to a diNerent antidepressant
treatment (mianserin) was beneficial compared with placebo. This
evidence was judged to be moderate quality due to imprecision in
the results.
No evidence was identified for other treatment strategies, such
as increasing the dose of existing antidepressant treatment or
augmenting with other medications (e.g. lithium or beta-blockers).
Implications for research
Only a small number of studies were included in our review and
most of these examined the eNectiveness of a single treatment
strategy - augmenting antidepressant treatment with a non-
antidepressant medication - most commonly, an antipsychotic
medication. Evidence is therefore needed on the eNectiveness
of other pharmacological approaches to the management of
treatment-resistant depression in adults in order to improve
outcomes for the large group of patients who do not respond to
antidepressant treatment. Future trials need to examine strategies
such as switching to a diNerent antidepressant, increasing the dose
of antidepressant monotherapy, combining two antidepressant
treatments, as well as evidence on other augmentation strategies.
Future trials in this area need to give careful consideration to their
design. Many of the trials that were excluded from this review
did not apply diagnostic criteria for depression at the point of
randomisation. We also excluded a large number of trials as they
lacked a suitable comparator. In order to make a meaningful
comparison that will inform clinical practice, studies need to
include a 'control' group that continues on existing antidepressant
monotherapy. In addition, it is important that future trials are
independent of the pharmaceutical industry to minimise the
potential for bias.
Future studies also need to ensure that they include outcomes that
are important to patients (and caregivers), such as quality of life,
which were rarely measured in studies included this review. Most of
the existing evidence only relates to outcomes over the short term.
It is important that future research evaluates longer-term outcomes
and gathers data about resource use in order to inform discussions
about allocation of resources based on evidence of both clinical and
cost-eNectiveness. Moreover, it is important that adverse eNects are
consistently recorded in future studies in order to enable patients
and clinicians to have an informed discussion about the potential
benefits of treatment in light of possible adverse events.
As the evidence base in this area increases, it will be
important that researchers compare the eNectiveness of diNerent
pharmacological interventions with each other, and with
psychological interventions. Advances in the development of
methods for network meta-analysis that enable multiple treatment
options to be compared simultaneously will provide evidence to
further inform policy and practice.
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Characteristics of included studies [ordered by study ID]
 
Methods Parallel group RCT
Participants Country: Finland
Setting: Outpatient care
N randomised: 108 (n = 64 (62.7%) female (of 102 participants included in analyses))
Age: Mean 44 years (SD not reported; range 18 - 61)
Inclusion: Patients being treated or seeking treatment for depression, 18 years of age or older, meeting
DSM-IV criteria for a major depressive episode
Exclusion: Psychotic or bipolar depression, being regarded by the clinician in charge of treatment to be
seriously suicidal, severe neurologic or somatic disease, mental disorder due to a general medical con-
dition, substance-induced disorders, and other psychiatric disorders (except generalised anxiety disor-
der and specific phobias)
Interventions Group 1: Augmentation of current SSRI with buspirone (20 mg/d - 60 mg/d) for six weeks
Group 2: Augmentation of current SSRI with placebo for six weeks
Outcomes Post-treatment assessment (6 weeks):
1. Depressive symptoms, continuous (MADRS)
2. Dropouts
Definition of TRD Had received fluoxetine or citalopram for at least 6 weeks without showing an antidepressant response
according to the psychiatrist in charge of treatment. For at least the last 4 weeks before inclusion, their
daily fluoxetine dose was at least 30 mg or their daily citalopram dose at least 40 mg
Notes Funding: Supported by a grant from Bristol-Myers Quibb, Finland. Respone to treatment (defined as an
improvement in CGI-S score ≥ 2 points; data not included in this review as the CGI-S is a generic mea-
sure of illness severity rather than specifically measuring depression symptomology)
Risk of bias
Bias Authors' judgement Support for judgement
Appelberg 2001 
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Random sequence genera-
tion (selection bias)




Unclear risk No information about how allocation was concealed. "After a single-blind
placebo wash-in period of 2 weeks while continuing their SSRI, the patients






Low risk "The study was designed as a placebo-controlled, double-blind ….. Buspirone
and placebo were administered as tablets that were identical in appearance".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "The investigators, but not the patients, were aware of the placebo wash-in
period. The double-blind phase began immediately after baseline and lasted





Unclear risk LOCF used to account for missing data. Six participants (3 from each arm) were
excluded from the analyses as no observations available. "The primary assess-
ment was based on last observation carried forward (LOCF) according to the
principle of intention to treat .... One hundred and thirteen patients were en-
rolled in the study … Five patients were removed from the study during the
placebo wash-in phase ... Six more patients (3 in the buspirone and 3 in the
placebo group) were removed from the study because of a protocol violation
before week 1 ... One hundred and two patients had at least 1 evaluation after
placebo wash-in phase and were included in the final analysis."
Selective reporting (re-
porting bias)
High risk No protocol available. MADRS scores reported as percentage mean change
and reported for weeks 1 and 6 only. Mean scores for all time points are shown
on a graph (with no measure of precision).




Methods Parallel group RCT
Participants Country: Australia, Canada, Europe, South Africa
Setting: Outpatient care
N randomised: (n = 329 (67.6%) female (of 487 included in analyses))
Age: Mean 45.44 years (SD 10.53).
Inclusion: Patients aged 18 to 65 years with a documented DSM-IV-TR diagnosis of MDD (single episode
[296.2x] or recurrent [296.3x]). Diagnoses confirmed by the Mini-International Neuropsychiatric Inter-
view. HAM-D-17 total score > 20 and HAM-D item 1 (depressed mood) score ≥ 2 at enrolment and ran-
domisation.
Exclusion: Any DSM-IV Axis I disorder other than MDD within 6 months prior to enrolment; any DSM-IV
Axis II disorder significantly impacting the patient’s current psychiatric status; duration of current MDD
episode > 12 months or < 4 weeks from enrolment; substance or alcohol abuse or dependence, as de-
fined by DSM-IV criteria, within 6 months prior to enrolment; any clinically significant medical illness,
such as renal or hepatic impairment, or coronary artery disease; conditions that could affect absorp-
tion or metabolism of study medication risk of suicide or homicide; HAM-D item 3 score of ≥ 3; or sui-
cide attempt within the past 6 months. Patients requiring psychotherapy (other than supportive thera-
Bauer 2009 (ONYX) 
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py), unless psychotherapy had been ongoing for ≥ 3 months before randomisation. Drugs that induce
or inhibit the hepatic metabolising cytochrome P450 3A4 enzymes within 2 weeks prior to randomisa-
tion. Quetiapine > 25 mg/d for insomnia within 7 days before randomisation, known lack of response
following 4 weeks’ treatment with quetiapine ≥ 50 mg/d for depression or were receiving quetiapine ≥
50 mg/d at enrolment
Interventions Group 1: Augmentation of current antidepressant with quetiapine XR (150 mg/d) for six weeks
Group 2: Augmentation of current antidepressant with quetiapine XR (300 mg/d) for six weeks
Group 3: Augmentation of current antidepressant with placebo for six weeks
Outcomes Post-treatment assessment (6 weeks):
1. Depressive symptoms, continuous (MADRS, HAM-D)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in MADRS total score from randomisation)
4. Remission, dichotomous (MADRAS total score ≤ 8)
5. Quality of life, continuous (Q-LES-Q-SF)
6. Adverse events
Definition of TRD Inadequate response during the current episode to amitriptyline, bupropion, citalopram, duloxetine,
escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine given for ≥ 6 weeks at adequate doses
(minimum effective dose according to label and including at least 1 dose increase as permitted by la-
bel)
Notes Funding: Study funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised but no information given about how the randomi-
sation sequence was generated. "eligible patients ... were randomly assigned




Unclear risk Insufficient information provided to enable a judgment ''eligible patients ...





Low risk Described as double-blind and placebo given to control group so unlikely that
either participants or study personnel would have been aware of treatment al-
location. "This was a 6-week, randomized, double-blind, parallel-group, place-
bo-controlled, phase III, double-dummy study."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not specifically stated that outcome assessors were blind to treatment alloca-
tion but study described as double-blind and interventions that were identical
in appearance."'This was a 6-week, randomized, double-blind, parallel-group,




Low risk LOCF used to account for missing data. MITT analysis carried out. Six ran-
domised participants could not be included in it. Missing data balanced across
groups. "Efficacy analyses were based on the MITT [modified intention to
treat] population; a last-observation-carried-forward (LOCF) approach was
used for missing data ... modified intent-to-treat (MITT) population (all pa-
tients assigned to randomized treatment who took study medication and who
Bauer 2009 (ONYX)  (Continued)
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Unclear risk Very limited information in the protocol about which outcomes will be as-
sessed but all those mentioned were reported in the paper. Additional out-
comes reported that did not appear in the protocol (e.g. adverse events)




Methods Parallel group RCT
Participants Country: US
Setting: Outpatients
N randomised: 64 (n = 31 (50.8%) female (of 61 included in analyses))
Age: Mean 44 years (SD 11)
Inclusion: Adult outpatients aged 21 to 65 years meeting DSM-IV criteria for MDD and MADRS total score
≥ 20
Exclusion: Current DSM-IV diagnosis of any psychotic disorder, post-traumatic stress disorder, panic
disorder, or obsessive-compulsive disorder; DSM-IV substance abuse or dependence disorder in the
past 3 months; history of treatment with an atypical antipsychotic agent; treatment with fluoxetine, a
monoamine oxidase inhibitor, or electroconvulsive therapy during the 6 weeks prior to study entry; any
clinically significant abnormality on electrocardiogram (ECG); current therapy with medications known
to prolong the corrected QT interval; any acute or unstable medical illness; pregnancy or breast feeding
Interventions Group 1: Augmentation of sertraline with ziprasidone (160 mg) for eight weeks
Group 2: Augmentation of sertraline with ziprasidone (80 mg) for eight weeks
Group 3: Sertraline for eight weeks
Outcomes Post-treatment assessment (8 weeks):
1. Depressive symptoms, continuous (MADRS, HAM-D)
2. Dropouts
3. Response, dichotomous (≥ 50% decrease from baseline MADRS score)
4. Remission, dichotomous (MADRS score ≤ 10)
5. Adverse events
Definition of TRD Nonresponse to at least 1 course of treatment of at least 4 weeks’ duration with a clinically appropri-
ate dose of an SSRI or non-SSRI antidepressant. Also confirmed prospectively by a failure to achieve
at least a 30% decrease in MADRS score and a CGI-S score ≥ 4 following a 6-week open-label sertraline
(100 to 200 mg/d) treatment period
Notes Funding: Study funded by Pfizer Inc
Risk of bias
Bias Authors' judgement Support for judgement
Dunner 2007 
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Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised but no information given about how the randomi-
sation sequence was generated. "Subjects who continued to meet TRD crite-
ria at the conclusion of the 6-week sertraline lead-in period were randomly as-
signed, in a 1:1:1 ratio".
Allocation concealment
(selection bias)
Unclear risk Insufficient information to make a judgment. "Subjects who continued to meet
TRD criteria at the conclusion of the 6-week sertraline lead-in period were ran-





High risk Open-label trial so likely that participants and those delivering the interven-
tion knew their treatment allocation. "After completion of the 6-week lead-in
study, nonresponders were randomized to open-label treatment with 8 weeks
of …"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were blinded to participants' treatment assignment. ''The
clinician who rated efficacy was blind to the subject's treatment assignment,
and, whenever possible, the rater who conducted a subject's baseline assess-




Low risk Three randomised participants discontinued prior to taking the study drug
and were not included in the analyses. LOCF used to account for missing data
for the remaining participants. Minor discrepancy between the text and the ta-
ble with regards to numbers of participants (text stated 61 but table reported
data for 60 participants)
Selective reporting (re-
porting bias)
Unclear risk No study protocol available. All outcomes detailed in the methods are report-
ed in the study results.




Methods Parallel group RCT
Participants Country: USA, Estonia, Finland, Slovakia, Sweden, Ukraine
Setting: Outpatients
N randomised: 819 (n = 578 (71.2%) female (of 812 included in the safety population))
Age: 45.7 years (mean 11.6)
Inclusion: Outpatients, aged 18-65 years, meeting DSM-IV-TR criteria for MDD without psychotic fea-
tures and had a current depressive episode (duration ≥ 8 weeks to ≤ 24 months). MADRS total score ≥
22, BMI between 18 and 40, normal results from physical examinations, laboratory tests and electrocar-
diogram or abnormal results that were not considered clinically significant
Exclusion: Principal Axis I disorder other than MDD, or any Axis I disorder other than MDD that was the
primary focus of treatment within 6 months of screening; and Axis II disorder that might interfere with
participation and judged by the investigator; alcohol/substance abuse or dependence within 6 months
of screening; or lifetime history of depressive episodes with psychotic or catatonic features, bipolar
disorder, schizophrenia or other psychotic disorder, panic disorder, obsessive-compulsive disorder,
anorexia or bulimia, and dementia or other cognitive disorder, suicide risk. Refractory depression (in-
adequate response ≥ 3 antidepressants at sufficient dosages and duration for the current episode);
antidepressant augmentation with any medication within 1 week of baseline (up to 4 weeks for some
medications) or 5 half-lives of the medication concomitant use of antipsychotics, anxiolytics, or stimu-
lants; or psychotherapy for depression within 3 months of screening.
Durgam 2016 
Pharmacological interventions for treatment-resistant depression in adults (Review)









Cochrane Database of Systematic Reviews
Interventions Group 1: Augmentation of current antidepressant with cariprazine (1 mg/d to 2 mg/d) for eight weeks
Group 2: Augmentation of current antidepressant with cariprazine (2 mg/d to 4.5 mg/d) for eight weeks
Group 3: Augmentation of current antidepressant with placebo for eight weeks
Outcomes Post-treatment assessment (8 weeks):
1. Depressive symptoms, continuous (MADRS)
2. Dropouts
3. Response, dichotomous (≥ 50% decrease from baseline MADRS score)
4. Remission, dichotomous (MADRS score ≤ 10)
5. Adverse events
Definition of TRD Ongoing inadequate response during the current episode to antidepressant treatment for ≥ 6 weeks at
recommended doses per label guidelines
Notes Funding: Supported by funding from Forest Laboratories, LLC (Jersey City, New Jersey), an Allergan af-
filiate and Gedeon Richter Plc (Budapest, Hungary)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sequence generated by web based software. "Patient identification and ran-
domization codes were generated by an interactive voice/web system".
Allocation concealment
(selection bias)
Low risk Centralised allocation using a web-based system. "Patient identification and
randomization codes were generated by an interactive voice/web system, and





Low risk Placebo-administered. Study participants reported to be blind to treatment al-
location. "Patients and study staN were blinded throughout treatment … and
study medication was identical in appearance. Breaking the blind resulted in
discontinuation from the study."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Placebo-administered. Study staN reported to be blind to treatment alloca-
tion. "Patients and study staN were blinded throughout treatment … and
study medication was identical in appearance. Breaking the blind resulted in




Low risk ITT population included all those with at least one post-baseline assessment.
LOCF used. 11 randomised participants not included in the ITT population. 1
and 5 from the cariprazine 1 mg/d to 2 mg/d and 2 mg/d to 4.5 mg/d groups,
and 5 from the placebo group. No significant imbalance between arms. "The
safety population included all patients who received ≥ 1 dose of double-blind
study drug. The intent-to-treat population included all patients in the safety
population who had ≥ 1 post-baseline MADRS total score assessment." "The
safety population included 812 patients 4 of whom (2 each for placebo and
cariprazine 2 mg/d to 4.5 mg/d) did not have a post-baseline MADRS assess-
ment and were excluded from efficacy analyses".
Selective reporting (re-
porting bias)
Unclear risk Very limited information in the protocol about which outcomes would be as-
sessed but all those mentioned were reported in the paper. Additional out-
comes reported that did not appear in the protocol (e.g. adverse events, re-
sponse/remission)
Durgam 2016  (Continued)
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Methods Parallel group RCT
Participants Country: US
Setting: Outpatients
N randomised: 446 (n = 313 (72.5%) female (of 432 included in the analyses))
Age: Mean 44.5 years (SD 12.8)
Inclusion: Patients aged 18 to 65 years with a documented DSM-IV-TR diagnosis of MDD (single episode
[296.2x] or recurrent [296.3x], confirmed by the Mini-International Neuropsychiatric Interview). HAM-
D-17 total score > 20 and HAM-D item 1 (depressed mood) score ≥ 2 at enrolment and randomisation
Exclusion: Any DSM-IV Axis I disorder other than MDD within 6 months prior to enrolment; any DSM-
IV Axis II disorder significantly impacting the patient’s current psychiatric status; duration of current
MDD episode > 12 months or < 4 weeks from enrolment; history of substance or alcohol abuse or de-
pendence, as defined by DSM-IV criteria, within 6 months prior to enrolment; clinically significant med-
ical illness; risk of suicide or homicide; HAM-D item 3 score of ≥ 3; or suicide attempt within the past 6
months; requiring psychotherapy (other than supportive therapy), unless psychotherapy had been on-
going for ≥ 3 months before randomisation
Interventions Group 1: Augmentation of current antidepressant with quetiapine XR (150 mg/d) for six weeks
Group 2: Augmentation of current antidepressant with quetiapine XR (300 mg/d) for six weeks
Group 3: Augmentation of current antidepressant with placebo for six weeks
Outcomes Post-treatment assessment (6 weeks):
1. Depressive symptoms, continuous (MADRS, HAM-D)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in MADRS total score from randomisation)
4. Remission, dichotomous (MADRS total score <= 8)
5. Quality of life, continuous (Q-LES-Q-SF)
6. Adverse events
Definition of TRD Inadequate response during the current episode to amitriptyline, bupropion, citalopram, duloxetine,
escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine given for ≥ 6 weeks at adequate doses
(minimum effective dose according to label and including at least 1 dose increase as permitted by la-
bel)
Notes Funding: Study funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
El-Khalili 2010 (PEARL) 
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Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence used. "Patients were random-




Low risk Sequence generation done by computer so would not have been possible to
anticipate. Study treatments administered in identical packaging. "Patients
were randomized (in a 1:1:1 ratio) in a non-centre-specific manner using a
computer-based system … Quetiapine XR 50 mg and 300 mg tablets were





Low risk Study described as double-blind. Identical interventions administered to par-
ticipants. Not specifically stated that study personnel were blind to treatment
but likely due to the use of interventions that were identical in appearance.
"Quetiapine XR 50 mg and 300 mg tablets were identical in appearance, smell,
and taste to their respective placebo tablets".
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Study described as double-blind. Not specifically stated that outcome asses-
sors were blind to treatment but likely due to the use of interventions that
were identical in appearance. "Quetiapine XR 50 mg and 300 mg tablets were




Unclear risk LOCF used to account for missing data for all but 14 participants. Slightly larg-
er number missing from the quetiapine 300 mg/d group. "The modified in-
tent-to-treat (MITT) population (randomized patients who received study
drug, and had randomization and ≥ 1 post-randomization MADRS total scores)
was used for analysis of primary and secondary variables. For all efficacy
analyses, missing data were handled using a last observation carried forward
(LOCF) approach. 446 patients were randomised .... and 432 were analysed for
efficacy (MITT population) after 13 patients were excluded due to missing/in-
valid randomization or post-randomization MADRS scores."
Selective reporting (re-
porting bias)
Low risk All outcomes listed in the protocol were reported. Missing standard deviations
for mean change from baseline in depression symptoms (but these could be
calculated from other information provided)




Methods Parallel group RCT
Participants Country: France
Setting: Inpatients and outpatients
N randomised: 104
Age: Mean 46.6 years (SD 12.6)
Inclusion: Diagnosis of major depression according to DSM-III-R and have scores ≥ 25 on the Hamil-
ton Depression Rating Scale 17 items (HAM-D) and scores ≥ 28 on the HARD diagram scale [Mood-Anx-
iety-Retardation-Danger (Humeur-Angoisse-Ralentissement-Danger)], after at least 6 weeks of treat-
ment with 20 mg/day of fluoxetine. Both in- and outpatients were included.
Exclusion: Pregnant or lactating women, women without contraception at childbearing age, somatic
disease condition that could interfere with everyday life activities, psychiatric disorders with psychot-
ic features (with the exception of psychotic mood disorder), unreliable patients, in particular drug and
alcohol abuse and dependence, treatment with psychotropic drugs other than fluoxetine, with the ex-
Ferreri 2001 
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ception of benzodiazepines if benzodiazepine equivalent dosage was equal to or lower than 15 mg/day
of diazepam
Interventions Group 1: Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) for six
weeks
Group 2: Switched treatment to Mianserin (60 mg/d) given with placebo for six weeks
Group 3: Augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo for six weeks
Outcomes Post-treatment assessment (6 weeks):
1. Depressive symptoms, continuous (HAM-D-17)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in HAM-D score from baseline)
4. Remission, dichotomous (HAM-D total score ≤ 8)
5. Adverse events
Definition of TRD Inadequate response after at least 6 weeks of treatment with 20 mg/d of fluoxetine
Notes Funding: Study funded by Organon Pharmaceuticals, France
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Limited information about how sequence was generated but likely random.
"Patients were randomized according to a randomization schedule by blocks
of four up to 120."
Allocation concealment
(selection bias)





Low risk Described as double-blind and placebo given to control group so unlikely that
either participants or study personnel would have been aware of treatment al-
location. "Placebo of fluoxetine was provided in the form of identical capsules
and, similarly, placebo of mianserin and mianserin were also indistinguish-
able."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not specifically stated that outcome assessors were blind to treatment alloca-
tion but study described as double-blind and interventions were identical in
appearance. "Placebo of fluoxetine was provided in the form of identical cap-





Low risk ITT population included all participants who had taken at least one dose of
the study drug. LOCF used to account for missing data. "For missing data the
method of Last Observation Carried Forward was used … The intent-to-treat
population consisted of all randomized patients who took at least one dose of
a study drug … One patient was lost at day 0; thus, the intent-to-treat popula-
tion consisted of 103 patients treated."
Selective reporting (re-
porting bias)
Unclear risk No study protocol available. All outcomes detailed in the methods were re-
ported in the study results.
Other bias Low risk No other concerns identified
Ferreri 2001  (Continued)
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Age: 50.15 years (SD 13.16)
Inclusion: Aged 18-75 years. Treated for depression with any of the following SSRI or SNRI antidepres-
sants for at least 6 weeks at recommended (British National Formulary, BNF) doses: fluoxetine, sertra-
line, citalopram, escitalopram, fluvoxamine, paroxetine, duloxetine or venlafaxine; scored 14 or more
on the Beck Depression Inventory (BDI) and have adhered to their medication and meet ICD-10 criteria
for depression (assessed using the Computerised Interview Schedule – Revised version (CIS-R).
Exclusion: Currently taking combined or augmented antidepressant treatment, having their medica-
tion managed by a psychiatrist, dementia (formal diagnosis), bipolar disorder, psychosis or alcohol
or substance abuse/dependence, pregnant, planning a pregnancy or breastfeeding, unable to com-
plete the study questionnaires, previous adverse reaction to mirtazapine, currently being treated with
a monoamine oxidase inhibitor (MAOI), including moclobemide, or with other medical contraindica-
tions to mirtazapine
Interventions Group 1: Augmentation of current antidepressant with mirtazapine (30 mg/d) for up to 52 weeks
Group 2: Augmentation of current antidepressant with placebo for up to 52 weeks
Outcomes Assessed at 12, 24 and 52 weeks (unless specified):
1. Depressive symptoms, continuous (BDI-II, PHQ-9)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in BDI-II total score from baseline)
4. Remission, dichotomous (BDI-II < 10)
5. Social functioning (SF-12 aggregate mental functioning, SF-12 aggregate physical functioning)
6. Quality of life, continuous (EQ-5D-5L)
7. Economic outcomes (health and social care use, costs to patients/carers, time oN work)
8. Adverse events (12 and 52 weeks)
Definition of TRD Inadequate response to fluoxetine, sertraline, citalopram, escitalopram, fluvoxamine, paroxetine, du-
loxetine or venlafaxine given for at least six weeks at BNF recommended dose and adherent to antide-
pressant treatment
Notes Funding: National Institute for Health Research (NIHR) Health Technology Assessment programme, UK
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation sequence generated by a computer. "Participants were ran-
domised using the automated randomisation service provided by the Bristol
Randomised Trials Collaboration (BRTC). Randomisation was carried out by
means of a computer-generated code to ensure concealment of allocation."
Kessler 2018 
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Allocation concealment
(selection bias)
Low risk Centralised allocation provided by an independent organisation using a com-
puter-generated code. "Participants were randomised using the automated
randomisation service provided by the Bristol Randomised Trials Collabora-
tion (BRTC). Randomisation was carried out by means of a computer-generat-





Low risk Placebo-administered. Study participants reported to be blind to treatment
allocation. "Participants were randomly assigned to one of two treatments:
(1) 1 × 15 mg encapsulated mirtazapine tablet daily for 2 weeks followed by
2 × 15 mg encapsulated mirtazapine tablets for up to 50 weeks or (2) identi-
cal placebo tablets…. Participants, clinicians, outcome assessors and the re-
search team were blinded to allocation."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Placebo-administered. Study staN reported to be blind to treatment alloca-
tion. "Participants were randomly assigned to one of two treatments: (1) 1 ×
15 mg encapsulated mirtazapine tablet daily for 2 weeks followed by 2 × 15 mg
encapsulated mirtazapine tablets for up to 50 weeks or (2) identical placebo
tablets…. Participants, clinicians, outcome assessors and the research team




Low risk ITT analyses carried out. "The primary comparative analyses of clinical effec-
tiveness were conducted according to the principle of intention to treat (ITT)
…. A number of sensitivity analyses were conducted to assess the impact of
missing primary outcome data on the main findings."
Selective reporting (re-
porting bias)
Unclear risk PHQ-9 measured at 12, 24 and 52 weeks but only data for 12 weeks was report-
ed.








Age: 44.5 years (SD 11)
Inclusion: Adults (18–65 years of age) with a DSM-IV diagnosis of major depression; a 17-item Hamil-
ton Depression Scale (HAM-D) score of ≥ 18; a Clinical Global Impression of Severity (CGI-S) score of ≥
4 (moderately ill); and a 14-item Hamilton Anxiety Scale (HAM-A) score of ≥ 14. These criteria had to be
met both at screening and baseline. In addition, all patients had been treated for their current episode
of major depressive disorder with a single SSRI/venlafaxine tablet at a therapeutic dose for at least 6
weeks.
Exclusion: Exclusion criteria included: a DSM-IV diagnosis of substance abuse or dependence within 6
months of screening, and patients who received an antipsychotic or benzodiazepine 7 days prior to en-
tering the study, or a potent cytochrome P450 inhibitor or inducer 14 days prior to entering the study.
Patients who were pregnant, breastfeeding, or at risk of suicide in the investigator’s opinion were also
excluded.
Interventions Group 1: Augmentation of SSRI/venlafaxine with quetiapine (mean 182 mg/d) for 8 weeks
McIntyre 2007 
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Group 2: Augmentation of SSRI/venlafaxine with placebo for 8 weeks
Outcomes Post-treatment assessment (8 weeks):
1. Depressive symptoms, continuous (HAM-D-17)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in HAM-D score from baseline)
4. Remission, dichotomous (HAM-D total score ≤ 7)
5. Adverse events
Definition of TRD Inadequate response to at least six weeks of a single SSRI or venlafaxine at an acceptable therapeutic
dose
Notes Funding: Study funded by AstraZeneca
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Described as double-blind and placebo given to control group so unlikely that
either participants or study personnel would have been aware of treatment al-
location
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not specifically stated that outcome assessors were blind to treatment alloca-




Low risk All randomised participants were included in the analyses. "The intent-to-treat
(ITT) population (any randomized patient who received at least one dose of
study medication) was used in all statistical analyses... LOCF analyses are re-
ported for the above measures".
Selective reporting (re-
porting bias)
Unclear risk Study protocol did not provide details of the outcomes to be assessed. All out-
comes and time points described in the methods were reported in the results.




Methods Parallel group RCT
Participants Country: US
Setting: Outpatient
N randomised: 139 (n = 98 (70.5%) female))
Papakostas 2015 
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Age: Mean 44.5 years (SD 12.8)
Inclusion: men and women 18–65 years of age with a primary diagnosis of current major depressive dis-
order according to DSM-IV criteria and confirmed with the Structured Clinical Interview for DSM-IV and
a score >= 10 on the 16-item Quick Inventory of Depressive Symptomatology–Self-Rated (QIDS-SR) at
screening
Exclusion: Patients were considered ineligible for participation in the study if they were pregnant,
breastfeeding, or lactating or if they were women of childbearing potential who were not using a med-
ically accepted means of contraception; high risk of suicide or homicide or other reasons the investiga-
tor might deem a patient unsafe to enrol in the study; an unstable medical illness or an uncontrolled
seizure disorder; a history of multiple adverse reactions or an allergy to the study drug; and a DSM-IV di-
agnosis of a substance use disorder (including alcohol) active within the past 6 months, bipolar disor-
der (current or past), or any psychotic disorder or psychotic symptoms (current or past). Patients who
had received an adequate trial of escitalopram during the current major depressive episode (prior to
study entry) or any lifetime trial of ziprasidone were also excluded, as were patients who had received
an investigational psychotropic drug within 3 months of their screening visit. In addition, patients who
had failed to benefit after more than three antidepressant trials of adequate dose and duration during
the current major depressive episode were excluded.
Interventions Group 1: Augmentation of escitalopram with ziprasidone (40 mg/d to 160 mg/d) for eight weeks
Group 2: Augmentation of escitalopram with placebo for eight weeks
Outcomes Post-treatment assessment (8 weeks):
1. Depressive symptoms, continuous (HAM-D, QIDS-SR)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in MADRS total score from randomisation; ≥ 50% reduction
in QIDS-SR score from randomisation)
4. Remission, dichotomous (HAM-D score ≤ 7; QIDS-SR score ≤ 5)
5. Adverse events
Definition of TRD Confirmed prospectively by failure to respond to an 8-week open-label trial of escitalopram (10 mg/d
to 30 mg/d). Continuing to meet DSM-IV criteria for MDD and had a QIDS-SR score ≥10
Notes Funding: Supported by a National Institute of Mental Health (NIMH) grant, Pfizer (which supplied blind-
ed ziprasidone and placebo pills), and Forest Laboratories (which supplied escitalopram)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence. "Patients were randomly as-
signed to receive adjunctive ziprasidone or placebo, in a 1:1 ratio, throughout
the remainder of the study. A central randomization center used a comput-
er-generated list of random numbers to allocate treatments."
Allocation concealment
(selection bias)
Low risk Centralised allocation, adequately concealed. "A central randomization cen-
ter used a computer-generated list of random numbers to allocate treatments.
None of the investigators, study clinicians, clinical raters, or participants at any





Low risk Participants and study personnel were blind to treatment allocation due to
the use of a placebo. "Ziprasidone (20 mg per capsule) and placebo were in
capsule form and identical in appearance. Independent pharmacists prepared
ziprasidone and placebo capsules. Study drugs were prepackaged in bottles
Papakostas 2015  (Continued)
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and consecutively numbered for each patient according to the randomization
schedule."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors were kept blind to treatment allocation. "None of the in-
vestigators, study clinicians, clinical raters, or participants at any of the study
sites had access to the randomization list. Ziprasidone (20 mg per capsule)
and placebo were in capsule form and identical in appearance. Independent
pharmacists prepared ziprasidone and placebo capsules. Study drugs were
prepackaged in bottles and consecutively numbered for each patient accord-




Unclear risk 37 participants reported as having dropped out. ITT analyses carried out (in-
cluding all 139 randomised participants). No information about how any miss-




Unclear risk All outcomes listed in the clinical trial registry entry were reported in the pa-
per. Authors reported carrying out additional analyses; they reported an addi-
tional measure QIDS-SR for secondary outcomes compared with what was list-
ed in the protocol.




Methods Parallel group RCT
Participants Country: US
Setting: Outpatients
N randomised: 28 (8 of whom randomised to a treatment arm not included in this review) (n = 21 (75%)
female (of 28 included in whole study))
Age: Mean 42 years (SD 11)
Inclusion: Outpatients who met DSM-IV criteria for recurrent major depression without psychotic fea-
tures and were resistant to conventional antidepressant pharmacotherapy
Exclusion: History of psychosis, dysthymic disorder, or bipolar disorder
Interventions Group 1: Augmentation of fluoxetine with olanzapine (5 mg/d to 20 mg/d) for eight weeks
Group 2: Augmentation of fluoxetine with placebo for eight weeks
(Other arms not relevant to this review: olanzapine (5 mg/d to 20 mg/d) plus placebo for eight weeks)
Outcomes Post-treatment assessment (8 weeks):
1. Depressive symptoms, continuous (MADRS, HAM-D)
2. Dropouts
3. Response, dichotomous (≥ 50% reduction in MADRS total score from randomisation)
4. Adverse events
Definition of TRD History of failure to respond to antidepressants of two different classes, one of which was not an SSRI,
after at least 4 weeks of therapy at an acceptable therapeutic dose. Failure to respond was confirmed
Shelton 2001 
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prospectively during a six-week screening period in which fluoxetine (20 mg/d to 60 mg/d) was given.
At entry, patients were required to score ≥ 20 on the 21-item Hamilton Depression Rating Scale and still
meet DSM-IV criteria (confirmed by study author).
Notes Funding: Supported in part by Eli Lilly and Company
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Stated randomised but sequence generation not described. "Non-responders
to fluoxetine were randomly assigned in a 1:1:1 ratio".
Allocation concealment
(selection bias)





Low risk Described as double-blind. Placebo used in the arm that did not receive aug-
mentation with antipsychotic. "The second phase was an 8-week double-blind
trial in which non-responders to fluoxetine were randomly assigned in a 1:1:1
ratio to receive … fluoxetine plus placebo ('fluoxetine') or olanzapine plus flu-
oxetine ('combination')".
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk All participants were analysed in the group to which they were randomised
with LOCF used to account for missing data. 'Analyses were performed on




High risk HAM-D reported to be the primary outcome in the published paper. Dichoto-
mous data not given for HAM-D but were for MADRS. FDA documentation sug-
gested that MADRS was a post hoc analysis and that the ‘response’ outcome
was originally based on reduction in HAM-D score.
Other bias Low risk No other concerns identified
Shelton 2001  (Continued)
BDI and BDI-II: Beck Depression Inventory
BMI: body mass index
BNF: British National Formulary
BRTC: Bristol Randomised Trials Collaboration
CGI-S: Clinical Global Impressions - Severity
DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders (version 3, revised).
DSM-IV and DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders (version 4, text revision).
ECG: electrocardiogram
EQ-5D-5L: EuroQoL 5 level version
FDA: Food and Drug Administration
HAM-A: Hamilton Anxiety Rating Scale
HAM-D and HAM-D-17: Hamilton Depression Rating Scale
HARD: Humeur-Angoisse-Ralentissement-Danger diagramme [Mood-Anxiety-Retardation-Danger depression scale]
ICD-10: International Classification of Diseases
ITT: intention-to-treat
LOCF: last observation carried forward
MADRS: Montgomery Asberg Depression Rating Scale
MAOI: monoamine oxidase inhibitor
MDD: major depressive disorder
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MITT: modified intention-to treat
PHQ-9: Patient Health Questionnaire
QIDS-SR: Quick Inventory of Depressive Symptomatology - Self Report
Q-LES-Q-SF: Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
RCT: randomised controlled trial
SD: standard deviation
SF-12: Short-Form
SNRI: serotonin-norepinephrine reuptake inhibitor
SSRI: selective serotonin reuptake inhibitor
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aarnell 2002 Not TRD (no duration criteria defined for prior antidepressant treatment)
ADAPT-A 2012 Diagnostic criteria not applied at point of randomisation
Baca 2005 Not TRD (included participants that were intolerant to AD)
Barbee 2011 Diagnostic criteria not applied at point of randomisation
Bares 2013 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Bauer 2013 (RUBY) Compared switching to an antipsychotic (not a treatment strategy covered by the review) with aug-
menting with quetiapine or augmenting with lithium. No control comparison of continuing on ini-
tial antidepressant monotherapy
Bauer 2018 Diagnostic criteria not applied at point of randomisation
Benkert 1997 Not TRD (prior antidepressant therapy for 3 weeks only). Not MDD (included patients with minor
depression)
Berman 2007 Diagnostic criteria not applied at point of randomisation
Berman 2009 Diagnostic criteria not applied at point of randomisation
Birkenhager 2004 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy.
Bose 2012 Compared dose increase with switch. No control comparison of continuing on initial antidepres-
sant monotherapy
Brecht 2011 Not TRD (MDD only were randomised, non-responders during trial all got a dose increase)
Chaput 2004 Not a comparison of interest. Compared switch to cognitive behavioural therapy plus quetiapine
augmentation to CBT plus placebo. No control comparison of continuing on initial antidepressant
monotherapy
Cheon 2017 Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Cipriani 2013 Not TRD (dose and duration of prior antidepressant treatment not specified)
Corya 2006 Diagnostic criteria not applied at point of randomisation
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Study Reason for exclusion
Doree 2007 Compared augmentation with lithium with augmentation with quetiapine. No control comparison
of continuing on initial antidepressant monotherapy
e-Therapeutics 2013 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy.
Earley 2018 Diagnostic criteria not applied at point of randomisation
Edwards 1998 Not TRD (dose and duration of prior antidepressant not defined)
Fang 2010 Diagnostic criteria not applied at point of randomisation
Fang 2011 Not TRD (medical history-based definition of TRD, no dose or duration for prior AD defined)
Fava 1994 Three-arm trial that compared increasing dose of current antidepressant with two augmentation
strategies (desipramine or lithium). No control comparison of continuing on initial antidepressant
monotherapy
Fava 2001 Not TRD (included patients who were intolerant as well as resistant)
Fava 2002 Three-arm trial that compared increasing dose of current antidepressant with two augmentation
strategies (desipramine or lithium). No control comparison of continuing on initial antidepressant
monotherapy
Fava 2018 Diagnostic criteria not applied at point of randomisation
Fornaro 2014 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Franco-Chaves 2013 Compared two switching strategies and combination treatment. No control comparison of contin-
uing on initial antidepressant monotherapy
Furukawa 2011 Not TRD (3 weeks duration of prior AD treatment)
Garry 1963 Not TRD (all treatments for depression were discontinued for two weeks prior to randomisation in-
to the trial)
Gonul 1999 Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Grant 2017 Compared dose escalation with a switching strategy. No control comparison of continuing on ini-
tial antidepressant monotherapy
Han 2015 Compared augmenting current antidepressant treatment with an antipsychotic and switching to
another antidepressant. No control comparison of continuing on initial antidepressant monothera-
py
Hides 2006 Not TRD (participants had major depression which had not responded to CBT, participants had no
prior antidepressant treatment)
Hobart 2018 Diagnostic criteria not applied at point of randomisation
Horikoshi 2017 Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
JoNe 1993 Diagnostic criteria not applied at point of randomisation
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Study Reason for exclusion
JoNe 2006 Not TRD (range of doses reported for previous antidepressant use included subtherapeutic dose)
Kamijima 2013 Diagnostic criteria not applied at point of randomisation
Kamijima 2018 Diagnostic criteria not applied at point of randomisation
Keitner 2009 Not TRD (only three weeks of prior antidepressant treatment)
Kennedy 2003 Compared cognitive therapy and lithium augmentation of current antidepressant treatment. No
control comparison of continuing on initial antidepressant monotherapy
Kocsis 1988 Not TRD (participants had chronic depression and had failed to respond to two weeks treatment
with imipramine)
Lejoyeux 2015 Not a comparison of interest. Compared three tapering strategies. No control comparison of con-
tinuing on initial antidepressant monotherapy
Lenox-Smith 2008 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Lenze 2015 (IRL GREY) Diagnostic criteria not applied at point of randomisation
Li 2006 Compared augmentation of current antidepressant therapy with lithium and switching to another
antidepressant. No control comparison of continuing on initial antidepressant monotherapy
Li 2013 Compared two switching strategies. No control comparison of continuing on antidepressant
monotherapy
Licht 2002 Diagnostic criteria not applied at point of randomisation
Maes 1996 Not TRD at the point of randomisation. Participants who had not responded to previous antide-
pressant medication underwent a ten-day washout followed by a week of trazadone. Participants
who then had HAM-D ≥ 14 were randomised to augment with pindolol, fluoxetine or placebo.
Maes 1999 Not TRD (no dose or duration criteria defined)
Marcus 2008 Diagnostic criteria not applied at point of randomisation
Marwood 2017 Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Mattingly 2006 Not TRD (dosage criteria for prior antidepressant treatment not defined)
Medhus 1994 Not TRD (no dosage criteria defined, "presumed adequate dosage")
Mohamed 2017 (VAST-D) Compared switching to another antidepressant with augmenting with an antidepressant. No con-
trol comparison of continuing on initial antidepressant monotherapy
Montgomery 2014 (REVIVE) Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Moreno 1997 Not all participants had received an antidepressant at the manufacturer's minimum recommended
therapeutic dose.
Nakajima 2011 Not TRD (run-in phase with antidepressant was two weeks duration at which point non-responders
were randomised)
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Study Reason for exclusion
NCT00273624 Study terminated early. No results available. TRD defined as two courses of antidepressants from
different classes for at least three weeks at an adequate dose
NCT00296517 Not a comparison of interest. Nonresponders to paroxetine had their dose tapered down and aug-
mented with either bupropion or placebo.
NCT01052077 Diagnostic criteria not applied at point of randomisation
NCT02272517 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
NCT02960763 Compared an augmentation strategy with switching to another antidepressant. No control com-
parison of continuing on initial antidepressant monotherapy
NCT02977299 Compared augmentation with aripiprazole with augmentation with rTMS. No control comparison
of continuing on initial antidepressant monotherapy
Nierenberg 2003 Diagnostic criteria not applied at point of randomisation
Nolen 1993 Not TRD (only three weeks of prior antidepressant treatment)
Perahia 2008 Compared two switching strategies (immediate switch versus immediate switch with tapering
down of original antidepressant). No control comparison of continuing on initial antidepressant
monotherapy
Perez 1999 TRD defined as failure to respond to a minimum of six weeks of antidepressant treatment, however
dose was only required to have been fixed at a therapeutic level for the final two weeks.
Petrescu 2014 Compared dose escalation with switching to another antidepressant. No control comparison of
continuing on initial antidepressant monotherapy
Poirier 1999 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Rapaport 2006 (ARISe-RD) Diagnostic criteria not applied at point of randomisation
Ravindran 2006 Compared adjunctive olanzapine with adjunctive risperidone. No control comparison of continu-
ing on initial antidepressant monotherapy
Rele 2015 Compared three switching strategies. No control comparison of continuing on initial antidepres-
sant monotherapy
Romera 2010 Compared two switching strategies (early or delayed switch). No control comparison of continuing
on initial antidepressant monotherapy
Ruhe 2009 Diagnostic criteria not applied at point of randomisation
Russell 1995 Not treatment-resistant depression. Participants with chronic depression (with or without dys-
thymia, 'double depression') were randomised to sertraline or imipramine (i.e. not TRD). In a sec-
ond part of the study, those who did not respond were crossed over to the other treatment (i.e. not
randomised). Responders continued in a maintenance study.
Rybakowski 1999 Compared augmentation with lithium to augmentation with carbamazine. No control comparison
of continuing on initial antidepressant monotherapy
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Study Reason for exclusion
Santos 2008 Participants had a history of TRD. Study did not state that treatment resistance had to be in the
current episode. TRD defined as failure to respond to a minimum of two antidepressants of differ-
ent classes at the maximum-tolerated dose for at least six weeks
Schindler 2007 Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Schweizer 1990 TRD defined as failure to respond to fluoxetine 20 mg/day for 3 weeks
Schweizer 2001 TRD defined as failure to respond to three weeks of antidepressant therapy
Shelton 2005a Compared two augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Shelton 2005b Diagnostic criteria not applied at point of randomisation
Small 1981 Not TRD. Included participants who had received lower than recommended tricyclic antidepres-
sant dose who had been unable to tolerate side effects
Song 2007 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Souche 1991 Diagnostic criteria not applied at point of randomisation
Souery 2011 Phase 1: compared two switching strategies (no control group). Phase 2: not randomised
STAR*D 2004 Evaluated a sequence of different treatment options for depression. Participants who failed to re-
spond to treatment were randomised into the next phase of the study. Continuation of current an-
tidepressant therapy was not a treatment option at any phase of the study. There was, therefore,
no control comparison of continuing on initial antidepressant monotherapy.
Stein 1993 Not TRD (only three weeks of prior antidepressant treatment)
Sun 2004 Described as 'refractory depression' but participants had not received prior treatment for their de-
pression
Sunderland 1994 Not TRD (patients were drug-free for three weeks before randomisation)
Tanghe 1997 Not TRD (no dose or duration criteria for prior AD treatment)
Thase 2000 Compared switching to mirtazapine with switching to sertraline. No control comparison of contin-
uing on initial antidepressant monotherapy
Thase 2006 Not TRD (included participants intolerant to medication)
Thase 2007 Diagnostic criteria not applied at point of randomisation
Thase 2011 Diagnostic criteria not applied at point of randomisation
Thase 2015 (PYXIS) Diagnostic criteria not applied at point of randomisation
Thase 2015a (POLARIS) Diagnostic criteria not applied at point of randomisation
Yang 2005 Compared two switching therapies. No control comparison of continuing on initial antidepressant
monotherapy
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Study Reason for exclusion
Yoshimura 2012 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Yoshimura 2014 Compared three augmentation strategies. No control comparison of continuing on initial antide-
pressant monotherapy
Zhao 2003 Compared two switching strategies. No control comparison of continuing on initial antidepressant
monotherapy
Zusky 1988 Not TRD. Included participants unable to tolerate manufacturer's recommended dose
AD: Antidepressant
CBT: Cognitive behavioural therapy
MDD: Major depressive disorder
rTMS: Repetitive transcranial magnetic stimulation
TRD: Treatment-resistant depression
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised controlled trial
Participants Chinese depression diagnosis. Failure to respond to two antidepressants for at least six weeks
Interventions 1. Venlafaxine
2. Venlafaxine and quetiapine
Outcomes Measured at 1, 2, 4 and 6 weeks.
1. Depression severity HAM-D
2. Treatment-emergent symptom scales (TESS)
3. Treatment efficacy (dichotomous outcome)
Notes No information about the dose of prior antidepressants reported and no response received from





Methods Randomised controlled trial
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Notes Trial protocol from National Institute for Health Research Research Registry. No publications relat-
ing to the study identified. No information about method of diagnosis or duration and dose of pri-
or treatment. Unclear whether there was a control group that continued on current antidepressant




Methods Randomised controlled trial
Participants Diagnosis of depression according to DSM-IV-TR criteria, failure to respond to SSRI at correct dose
for a minimum of 6 weeks, score of >= 14 of HAM-D-17
Interventions 1. Venlafaxine 75 mg to 150 mg
2. Lithium carbonate 400 mg
3. Nortriptyline 25 mg
4. Control group
Outcomes Primary outcome measure: HAM-D-17
Notes Trial registry entry. No publications relating to the study identified. Study authors could not be
identified to enable requests for further information. Unclear whether interventions were given as





Methods Randomised controlled trial
Participants Diagnosis of MDD according to DSM-IV-TR criteria, HAM-D score of >= 16 after 4 weeks of treatment
with an SSRI
Interventions 1. Bupropion, starting at 150 mg/d and increasing to 300 mg/d after 1 week, in addition to SSRI
2. Placebo in addition to SSRI
Outcomes Change in HAM-D and MADRS scores
Remission: HAM-D score <= 7 or MADRS score <= 12
Spontaneously reported adverse events
Notes Dose of previous SSRI treatment could not be determined from the paper and no response received




Methods Randomised controlled trial
Participants Major depressive disorder, single or recurrent, without psychotic symptoms and an inadequate re-
sponse to the antidepressant therapy (the use of minimal doses accepted as effective for a period
Moica 2018 
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of at least 4 to 6 weeks). At the time of the enrolment, all participants were treated with duloxetine
60 mg per day.
Interventions 1. Current antidepressant treatment (duloxetine 60 mg/d) augmented with quetiapine (150 mg/d)
2. Continue on duloxetine (60 mg/d) monotherapy
Outcomes Change in HAM-D score
Notes Unclear how long participants had been receiving current antidepressant (duloxetine) treatment.





Methods Randomised controlled trial
Participants Diagnosis of depression according to CCMD-3 (Chinese Classification of Mental Disorders). Failure
to respond to 6 weeks of treatment with an SSRI. HAM-D score >= 18
Interventions 1. Mirtazapine (30 mg/d to 45 mg/d) for 6 weeks
2. Continue on original antidepressant therapy for 6 weeks
Outcomes Measured at 1, 2, 4 and 6 weeks
1. Depression severity (HAM-D)
2. Treatment-emergent symptom scales (TESS)
Notes Details of treatment resistance could not be determined. Unable to contact study author
Zhu 2003 
CCMD-3: Chinese Classification of Mental Disorders version 3
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders
HAM-D: Hamilton Depression Rating Scale
HAM-D-17: Hamilton Depression Rating Scale-17
MADRS: Montgomery Asberg Depression Rating Scale
SSRI: selective serotonin reuptake inhibitor
TESS: Treatment Emergent Symptoms Scale
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Switch to mianserin





Statistical method Effect size
1 Depressive symptoms (HAM-D) 1 71 Mean Difference (IV, Fixed, 95% CI) -1.80 [-5.23, 1.63]
2 Dropouts 1 72 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.94, 4.59]
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Statistical method Effect size
3 Response (≥ 50% improvement in
HAM-D score)
1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.76, 2.27]
4 Remission (HAM-D total score ≤ 8) 1 71 Risk Ratio (M-H, Fixed, 95% CI) 1.97 [0.88, 4.42]
 
 
Analysis 1.1.   Comparison 1 Switch to mianserin, Outcome 1 Depressive symptoms (HAM-D).
Study or subgroup Switch to mianserin Fluoxetine
monotherapy
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Ferreri 2001 33 -13.1 (7.3) 38 -11.3 (7.4) 100% -1.8[-5.23,1.63]
   
Total *** 33   38   100% -1.8[-5.23,1.63]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours mianserin switch 105-10 -5 0 Favours control
 
 
Analysis 1.2.   Comparison 1 Switch to mianserin, Outcome 2 Dropouts.




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 13/34 7/38 100% 2.08[0.94,4.59]
   
Total (95% CI) 34 38 100% 2.08[0.94,4.59]
Total events: 13 (Switch to mianserin), 7 (Fluoxetine monotherapy)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.8(P=0.07)  
Favours mianserin switch 1000.01 100.1 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Switch to mianserin, Outcome 3 Response (≥ 50% improvement in HAM-D score).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 16/33 14/38 100% 1.32[0.76,2.27]
   
Total (95% CI) 33 38 100% 1.32[0.76,2.27]
Total events: 16 (Switch to mianserin), 14 (Fluoxetine monotherapy)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
Favours control 1000.01 100.1 1 Favours mianserin switch
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Analysis 1.4.   Comparison 1 Switch to mianserin, Outcome 4 Remission (HAM-D total score ≤ 8).




Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 12/33 7/38 100% 1.97[0.88,4.42]
   
Total (95% CI) 33 38 100% 1.97[0.88,4.42]
Total events: 12 (Switch to mianserin), 7 (Fluoxetine monotherapy)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.65(P=0.1)  
Favours control 1000.01 100.1 1 Favours mianserin switch
 
 
Comparison 2.   Augment current antidepressant with mianserin





Statistical method Effect size
1 Depressive symptoms (HAM-D) 1 70 Mean Difference (IV, Fixed, 95%
CI)
-4.80 [-8.18, -1.42]
2 Dropouts 1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.38, 2.72]
3 Response (≥ 50% reduction in HAM-D
score)
1 70 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.03, 2.78]
4 Remission (HAM-D total score ≤ 7) 1 70 Risk Ratio (M-H, Fixed, 95% CI) 2.38 [1.09, 5.16]
 
 
Analysis 2.1.   Comparison 2 Augment current antidepressant
with mianserin, Outcome 1 Depressive symptoms (HAM-D).
Study or subgroup Mianserin Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Ferreri 2001 32 -16.1 (7) 38 -11.3 (7.4) 100% -4.8[-8.18,-1.42]
   
Total *** 32   38   100% -4.8[-8.18,-1.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.78(P=0.01)  
Favours mianserin 5025-50 -25 0 Favours control
 
 
Analysis 2.2.   Comparison 2 Augment current antidepressant with mianserin, Outcome 2 Dropouts.
Study or subgroup Mianserin Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 6/32 7/38 100% 1.02[0.38,2.72]
   
Favours mianserin 1000.01 100.1 1 Favours control
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Study or subgroup Mianserin Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total (95% CI) 32 38 100% 1.02[0.38,2.72]
Total events: 6 (Mianserin), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
Favours mianserin 1000.01 100.1 1 Favours control
 
 
Analysis 2.3.   Comparison 2 Augment current antidepressant with
mianserin, Outcome 3 Response (≥ 50% reduction in HAM-D score).
Study or subgroup Mianserin Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 20/32 14/38 100% 1.7[1.03,2.78]
   
Total (95% CI) 32 38 100% 1.7[1.03,2.78]
Total events: 20 (Mianserin), 14 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.09(P=0.04)  
Favours control 1000.01 100.1 1 Favours mianserin
 
 
Analysis 2.4.   Comparison 2 Augment current antidepressant
with mianserin, Outcome 4 Remission (HAM-D total score ≤ 7).
Study or subgroup Mianserin Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Ferreri 2001 14/32 7/38 100% 2.38[1.09,5.16]
   
Total (95% CI) 32 38 100% 2.38[1.09,5.16]
Total events: 14 (Mianserin), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.19(P=0.03)  
Favours control 1000.01 100.1 1 Favours mianserin
 
 
Comparison 3.   Augment current antidepressant with mirtazapine





Statistical method Effect size
1 Depressive symptoms (BDI-II) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 12 weeks 1 431 Mean Difference (IV, Fixed, 95% CI) -1.70 [-4.03, 0.63]
1.2 24 weeks 1 402 Mean Difference (IV, Fixed, 95% CI) -0.90 [-3.39, 1.59]
1.3 52 weeks 1 388 Mean Difference (IV, Fixed, 95% CI) 0.10 [-2.38, 2.58]
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Statistical method Effect size
2 Depressive symptoms (PHQ-9,
12 weeks)
1 429 Mean Difference (IV, Fixed, 95% CI) -0.89 [-2.08, 0.30]
3 Dropouts 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 12 weeks 1 480 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.15, 1.62]
3.2 24 weeks 1 480 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.19, 1.30]
3.3 52 weeks 1 480 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.18, 1.18]
4 Response (≥ 50% improve-
ment in BDI-II score)
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 12 weeks 1 431 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.97, 1.54]
4.2 24 weeks 1 402 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.83, 1.23]
4.3 52 weeks 1 388 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.82, 1.22]
5 Remission (BDI-II total score ≤
9)
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 12 weeks 1 431 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.88, 1.65]
5.2 24 weeks 1 402 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.86, 1.55]
5.3 52 weeks 1 388 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.30]
6 Quality of life (EQ-5D-5L) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 12 weeks 1 447 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.06, 0.04]
6.2 24 weeks 1 403 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.07, 0.03]
6.3 52 weeks 1 388 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.08, 0.02]
7 Quality of life (SF-12 - aggre-
gate mental functioning)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 12 weeks 1 418 Mean Difference (IV, Fixed, 95% CI) 3.61 [1.23, 5.99]
7.2 24 weeks 1 392 Mean Difference (IV, Fixed, 95% CI) 1.98 [-0.64, 4.60]
7.3 52 weeks 1 373 Mean Difference (IV, Fixed, 95% CI) 1.29 [-1.44, 4.02]
8 Quality of life (SF-12 - aggre-
gate physical functioning)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 12 weeks 1 418 Mean Difference (IV, Fixed, 95% CI) -1.76 [-4.20, 0.68]
8.2 24 weeks 1 392 Mean Difference (IV, Fixed, 95% CI) -2.49 [-5.04, 0.06]
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Statistical method Effect size
8.3 52 weeks 1 373 Mean Difference (IV, Fixed, 95% CI) -0.98 [-3.61, 1.65]
 
 
Analysis 3.1.   Comparison 3 Augment current antidepressant
with mirtazapine, Outcome 1 Depressive symptoms (BDI-II).
Study or subgroup Mirtazapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.1.1 12 weeks  
Kessler 2018 214 18 (12.3) 217 19.7 (12.4) 100% -1.7[-4.03,0.63]
Subtotal *** 214   217   100% -1.7[-4.03,0.63]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.43(P=0.15)  
   
3.1.2 24 weeks  
Kessler 2018 196 17.3 (12.9) 206 18.2 (12.6) 100% -0.9[-3.39,1.59]
Subtotal *** 196   206   100% -0.9[-3.39,1.59]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
3.1.3 52 weeks  
Kessler 2018 190 16.8 (12.7) 198 16.7 (12.2) 100% 0.1[-2.38,2.58]
Subtotal *** 190   198   100% 0.1[-2.38,2.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.94)  
Favours mirtazapine 105-10 -5 0 Favours control
 
 
Analysis 3.2.   Comparison 3 Augment current antidepressant with
mirtazapine, Outcome 2 Depressive symptoms (PHQ-9, 12 weeks).
Study or subgroup Mirtazapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Kessler 2018 212 9.7 (6.4) 217 10.6 (6.2) 100% -0.89[-2.08,0.3]
   
Total *** 212   217   100% -0.89[-2.08,0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.47(P=0.14)  
Favours mirtazapine 105-10 -5 0 Favours control
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Analysis 3.3.   Comparison 3 Augment current antidepressant with mirtazapine, Outcome 3 Dropouts.
Study or subgroup Mirtazapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.3.1 12 weeks  
Kessler 2018 4/241 8/239 100% 0.5[0.15,1.62]
Subtotal (95% CI) 241 239 100% 0.5[0.15,1.62]
Total events: 4 (Mirtazapine), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
   
3.3.2 24 weeks  
Kessler 2018 6/241 12/239 100% 0.5[0.19,1.3]
Subtotal (95% CI) 241 239 100% 0.5[0.19,1.3]
Total events: 6 (Mirtazapine), 12 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
   
3.3.3 52 weeks  
Kessler 2018 6/241 13/239 100% 0.46[0.18,1.18]
Subtotal (95% CI) 241 239 100% 0.46[0.18,1.18]
Total events: 6 (Mirtazapine), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
Favours mirtazapine 1000.01 100.1 1 Favours control
 
 
Analysis 3.4.   Comparison 3 Augment current antidepressant with
mirtazapine, Outcome 4 Response (≥ 50% improvement in BDI-II score).
Study or subgroup Mirtazapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.4.1 12 weeks  
Kessler 2018 94/214 78/217 100% 1.22[0.97,1.54]
Subtotal (95% CI) 214 217 100% 1.22[0.97,1.54]
Total events: 94 (Mirtazapine), 78 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
   
3.4.2 24 weeks  
Kessler 2018 96/196 100/206 100% 1.01[0.83,1.23]
Subtotal (95% CI) 196 206 100% 1.01[0.83,1.23]
Total events: 96 (Mirtazapine), 100 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.09(P=0.93)  
   
3.4.3 52 weeks  
Kessler 2018 97/190 101/198 100% 1[0.82,1.22]
Subtotal (95% CI) 190 198 100% 1[0.82,1.22]
Total events: 97 (Mirtazapine), 101 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.01(P=0.99)  
Favours control 200.05 50.2 1 Favours mirtazapine
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Analysis 3.5.   Comparison 3 Augment current antidepressant
with mirtazapine, Outcome 5 Remission (BDI-II total score ≤ 9).
Study or subgroup Mirtazapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.5.1 12 weeks  
Kessler 2018 63/214 53/217 100% 1.21[0.88,1.65]
Subtotal (95% CI) 214 217 100% 1.21[0.88,1.65]
Total events: 63 (Mirtazapine), 53 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
   
3.5.2 24 weeks  
Kessler 2018 65/196 59/206 100% 1.16[0.86,1.55]
Subtotal (95% CI) 196 206 100% 1.16[0.86,1.55]
Total events: 65 (Mirtazapine), 59 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.98(P=0.33)  
   
3.5.3 52 weeks  
Kessler 2018 63/190 67/198 100% 0.98[0.74,1.3]
Subtotal (95% CI) 190 198 100% 0.98[0.74,1.3]
Total events: 63 (Mirtazapine), 67 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
Favours control 1000.01 100.1 1 Favours mirtazapine
 
 
Analysis 3.6.   Comparison 3 Augment current antidepressant
with mirtazapine, Outcome 6 Quality of life (EQ-5D-5L).
Study or subgroup Mirtazapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.6.1 12 weeks  
Kessler 2018 231 0.7 (0.3) 216 0.7 (0.3) 100% -0.01[-0.06,0.04]
Subtotal *** 231   216   100% -0.01[-0.06,0.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
3.6.2 24 weeks  
Kessler 2018 196 0.7 (0.3) 207 0.7 (0.3) 100% -0.02[-0.07,0.03]
Subtotal *** 196   207   100% -0.02[-0.07,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.8(P=0.42)  
   
3.6.3 52 weeks  
Kessler 2018 189 0.7 (0.3) 199 0.8 (0.3) 100% -0.03[-0.08,0.02]
Subtotal *** 189   199   100% -0.03[-0.08,0.02]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.11(P=0.27)  
Favours mirtazapine 0.20.1-0.2 -0.1 0 Favours control
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Analysis 3.7.   Comparison 3 Augment current antidepressant with
mirtazapine, Outcome 7 Quality of life (SF-12 - aggregate mental functioning).
Study or subgroup Mirtazapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.7.1 12 weeks  
Kessler 2018 208 39.9 (12.3) 210 36.3 (12.5) 100% 3.61[1.23,5.99]
Subtotal *** 208   210   100% 3.61[1.23,5.99]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.98(P=0)  
   
3.7.2 24 weeks  
Kessler 2018 191 39.9 (13.9) 201 37.9 (12.4) 100% 1.98[-0.64,4.6]
Subtotal *** 191   201   100% 1.98[-0.64,4.6]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.48(P=0.14)  
   
3.7.3 52 weeks  
Kessler 2018 182 40.5 (13.8) 191 39.3 (13.1) 100% 1.29[-1.44,4.02]
Subtotal *** 182   191   100% 1.29[-1.44,4.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Favours mirtazapine 105-10 -5 0 Favours control
 
 
Analysis 3.8.   Comparison 3 Augment current antidepressant with
mirtazapine, Outcome 8 Quality of life (SF-12 - aggregate physical functioning).
Study or subgroup Mirtazapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.8.1 12 weeks  
Kessler 2018 208 44.1 (12.9) 210 45.9 (12.5) 100% -1.76[-4.2,0.68]
Subtotal *** 208   210   100% -1.76[-4.2,0.68]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.42(P=0.16)  
   
3.8.2 24 weeks  
Kessler 2018 191 42.9 (13) 201 45.4 (12.8) 100% -2.49[-5.04,0.06]
Subtotal *** 191   201   100% -2.49[-5.04,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
   
3.8.3 52 weeks  
Kessler 2018 182 43.3 (13.4) 191 44.3 (12.5) 100% -0.98[-3.61,1.65]
Subtotal *** 182   191   100% -0.98[-3.61,1.65]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.73(P=0.47)  
Favours mirtazapine 105-10 -5 0 Favours control
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Comparison 4.   Augment current antidepressant with buspirone (anxiolytic)




Statistical method Effect size
1 Depressive symptoms (MADRS) 1 102 Mean Difference (IV, Random, 95% CI) -0.30 [-9.48, 8.88]
2 Dropouts 1 108 Risk Ratio (M-H, Random, 95% CI) 0.6 [0.23, 1.53]
 
 
Analysis 4.1.   Comparison 4 Augment current antidepressant with
buspirone (anxiolytic), Outcome 1 Depressive symptoms (MADRS).
Study or subgroup Augmentation of AD Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Appelberg 2001 51 30.5 (23.8) 51 30.8 (23.5) 100% -0.3[-9.48,8.88]
   
Total *** 51   51   100% -0.3[-9.48,8.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Favours augmentation 105-10 -5 0 Favours control
 
 
Analysis 4.2.   Comparison 4 Augment current antidepressant with buspirone (anxiolytic), Outcome 2 Dropouts.
Study or subgroup Buspirone
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Appelberg 2001 6/54 10/54 100% 0.6[0.23,1.53]
   
Total (95% CI) 54 54 100% 0.6[0.23,1.53]
Total events: 6 (Buspirone augmentation), 10 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.07(P=0.29)  
Favours buspirone 1000.01 100.1 1 Favours control
 
 
Comparison 5.   Augment current antidepressant with cariprazine (antipsychotic)





Statistical method Effect size
1 Depressive symptoms
(MADRS)
1   Mean Difference (Fixed, 95% CI) Subtotals only
1.1 1-2 mg/d 1 537 Mean Difference (Fixed, 95% CI) -0.9 [-2.29, 0.49]
1.2 2-4.5mg/d 1 535 Mean Difference (Fixed, 95% CI) -2.1 [-3.63, -0.57]
1.3 Any dose 1 808 Mean Difference (Fixed, 95% CI) -1.50 [-2.74, -0.25]
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Statistical method Effect size
2 Dropouts 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 1-2 mg/d 1 545 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.94, 2.17]
2.2 2-4.5mg/d 1 545 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [1.30, 2.84]
2.3 Pooled dose 1 821 Risk Ratio (M-H, Fixed, 95% CI) 1.68 [1.16, 2.41]
3 Response (≥ 50% improve-
ment in MADRS score)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 1-2 mg/d 1 537 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.03, 1.53]
3.2 2-4.5mg/d 1 535 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.06, 1.57]
3.3 Pooled dose 1 808 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.07, 1.52]
4 Remission (MADRS total
score ≤ 10)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 1-2mg/d 1 537 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.83, 1.37]
4.2 2-4.5mg/d 1 535 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.83, 1.38]
4.3 Pooled data 1 808 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.86, 1.33]
 
 
Analysis 5.1.   Comparison 5 Augment current antidepressant with
cariprazine (antipsychotic), Outcome 1 Depressive symptoms (MADRS).
Study or subgroup Cariprazine Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
5.1.1 1-2 mg/d  
Durgam 2016 273 264 -0.9 (0.707) 100% -0.9[-2.29,0.49]
Subtotal (95% CI)       100% -0.9[-2.29,0.49]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
   
5.1.2 2-4.5mg/d  
Durgam 2016 271 264 -2.1 (0.781) 100% -2.1[-3.63,-0.57]
Subtotal (95% CI)       100% -2.1[-3.63,-0.57]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.69(P=0.01)  
   
5.1.3 Any dose  
Durgam 2016 544 264 -1.5 (0.635) 100% -1.5[-2.74,-0.25]
Subtotal (95% CI)       100% -1.5[-2.74,-0.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.36(P=0.02)  
Favours cariprazine 52.5-5 -2.5 0 Favours control
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Analysis 5.2.   Comparison 5 Augment current antidepressant with cariprazine (antipsychotic), Outcome 2 Dropouts.
Study or subgroup Cariprazine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.2.1 1-2 mg/d  
Durgam 2016 47/276 32/269 100% 1.43[0.94,2.17]
Subtotal (95% CI) 276 269 100% 1.43[0.94,2.17]
Total events: 47 (Cariprazine augmentation), 32 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
   
5.2.2 2-4.5mg/d  
Durgam 2016 63/276 32/269 100% 1.92[1.3,2.84]
Subtotal (95% CI) 276 269 100% 1.92[1.3,2.84]
Total events: 63 (Cariprazine augmentation), 32 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.27(P=0)  
   
5.2.3 Pooled dose  
Durgam 2016 110/552 32/269 100% 1.68[1.16,2.41]
Subtotal (95% CI) 552 269 100% 1.68[1.16,2.41]
Total events: 110 (Cariprazine augmentation), 32 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.77(P=0.01)  
Favours cariprazine 1000.01 100.1 1 Favours control
 
 
Analysis 5.3.   Comparison 5 Augment current antidepressant with cariprazine
(antipsychotic), Outcome 3 Response (≥ 50% improvement in MADRS score).
Study or subgroup Cariprazine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.3.1 1-2 mg/d  
Durgam 2016 131/273 101/264 100% 1.25[1.03,1.53]
Subtotal (95% CI) 273 264 100% 1.25[1.03,1.53]
Total events: 131 (Cariprazine), 101 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.26(P=0.02)  
   
5.3.2 2-4.5mg/d  
Durgam 2016 134/271 101/264 100% 1.29[1.06,1.57]
Subtotal (95% CI) 271 264 100% 1.29[1.06,1.57]
Total events: 134 (Cariprazine), 101 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.58(P=0.01)  
   
5.3.3 Pooled dose  
Durgam 2016 265/544 101/264 100% 1.27[1.07,1.52]
Subtotal (95% CI) 544 264 100% 1.27[1.07,1.52]
Total events: 265 (Cariprazine), 101 (Control)  
Favours control 1000.01 100.1 1 Favours cariprazine
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Study or subgroup Cariprazine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=2.69(P=0.01)  
Favours control 1000.01 100.1 1 Favours cariprazine
 
 
Analysis 5.4.   Comparison 5 Augment current antidepressant with
cariprazine (antipsychotic), Outcome 4 Remission (MADRS total score ≤ 10).
Study or subgroup Cariprazine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.4.1 1-2mg/d  
Durgam 2016 87/273 79/264 100% 1.06[0.83,1.37]
Subtotal (95% CI) 273 264 100% 1.06[0.83,1.37]
Total events: 87 (Cariprazine), 79 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.63)  
   
5.4.2 2-4.5mg/d  
Durgam 2016 87/271 79/264 100% 1.07[0.83,1.38]
Subtotal (95% CI) 271 264 100% 1.07[0.83,1.38]
Total events: 87 (Cariprazine), 79 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
5.4.3 Pooled data  
Durgam 2016 174/544 79/264 100% 1.07[0.86,1.33]
Subtotal (95% CI) 544 264 100% 1.07[0.86,1.33]
Total events: 174 (Cariprazine), 79 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
Favours control 1000.01 100.1 1 Favours cariprazine
 
 
Comparison 6.   Augment current antidepressant with olanzapine (antipsychotic)





Statistical method Effect size
1 Depressive symptoms (MADRS) 1 20 Mean Difference (IV, Fixed, 95%
CI)
-12.4 [-22.44, -2.36]
2 Depressive symptoms (HAM-D) 1 20 Mean Difference (IV, Random,
95% CI)
-7.90 [-16.76, 0.96]
3 Dropouts 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.69]
4 Response (≥ 50% reduction in MADRS
score)
1 20 Risk Ratio (M-H, Random, 95%
CI)
6.0 [0.87, 41.21]
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Analysis 6.1.   Comparison 6 Augment current antidepressant with
olanzapine (antipsychotic), Outcome 1 Depressive symptoms (MADRS).
Study or subgroup Olanzapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Shelton 2001 10 -13.6 (11.9) 10 -1.2 (11) 100% -12.4[-22.44,-2.36]
   
Total *** 10   10   100% -12.4[-22.44,-2.36]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.42(P=0.02)  
Favours olanzapine 10050-100 -50 0 Favours control
 
 
Analysis 6.2.   Comparison 6 Augment current antidepressant with
olanzapine (antipsychotic), Outcome 2 Depressive symptoms (HAM-D).
Study or subgroup Olanzapine Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Shelton 2001 10 -11.7 (10.6) 10 -3.8 (9.6) 100% -7.9[-16.76,0.96]
   
Total *** 10   10   100% -7.9[-16.76,0.96]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.75(P=0.08)  
Favours olanzapine 10050-100 -50 0 Favours control
 
 
Analysis 6.3.   Comparison 6 Augment current antidepressant with olanzapine (antipsychotic), Outcome 3 Dropouts.
Study or subgroup Olanzapine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Shelton 2001 1/10 3/10 100% 0.33[0.04,2.69]
   
Total (95% CI) 10 10 100% 0.33[0.04,2.69]
Total events: 1 (Olanzapine augmentation), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours olanzapine 1000.01 100.1 1 Favours control
 
 
Analysis 6.4.   Comparison 6 Augment current antidepressant with olanzapine
(antipsychotic), Outcome 4 Response (≥ 50% reduction in MADRS score).
Study or subgroup Olanzapine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Shelton 2001 6/10 1/10 100% 6[0.87,41.21]
   
Favours control 1000.01 100.1 1 Favours olanzapine
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Study or subgroup Olanzapine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 10 10 100% 6[0.87,41.21]
Total events: 6 (Olanzapine augmentation), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Favours control 1000.01 100.1 1 Favours olanzapine
 
 
Comparison 7.   Augment current antidepressant with quetiapine (antipsychotic)





Statistical method Effect size
1 Depressive symptoms (MADRS
or HAM-D)
3   Std. Mean Difference (Random, 95%
CI)
Subtotals only
1.1 150 -200 mg/d 3 670 Std. Mean Difference (Random, 95%
CI)
-0.34 [-0.53, -0.14]
1.2 300mg/d 2 610 Std. Mean Difference (Random, 95%
CI)
-0.33 [-0.49, -0.17]
1.3 Any dose 3 977 Std. Mean Difference (Random, 95%
CI)
-0.32 [-0.46, -0.18]
2 Dropouts 3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 150 - 200 mg/d 3 684 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.86, 1.63]
2.2 300 mg/d 2 624 Risk Ratio (M-H, Random, 95% CI) 1.82 [1.29, 2.57]
2.3 Any dose 3 997 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.90, 1.95]
3 Response (≥ 50% reduction in
MADRS or HAM-D score)
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 150 -200 mg/d 3 673 Risk Ratio (M-H, Random, 95% CI) 1.20 [1.02, 1.40]
3.2 300 mg/d 2 610 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.10, 1.50]
3.3 Any dose 3 977 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.09, 1.43]
4 Quality of life (% max score of
Q-LES-Q-SF)
2   Mean Difference (Random, 95% CI) Subtotals only
4.1 150 mg/d 2 591 Mean Difference (Random, 95% CI) 0.70 [-2.31, 3.71]
4.2 300 mg/d 2 589 Mean Difference (Random, 95% CI) 0.35 [-2.06, 2.77]
4.3 Any dose 2 884 Mean Difference (Random, 95% CI) 0.57 [-1.52, 2.65]
5 Remission (MADRS score ≤ 8/
HAM-D score ≤ 7)
3   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
5.1 150 - 200 mg/d 3 673 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.18, 1.92]
5.2 300 mg/d 2 610 Risk Ratio (M-H, Random, 95% CI) 1.53 [1.13, 2.07]
5.3 Any dose 3 977 Risk Ratio (M-H, Random, 95% CI) 1.53 [1.22, 1.90]
 
 
Analysis 7.1.   Comparison 7 Augment current antidepressant with quetiapine
(antipsychotic), Outcome 1 Depressive symptoms (MADRS or HAM-D).





Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
7.1.1 150 -200 mg/d  
Bauer 2009 (ONYX) 166 160 -0.4 (0.112) 45.78% -0.35[-0.57,-0.13]
El-Khalili 2010 (PEARL) 143 143 -0.2 (0.119) 42.54% -0.22[-0.45,0.02]
McIntyre 2007 29 29 -0.7 (0.271) 11.68% -0.7[-1.23,-0.17]
Subtotal (95% CI)       100% -0.34[-0.53,-0.14]
Heterogeneity: Tau2=0.01; Chi2=2.79, df=2(P=0.25); I2=28.32%  
Test for overall effect: Z=3.43(P=0)  
   
7.1.2 300mg/d  
Bauer 2009 (ONYX) 161 160 -0.3 (0.112) 52.68% -0.32[-0.54,-0.1]
El-Khalili 2010 (PEARL) 143 146 -0.3 (0.119) 47.32% -0.34[-0.57,-0.11]
Subtotal (95% CI)       100% -0.33[-0.49,-0.17]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=4(P<0.0001)  
   
7.1.3 Any dose  
Bauer 2009 (ONYX) 327 160 -0.3 (0.097) 48.92% -0.3[-0.49,-0.11]
El-Khalili 2010 (PEARL) 289 143 -0.3 (0.103) 44.16% -0.28[-0.48,-0.08]
McIntyre 2007 29 29 -0.7 (0.271) 6.92% -0.7[-1.23,-0.17]
Subtotal (95% CI)       100% -0.32[-0.46,-0.18]
Heterogeneity: Tau2=0; Chi2=2.14, df=2(P=0.34); I2=6.37%  
Test for overall effect: Z=4.43(P<0.0001)  
Favours quetiapine 21-2 -1 0 Favours control
 
 
Analysis 7.2.   Comparison 7 Augment current antidepressant with quetiapine (antipsychotic), Outcome 2 Dropouts.
Study or subgroup quetiapine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.2.1 150 - 200 mg/d  
Bauer 2009 (ONYX) 21/167 18/163 28.99% 1.14[0.63,2.06]
El-Khalili 2010 (PEARL) 34/148 23/148 44.3% 1.48[0.92,2.38]
McIntyre 2007 11/29 13/29 26.71% 0.85[0.46,1.57]
Favours quetiapine 1000.01 100.1 1 Favours control
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Study or subgroup quetiapine
augmentation
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 344 340 100% 1.18[0.86,1.63]
Total events: 66 (quetiapine augmentation), 54 (Control)  
Heterogeneity: Tau2=0; Chi2=2.01, df=2(P=0.37); I2=0.69%  
Test for overall effect: Z=1.02(P=0.31)  
   
7.2.2 300 mg/d  
Bauer 2009 (ONYX) 30/163 18/163 40.56% 1.67[0.97,2.87]
El-Khalili 2010 (PEARL) 45/150 23/148 59.44% 1.93[1.23,3.02]
Subtotal (95% CI) 313 311 100% 1.82[1.29,2.57]
Total events: 75 (quetiapine augmentation), 41 (Control)  
Heterogeneity: Tau2=0; Chi2=0.17, df=1(P=0.68); I2=0%  
Test for overall effect: Z=3.39(P=0)  
   
7.2.3 Any dose  
Bauer 2009 (ONYX) 51/330 18/163 33.47% 1.4[0.85,2.32]
El-Khalili 2010 (PEARL) 79/298 23/148 40.48% 1.71[1.12,2.6]
McIntyre 2007 11/29 13/29 26.05% 0.85[0.46,1.57]
Subtotal (95% CI) 657 340 100% 1.33[0.9,1.95]
Total events: 141 (quetiapine augmentation), 54 (Control)  
Heterogeneity: Tau2=0.05; Chi2=3.47, df=2(P=0.18); I2=42.43%  
Test for overall effect: Z=1.45(P=0.15)  
Test for subgroup differences: Chi2=3.36, df=1 (P=0.19), I2=40.45%  
Favours quetiapine 1000.01 100.1 1 Favours control
 
 
Analysis 7.3.   Comparison 7 Augment current antidepressant with quetiapine
(antipsychotic), Outcome 3 Response (≥ 50% reduction in MADRS or HAM-D score).
Study or subgroup Quetiapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.3.1 150 -200 mg/d  
Bauer 2009 (ONYX) 92/166 74/160 52.3% 1.2[0.97,1.49]
El-Khalili 2010 (PEARL) 74/143 66/146 42.73% 1.14[0.9,1.45]
McIntyre 2007 14/29 8/29 4.97% 1.75[0.87,3.52]
Subtotal (95% CI) 338 335 100% 1.2[1.02,1.4]
Total events: 180 (Quetiapine), 148 (Control)  
Heterogeneity: Tau2=0; Chi2=1.27, df=2(P=0.53); I2=0%  
Test for overall effect: Z=2.26(P=0.02)  
   
7.3.2 300 mg/d  
Bauer 2009 (ONYX) 93/161 74/160 52.29% 1.25[1.01,1.55]
El-Khalili 2010 (PEARL) 86/143 66/146 47.71% 1.33[1.06,1.66]
Subtotal (95% CI) 304 306 100% 1.29[1.1,1.5]
Total events: 179 (Quetiapine), 140 (Control)  
Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%  
Test for overall effect: Z=3.21(P=0)  
   
7.3.3 Any dose  
Bauer 2009 (ONYX) 185/327 74/160 51.42% 1.22[1.01,1.48]
Favours control 20.5 1.50.7 1 Favours quetiapine
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Study or subgroup Quetiapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
El-Khalili 2010 (PEARL) 160/286 66/146 44.7% 1.24[1.01,1.52]
McIntyre 2007 14/29 8/29 3.88% 1.75[0.87,3.52]
Subtotal (95% CI) 642 335 100% 1.25[1.09,1.43]
Total events: 359 (Quetiapine), 148 (Control)  
Heterogeneity: Tau2=0; Chi2=0.95, df=2(P=0.62); I2=0%  
Test for overall effect: Z=3.14(P=0)  
Test for subgroup differences: Chi2=0.42, df=1 (P=0.81), I2=0%  
Favours control 20.5 1.50.7 1 Favours quetiapine
 
 
Analysis 7.4.   Comparison 7 Augment current antidepressant with quetiapine
(antipsychotic), Outcome 4 Quality of life (% max score of Q-LES-Q-SF).
Study or subgroup Quetiapine Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
7.4.1 150 mg/d  
Bauer 2009 (ONYX) 160 160 2.1 (1.638) 53.94% 2.12[-1.09,5.33]
El-Khalili 2010 (PEARL) 135 136 -1 (1.852) 46.06% -0.96[-4.59,2.67]
Subtotal (95% CI)       100% 0.7[-2.31,3.71]
Heterogeneity: Tau2=1.69; Chi2=1.55, df=1(P=0.21); I2=35.56%  
Test for overall effect: Z=0.46(P=0.65)  
   
7.4.2 300 mg/d  
Bauer 2009 (ONYX) 157 160 0.2 (1.643) 56.23% 0.24[-2.98,3.46]
El-Khalili 2010 (PEARL) 136 136 0.5 (1.862) 43.77% 0.5[-3.15,4.15]
Subtotal (95% CI)       100% 0.35[-2.06,2.77]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
7.4.3 Any dose  
Bauer 2009 (ONYX) 317 160 1.2 (1.423) 56.07% 1.18[-1.61,3.97]
El-Khalili 2010 (PEARL) 271 136 -0.2 (1.608) 43.93% -0.22[-3.37,2.93]
Subtotal (95% CI)       100% 0.57[-1.52,2.65]
Heterogeneity: Tau2=0; Chi2=0.43, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.53(P=0.6)  
Test for subgroup differences: Chi2=0.03, df=1 (P=0.98), I2=0%  
Favours control 105-10 -5 0 Favours quetiapine
 
 
Analysis 7.5.   Comparison 7 Augment current antidepressant with quetiapine
(antipsychotic), Outcome 5 Remission (MADRS score ≤ 8/HAM-D score ≤ 7).
Study or subgroup Quetiapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.5.1 150 - 200 mg/d  
Bauer 2009 (ONYX) 60/166 38/160 49.73% 1.52[1.08,2.15]
El-Khalili 2010 (PEARL) 50/143 35/146 43.97% 1.46[1.01,2.1]
McIntyre 2007 9/29 5/29 6.31% 1.8[0.69,4.72]
Favours control 1000.01 100.1 1 Favours quetiapine
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Study or subgroup Quetiapine Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 338 335 100% 1.51[1.18,1.92]
Total events: 119 (Quetiapine), 78 (Control)  
Heterogeneity: Tau2=0; Chi2=0.16, df=2(P=0.92); I2=0%  
Test for overall effect: Z=3.33(P=0)  
   
7.5.2 300 mg/d  
Bauer 2009 (ONYX) 50/161 38/160 48.56% 1.31[0.91,1.88]
El-Khalili 2010 (PEARL) 61/143 35/146 51.44% 1.78[1.26,2.51]
Subtotal (95% CI) 304 306 100% 1.53[1.13,2.07]
Total events: 111 (Quetiapine), 73 (Control)  
Heterogeneity: Tau2=0.01; Chi2=1.46, df=1(P=0.23); I2=31.55%  
Test for overall effect: Z=2.77(P=0.01)  
   
7.5.3 Any dose  
Bauer 2009 (ONYX) 110/327 38/160 48.4% 1.42[1.03,1.94]
El-Khalili 2010 (PEARL) 111/286 35/146 46.38% 1.62[1.17,2.24]
McIntyre 2007 9/29 5/29 5.22% 1.8[0.69,4.72]
Subtotal (95% CI) 642 335 100% 1.53[1.22,1.9]
Total events: 230 (Quetiapine), 78 (Control)  
Heterogeneity: Tau2=0; Chi2=0.45, df=2(P=0.8); I2=0%  
Test for overall effect: Z=3.76(P=0)  
Test for subgroup differences: Chi2=0.01, df=1 (P=1), I2=0%  
Favours control 1000.01 100.1 1 Favours quetiapine
 
 
Comparison 8.   Augment current antidepressant with ziprasidone (antipsychotic)





Statistical method Effect size
1 Depressive symptoms (HAM-D) 2   Mean Difference (Fixed, 95% CI) Subtotals only
1.1 80 mg/d 1 41 Mean Difference (Fixed, 95% CI) -0.91 [-4.84, 3.02]
1.2 40 - 160 mg/d (mean 98 mg/d) 1 139 Mean Difference (Fixed, 95% CI) -3.1 [-5.19, -1.01]
1.3 160 mg/d 1 39 Mean Difference (Fixed, 95% CI) -2.56 [-6.72, 1.60]
1.4 Any dose 2 199 Mean Difference (Fixed, 95% CI) -2.73 [-4.53, -0.93]
2 Depressive symptoms (MADRS) 1   Mean Difference (Fixed, 95% CI) Subtotals only
2.1 80 mg/d 1 41 Mean Difference (Fixed, 95% CI) -1.53 [-6.94, 3.88]
2.2 160 mg/d 1 39 Mean Difference (Fixed, 95% CI) -3.82 [-9.64, 2.00]
2.3 Any dose 1 60 Mean Difference (Fixed, 95% CI) -2.62 [-7.47, 2.23]
3 Depressive symptoms (QIDS-SR) 1 139 Mean Difference (IV, Fixed, 95%
CI)
-2.5 [-3.83, -1.17]
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Statistical method Effect size
3.1 40 - 160 mg/d (mean 98 mg/d) 1 139 Mean Difference (IV, Fixed, 95%
CI)
-2.5 [-3.83, -1.17]
4 Dropouts 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 80 mg/d 1 41 Risk Ratio (M-H, Random, 95% CI) 2.10 [0.89, 4.96]
4.2 160 mg/d 1 39 Risk Ratio (M-H, Random, 95% CI) 2.11 [0.88, 5.03]
4.3 40 - 160 mg/d (mean 98 mg/d) 1 139 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.80, 2.47]
4.4 Any dose 2 199 Risk Ratio (M-H, Random, 95% CI) 1.60 [1.01, 2.55]
5 Response (≥ 50% reduction in
MADRS/HAM-D score)
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 80 mg/d (MADRS) 1 41 Risk Ratio (M-H, Random, 95% CI) 1.90 [0.39, 9.28]
5.2 160 mg/d (MADRS) 1 39 Risk Ratio (M-H, Random, 95% CI) 3.16 [0.72, 13.76]
5.3 40 - 160 mg/d (mean 98 mg/d)
(HAM-D)
1 139 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.97, 3.00]
5.4 Any dose 2 199 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.07, 3.04]
6 Response (≥ 50% reduction in QIDS-
SR)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 40 - 160 mg/d (mean 98 mg/d) 1 139 Risk Ratio (M-H, Random, 95% CI) 2.34 [1.16, 4.72]
7 Remission (MADRS/HAM-D) 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 80 mg/d 1 41 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.06, 14.22]
7.2 160 mg/d 1 39 Risk Ratio (M-H, Random, 95% CI) 4.21 [0.52, 34.36]
7.3 40 - 160 mg/d (mean 98 mg/d) 1 139 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.77, 1.96]
7.4 Any dose 2 199 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.81, 2.00]
8 Remission (QIDS-SR) 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 40 - 160 mg/d (mean 98 mg/d) 1 139 Risk Ratio (M-H, Random, 95% CI) 2.33 [1.03, 5.25]
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Analysis 8.1.   Comparison 8 Augment current antidepressant with
ziprasidone (antipsychotic), Outcome 1 Depressive symptoms (HAM-D).
Study or subgroup Ziprasidone Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
8.1.1 80 mg/d  
Dunner 2007 21 20 -0.9 (2.003) 100% -0.91[-4.84,3.02]
Subtotal (95% CI)       100% -0.91[-4.84,3.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.65)  
   
8.1.2 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 71 68 -3.1 (1.069) 100% -3.1[-5.19,-1.01]
Subtotal (95% CI)       100% -3.1[-5.19,-1.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.9(P=0)  
   
8.1.3 160 mg/d  
Dunner 2007 19 20 -2.6 (2.122) 100% -2.56[-6.72,1.6]
Subtotal (95% CI)       100% -2.56[-6.72,1.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
   
8.1.4 Any dose  
Dunner 2007 40 20 -1.7 (1.786) 26.37% -1.69[-5.19,1.81]
Papakostas 2015 71 68 -3.1 (1.069) 73.63% -3.1[-5.19,-1.01]
Subtotal (95% CI)       100% -2.73[-4.53,-0.93]
Heterogeneity: Tau2=0; Chi2=0.46, df=1(P=0.5); I2=0%  
Test for overall effect: Z=2.98(P=0)  
Test for subgroup differences: Chi2=0.94, df=1 (P=0.82), I2=0%  
Favours ziprasidone 105-10 -5 0 Favours control
 
 
Analysis 8.2.   Comparison 8 Augment current antidepressant with
ziprasidone (antipsychotic), Outcome 2 Depressive symptoms (MADRS).
Study or subgroup Ziprasidone Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
8.2.1 80 mg/d  
Dunner 2007 21 20 -1.5 (2.76) 100% -1.53[-6.94,3.88]
Subtotal (95% CI)       100% -1.53[-6.94,3.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.55(P=0.58)  
   
8.2.2 160 mg/d  
Dunner 2007 19 20 -3.8 (2.972) 100% -3.82[-9.64,2]
Subtotal (95% CI)       100% -3.82[-9.64,2]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
   
8.2.3 Any dose  
Favours ziprasidone 2010-20 -10 0 Favours control
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Study or subgroup Ziprasidone Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Fixed, 95% CI   IV, Fixed, 95% CI
Dunner 2007 40 20 -2.6 (2.476) 100% -2.62[-7.47,2.23]
Subtotal (95% CI)       100% -2.62[-7.47,2.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.85), I2=0%  
Favours ziprasidone 2010-20 -10 0 Favours control
 
 
Analysis 8.3.   Comparison 8 Augment current antidepressant with
ziprasidone (antipsychotic), Outcome 3 Depressive symptoms (QIDS-SR).
Study or subgroup Ziprasidone Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
8.3.1 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 71 -4.5 (4.7) 68 -2 (3.2) 100% -2.5[-3.83,-1.17]
Subtotal *** 71   68   100% -2.5[-3.83,-1.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.68(P=0)  
   
Total *** 71   68   100% -2.5[-3.83,-1.17]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.68(P=0)  
Favours ziprasidone 2010-20 -10 0 Favours control
 
 
Analysis 8.4.   Comparison 8 Augment current antidepressant with ziprasidone (antipsychotic), Outcome 4 Dropouts.
Study or subgroup Ziprasidone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.4.1 80 mg/d  
Dunner 2007 11/21 5/20 100% 2.1[0.89,4.96]
Subtotal (95% CI) 21 20 100% 2.1[0.89,4.96]
Total events: 11 (Ziprasidone), 5 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
   
8.4.2 160 mg/d  
Dunner 2007 10/19 5/20 100% 2.11[0.88,5.03]
Subtotal (95% CI) 19 20 100% 2.11[0.88,5.03]
Total events: 10 (Ziprasidone), 5 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
   
8.4.3 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 22/71 15/68 100% 1.4[0.8,2.47]
Subtotal (95% CI) 71 68 100% 1.4[0.8,2.47]
Total events: 22 (Ziprasidone), 15 (Control)  
Heterogeneity: Not applicable  
Favours ziprasidone 1000.01 100.1 1 Favours control
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Study or subgroup Ziprasidone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.18(P=0.24)  
   
8.4.4 Any dose  
Dunner 2007 21/40 5/20 32.56% 2.1[0.93,4.74]
Papakostas 2015 22/71 15/68 67.44% 1.4[0.8,2.47]
Subtotal (95% CI) 111 88 100% 1.6[1.01,2.55]
Total events: 43 (Ziprasidone), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=0.63, df=1(P=0.43); I2=0%  
Test for overall effect: Z=1.99(P=0.05)  
Test for subgroup differences: Chi2=0.92, df=1 (P=0.82), I2=0%  
Favours ziprasidone 1000.01 100.1 1 Favours control
 
 
Analysis 8.5.   Comparison 8 Augment current antidepressant with ziprasidone
(antipsychotic), Outcome 5 Response (≥ 50% reduction in MADRS/HAM-D score).
Study or subgroup Ziprasidone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.5.1 80 mg/d (MADRS)  
Dunner 2007 4/21 2/20 100% 1.9[0.39,9.28]
Subtotal (95% CI) 21 20 100% 1.9[0.39,9.28]
Total events: 4 (Ziprasidone), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.8(P=0.43)  
   
8.5.2 160 mg/d (MADRS)  
Dunner 2007 6/19 2/20 100% 3.16[0.72,13.76]
Subtotal (95% CI) 19 20 100% 3.16[0.72,13.76]
Total events: 6 (Ziprasidone), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.53(P=0.13)  
   
8.5.3 40 - 160 mg/d (mean 98 mg/d) (HAM-D)  
Papakostas 2015 25/71 14/68 100% 1.71[0.97,3]
Subtotal (95% CI) 71 68 100% 1.71[0.97,3]
Total events: 25 (Ziprasidone), 14 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
   
8.5.4 Any dose  
Dunner 2007 10/40 2/20 13.6% 2.5[0.6,10.34]
Papakostas 2015 25/71 14/68 86.4% 1.71[0.97,3]
Subtotal (95% CI) 111 88 100% 1.8[1.07,3.04]
Total events: 35 (Ziprasidone), 16 (Control)  
Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%  
Test for overall effect: Z=2.2(P=0.03)  
Favours control 1000.01 100.1 1 Favours ziprasidone
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Analysis 8.6.   Comparison 8 Augment current antidepressant with ziprasidone
(antipsychotic), Outcome 6 Response (≥ 50% reduction in QIDS-SR).
Study or subgroup Ziprasidone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.6.1 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 22/71 9/68 100% 2.34[1.16,4.72]
Subtotal (95% CI) 71 68 100% 2.34[1.16,4.72]
Total events: 22 (Ziprasidone), 9 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.38(P=0.02)  
Favours control 1000.01 100.1 1 Favours ziprasidone
 
 
Analysis 8.7.   Comparison 8 Augment current antidepressant with
ziprasidone (antipsychotic), Outcome 7 Remission (MADRS/HAM-D).
Study or subgroup Busiprone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.7.1 80 mg/d  
Dunner 2007 1/21 1/20 100% 0.95[0.06,14.22]
Subtotal (95% CI) 21 20 100% 0.95[0.06,14.22]
Total events: 1 (Busiprone), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
8.7.2 160 mg/d  
Dunner 2007 4/19 1/20 100% 4.21[0.52,34.36]
Subtotal (95% CI) 19 20 100% 4.21[0.52,34.36]
Total events: 4 (Busiprone), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
   
8.7.3 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 27/71 21/68 100% 1.23[0.77,1.96]
Subtotal (95% CI) 71 68 100% 1.23[0.77,1.96]
Total events: 27 (Busiprone), 21 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
8.7.4 Any dose  
Dunner 2007 5/40 1/20 4.73% 2.5[0.31,19.99]
Papakostas 2015 27/71 21/68 95.27% 1.23[0.77,1.96]
Subtotal (95% CI) 111 88 100% 1.27[0.81,2]
Total events: 32 (Busiprone), 22 (Control)  
Heterogeneity: Tau2=0; Chi2=0.44, df=1(P=0.51); I2=0%  
Test for overall effect: Z=1.05(P=0.29)  
Test for subgroup differences: Chi2=1.31, df=1 (P=0.73), I2=0%  
Favours control 1000.01 100.1 1 Favours ziprasidone
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Analysis 8.8.   Comparison 8 Augment current antidepressant with
ziprasidone (antipsychotic), Outcome 8 Remission (QIDS-SR).
Study or subgroup Ziprasidone Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.8.1 40 - 160 mg/d (mean 98 mg/d)  
Papakostas 2015 17/71 7/68 100% 2.33[1.03,5.25]
Subtotal (95% CI) 71 68 100% 2.33[1.03,5.25]
Total events: 17 (Ziprasidone), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.03(P=0.04)  
Favours control 1000.01 100.1 1 Favours ziprasidone
 
 
A D D I T I O N A L   T A B L E S
 
Reason for Exclusion No of articles excluded (%)
Not an RCT 106 (18.5)
Not a standard pharmacological treatment 131 (22.9)
No control group/not a comparison of interest 100 (17.5)
Not TRD/at point of randomisation 112 (19.5)
Not unipolar depression 27 (4.7)
Diagnostic criteria not applied at point of randomisation 59 (10.3)
Age 6 (1.0)
Trial terminated 1 (0.2)
Review article - refs checked 31 (5.4)
Total 573 (100)
Table 1.   Hierarchy of reasons for exclusion 












108 6 weeks Busiprone
(augmenta-
tion of AD)
Protocol violation n = 3
Side effects n = 1
Moved house n = 1
Protocol violation n = 3
Did not attend final assessment n = 2
Stopped taking study medication n = 2
Table 2.   Reasons for dropouts  (Continued)
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Did not attend final assessment n
= 1
Spouse threw away study medication
n = 1
Suspected angina n = 1
Heavy alcohol misuse n = 1
Dunner
2007





Treatment-related adverse event n
= 9
Withdrew consent n = 1
Miscellaneous n = 1
160 mg/d:
Treatment-related adverse event n
= 7
Withdrew consent n = 1
Miscellaneous n = 2
Withdrew consent n = 4
Miscellaneous n = 1
Durgam
2016
819 8 weeks Cariprazine
(augmenta-
tion of AD)
1 mg/d to 2 mg/d:
Adverse event n = 18
Insufficient response n = 4
Protocol violation n = 10
Withdrew consent n = 13
Lost to follow-up n = 2
2 mg/d to 4.5 mg/d:
Adverse event n = 36
Protocol violation n = 9
Withdrew consent n = 14
Lost to follow-up n = 4
Adverse event n = 8
Insufficient response n = 2
Protocol violation n = 6
Withdrew consent n = 11
Lost to follow-up n = 2








Adverse event n = 16
Lack of therapeutic response n = 2
Severe non-compliance with study
protocol n = 2
Did not complete ≥ 36 days of
study treatment n = 1
Lost to follow-up n = 8
Not willing to continue n = 4
Eligibility criteria not fulfilled n = 1
300 mg/d:
Adverse event n = 1
Lack of therapeutic response n = 4
Lost to follow-up n = 10
Not willing to continue n = 8
Table 2.   Reasons for dropouts  (Continued)
Pharmacological interventions for treatment-resistant depression in adults (Review)









Cochrane Database of Systematic Reviews
Adverse event n = 27
Did not complete ≥ 36 days of
study treatment n = 1
Lost to follow-up n = 7
Not willing to continue n = 6
Eligibility criteria not fulfilled n = 1
Other n = 3
Ferreri
2001






Switched to mianserin alone:
Ineffectiveness n = 1
Lost to follow-up n = 2
Intolerance/ adverse events n = 8
Substantial improvement n = 0
Personal reason n = 1
Augmented with mianserin:
Ineffectiveness n = 1
Lost to followup n = 2
Intolerance/ adverse events n = 2
Substantial improvement n = 1
Personal reason n = 1
Ineffectiveness n = 6
Lost to follow-up n = 1
Intolerance/ adverse events n = 0
Substantial improvement n = 0
Personal reason n = 1
Kessler
2018
480 52 weeks Mirtazapine
(augmenta-
tion of AD)
Withdrew from study n = 6
Not willing to take part n = 2
Health n = 1
Other n = 3
Lost to follow-up n = 44
Withdrew from study n = 12
Not willing to take part n = 8
Health n = 2
Other n = 2
Lost to follow-up n = 28
McIntyre
2007
58 6 weeks Quetiapine
(augmenta-
tion of AD)
Adverse events n = 8
Consent withdrawal n = 2
Protocol violation n = 1
Lack of efficacy n = 9
Adverse events n = 2








Intolerance n = 10
Inefficacy n = 3
Lost to follow-up n = 3
Other n = 6
Inefficacy n = 1
Lost to follow-up n = 7
Other n = 7
Shelton
2001
20 8 weeks Olanzapine
(augmenta-
tion of AD)
Protocol violation n = 1 Lack of efficacy n = 1
Personal conflict n = 1
Protocol violation n = 1
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n.r. n.r. 0/54 (0%) 0/54 (0%) "No serious adverse events were observed. No statistically
significant differences were observed in UKU scores between
treatment groups throughout the study" (p.450, Safety). 1 par-
ticipant in the busiprone arm was reported to have dropped
















































Serious AEs were depression (placebo); agitation (cariprazine
2 mg/d to 4.5 mg/d); and panic attack, dyspnoea and non-
cardiac chest pain (one patient experienced three events,



































0/148 "Two serious AEs were reported during the study period. One
patient experienced a transient ischaemic attack (placebo)
and one patient experienced worsening of cervical spondylitis
(quetiapine XR 150 mg/d); neither was considered treatment

































Serious SAEs at 12 weeks:
Mirtazapine: central nervous system/transient ischaemic at-
tack (TIA) (n = 1), cardiovascular (n = 1), dental (n = 1), gynae-
cological (n = 1), pancreatitis (n = 1), psychiatric (n = 2) and
respiratory (n = 1). Four serious SAEs in this group were con-
Table 3.   Adverse events  (Continued)
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sidered to be not related to the intervention, two unlikely to
be related and two possibly related.
Placebo: infection (n = 1) and musculoskeletal trauma (n = 2).
(all three serious SAEs in this group were considered to be not
related to the intervention).
Adverse events beyond 12 weeks were reported by frequency







n.r. n.r. 0/29 (0%) 0/29 (0%) "No serious AEs were reported." (p.491, Safety and tolerabil-
ity). Most commonly occurring adverse events reported in
table 2 (type and frequency broken down by treatment) but











Serious AEs: Ziprasidone (one hospitalisation because of
treatment-emergent suicidal thoughts and one because of a
fall). Placebo (hospitalisations for treatment-emergent viral
meningitis and pneumonia respectively).
Data for all adverse events reported by frequency of event.






n.r. n.r. n.r. n.r. Most commonly occurring adverse events described in the
text but numbers (and treatment) of participants experiencing
AEs not reported
Table 3.   Adverse events  (Continued)
AE: adverse event
n.r.: Not reported
TIA: transient ischaemic attack
 
 
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid): CCMD's core search strategy used to inform the Group's specialised register
A weekly search alert based on condition + RCT filter only
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or aNective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal aNective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or
agoraphobia/ or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or
munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions, psychological/ or vaginismus/ or Anhedonia/ or ANective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or aNective disorder* or bipolar i or bipolar ii or (bipolar and (aNective or disorder*)) or mania or manic or cyclothymic* or
depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia
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or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical*
unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue*
or gambling or trichotillomania or vaginismus or anhedoni* or aNective symptoms or mental disorder* or mental health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random* adj3
(administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place*
or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or study or
studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or random*)).ti,ab. or
((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records were screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of RCTs
were tagged to the appropriate study record.
Similar weekly search alerts were also be conducted on OVID Embase and PsycINFO, using relevant subject headings (controlled
vocabularies) and search syntax, appropriate to each resource.
Appendix 2. Review search strategies
1 MEDLINE (Ovid)
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
<(1 January 2016 to 31 December 2018) >
1 Depressive Disorder, Treatment-Resistant/
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic or
treatment* or respon*) adj2 fail*)).ti,ab,kf.
3 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication* or
treatment*) adj2 ("no respon*" or "not respon*" or nonrespon* or non-respon* or unrespon*))).ti,ab,kf.
4 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,kf.
5 (depress* adj3 (relaps* or recurr*)).ti,kf.
6 (depress* and (augment* or potentiat*)).mp.
7 or/1-6
8 randomized controlled trial.pt. or exp randomized controlled trial/ or exp Randomized Controlled Trials as Topic/
9 controlled clinical trial.pt.
10 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,kf.
11 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,kf.
12 double-blind*.ti,ab,kf,hw.
13 trial.ti.
14 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,kf.
15 or/8-14




20 exp historical article/
21 Anecdotes as topic/
22 comment/
23 case report/
24 (letter or comment*).ti.
25 exp animals/ not humans/
26 exp Animals, Laboratory/
27 exp Animal Experimentation/ not (exp human experimentation/ or humans/)
28 exp Models, Animal/
29 exp rodentia/
30 (rat or rats or mouse or mice or rodent*).ti.
31 or/17-30
32 16 not 31
33 (2016* or 2017*).yr,dc,ed,ep.
34 (in-data-review or in-process or publisher).st.
35 33 or 34
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36 32 and 35
2 Embase (Ovid)
(1 January 2016 to 31 December 2018)
1 treatment resistant depression/
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic or
treatment* or respon*) adj2 fail*)).ti,ab,kf.
3 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication* or
treatment*) adj2 ("no respon*" or "not respon*" or nonrespon* or non-respon* or unrespon*))).ti,ab,kf.
4 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,kf.
5 (depress* adj3 (relaps* or recurr*)).ti,kf.
6 (depress* and (augment* or potentiat*)).mp.
7 or/1-6
8 randomized controlled trial/ or "randomized controlled trial (topic)"/
9 crossover procedure/
10 "double blind procedure"/
11 "single-blind procedure"/
12 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,kf.
13 trial.ti.
14 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,kf.
15 double-blind*.ti,ab.
16 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,kf.
17 or/8-16
18 7 and 17
19 letter.pt. or letter/
20 note.pt.
21 editorial.pt.
22 case report/ or case study/
23 (letter or comment*).ti.
24 exp animal/ not human/
25 nonhuman/
26 exp experimental animal/
27 exp animal experiment/
28 exp animal model/
29 exp rodent/
30 (rat or rats or mouse or mice or rodent*).ti.
31 or/19-30
32 18 not 31
3 PsycINFO (Ovid)
(1 January 2016 to 31 December 2018)
1 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic or
treatment* or respon*) adj2 fail*)).ti,ab,id.
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication* or
treatment*) adj2 ("no respon*" or "not respon*" or nonrespon* or non-respon* or unrespon*))).ti,ab,id.
3 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,id.
4 (depress* and (augment* or potentiat*)).mp.
5 treatment resistant depression/
6 (depress* adj3 (relaps* or recurr*)).ti,id.
7 or/1-6
8 clinical trials/
9 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,id.
10 double-blind*.ti,ab,id,hw.
11 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,id.
12 trial.ti.
13 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,id.
14 or/8-13
15 7 and 14
16 (authored book or book or edited book).pt.
17 scientific communication/
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18 case report/
19 (letter or comment*).ti.
20 exp animals/ or animal models/
21 (rat or rats or mouse or mice or rodent*).ti.
22 or/16-21
23 15 not 22
4 Cochrane Central Register of Controlled Trials (CENTRAL), Issue 12, 2018
(1 January 2016 to 31 December 2018)
#1MeSH descriptor: [Depressive Disorder, Treatment-Resistant] explode all trees
#2(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or medication* or psychotropic
or treatment* or respon*) near/2 fail*)):ti,ab,kw
#3(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or "psychotropic medication" or
"psychotropic medications" or treatment*) near/2 ("no respon*" or "not respon*" or nonrespon* or non-respon* or unrespon*))):ti,ab,kw
#4(depress* near/3 (refractor* or resistan* or chronic* or persist*)):ti,ab,kw
#5(depress* near/3 (relaps* or recurr*)):ti,kw
#6(depress* and (augment* or potentiat*)):ti,ab,kw
#7#1 or #2 or #3 or #4 or #5 or #6
5 Web of Science (Clarivate Analytics)
(1 January 2016 to 31 December 2018)
# 15 #11 not #14
# 14 #13 OR #12
# 13 TS=((animal* near/2 experiment*) or (animal* near/2 model*) or (animal* near/2 laborator*))
# 12 TI= (rat or rats or mouse or mice or rodent* or animal* or comment* or letter or "case study" or "case report" or anecdote* or editorial*
or news )
# 11 #10 AND #6
# 10 #9 OR #8 OR #7
# 9 TI= trial
# 8 TS= (RCT or randomized or randomised or "at random" or (random* near/3 (assign* or allocat* or divide* or division or number*)))
# 7 TS= ((controlled near/2 "clinical trial") or double-blind* or ((placebo or sham or mock or fake or dummy) and (control* or group?)) or
((cluster or crossover* or cross-over*) near/3 (random* or trial or study or control* or group?)))
# 6 #5 OR #4 OR #3 OR #2 OR #1
# 5 TS=(depress* and (augment* or potentiat*))
# 4 TS=(depress* near/3 (relaps* or recurr*))
# 3 TS=(depress* near/3 (refractor* or resistan* or chronic* or persist*))
# 2 TS=(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or "psychotropic medication"
or "psychotropic medications" or treatment*) near/2 ("no respon*" or "not respon*" or nonrespon* or non-respon* or unrespon*)))
# 1 TS=((depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or medication* or
psychotropic or treatment* or respon*) near/2 fail*)))
6 International trials registers search (all years)
Types of Study = Interventional
Condition 1 = treatment resistant depression
Condition 2 = refractory depression
Condition 3 = recurrent depression
Condition 4 = chronic depression
C O N T R I B U T I O N S   O F   A U T H O R S
NW draMed the protocol, which was finalised following comments from all review authors. PD, SI and NW screened abstracts. PD, SI, NW,
CW, DK and GL assessed full papers for eligibility. PD and SI extracted data from included studies. PD carried out the analyses and wrote
the first draM of the review, which all review authors commented on. CW died in April 2018. Update searches were run, screening and data
extraction were carried out aMer this date and substantive changes to the review made.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol, we defined the comparator intervention as 'antidepressant medication - either continuing on the initial antidepressant
monotherapy or another antidepressant.'. Hence, switching to another antidepressant was listed in the protocol as both an intervention
and comparator of interest. In order to make a meaningful comparison, studies need to include a group that continue on existing
antidepressant monotherapy. We therefore decided not to consider switching to another antidepressant a suitable control condition and
amended our inclusion criteria accordingly.
We also stated that missing data would be addressed in additional analyses assuming best (all who dropped out had positive outcomes)
and worst (all who dropped out had negative outcomes) case scenarios. However, we later agreed that this was not necessary because
study level data were more robust than participant level data imputations determined by review authors.
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